<html>

<head>
<meta http-equiv=Content-Type content="text/html; charset=us-ascii">
<meta name=Generator content="Microsoft Word 15 (filtered)">
<title>Gardasil, INN-Human Papillomavirus Vaccine [Types 6, 11, 16, 18]
(Recombinant, adsorbed)</title>
<style>
<!--
 /* Font Definitions */
 @font-face
	{font-family:Helvetica;
	panose-1:2 11 6 4 2 2 2 2 2 4;}
@font-face
	{font-family:Courier;
	panose-1:2 7 4 9 2 2 5 2 4 4;}
@font-face
	{font-family:"Tms Rmn";
	panose-1:2 2 6 3 4 5 5 2 3 4;}
@font-face
	{font-family:Helv;
	panose-1:2 11 6 4 2 2 2 3 2 4;}
@font-face
	{font-family:"New York";
	panose-1:2 4 5 3 6 5 6 2 3 4;}
@font-face
	{font-family:System;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:Wingdings;
	panose-1:5 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"MS Mincho";
	panose-1:2 2 6 9 4 2 5 8 3 4;}
@font-face
	{font-family:Batang;
	panose-1:2 3 6 0 0 1 1 1 1 1;}
@font-face
	{font-family:SimSun;
	panose-1:2 1 6 0 3 1 1 1 1 1;}
@font-face
	{font-family:PMingLiU;
	panose-1:2 1 6 1 0 1 1 1 1 1;}
@font-face
	{font-family:"MS Gothic";
	panose-1:2 11 6 9 7 2 5 8 2 4;}
@font-face
	{font-family:Dotum;
	panose-1:2 11 6 0 0 1 1 1 1 1;}
@font-face
	{font-family:SimHei;
	panose-1:2 1 6 0 3 1 1 1 1 1;}
@font-face
	{font-family:MingLiU;
	panose-1:2 1 6 9 0 1 1 1 1 1;}
@font-face
	{font-family:Mincho;
	panose-1:2 2 6 9 4 3 5 8 3 5;}
@font-face
	{font-family:Gulim;
	panose-1:2 11 6 0 0 1 1 1 1 1;}
@font-face
	{font-family:Century;
	panose-1:2 4 6 4 5 5 5 2 3 4;}
@font-face
	{font-family:"Angsana New";
	panose-1:2 2 6 3 5 4 5 2 3 4;}
@font-face
	{font-family:"Cordia New";
	panose-1:2 11 3 4 2 2 2 2 2 4;}
@font-face
	{font-family:Mangal;
	panose-1:0 0 4 0 0 0 0 0 0 0;}
@font-face
	{font-family:Latha;
	panose-1:2 0 4 0 0 0 0 0 0 0;}
@font-face
	{font-family:Sylfaen;
	panose-1:1 10 5 2 5 3 6 3 3 3;}
@font-face
	{font-family:Vrinda;
	panose-1:0 0 4 0 0 0 0 0 0 0;}
@font-face
	{font-family:Raavi;
	panose-1:2 0 5 0 0 0 0 0 0 0;}
@font-face
	{font-family:Shruti;
	panose-1:2 0 5 0 0 0 0 0 0 0;}
@font-face
	{font-family:Sendnya;
	panose-1:0 0 4 0 0 0 0 0 0 0;}
@font-face
	{font-family:Gautami;
	panose-1:2 0 5 0 0 0 0 0 0 0;}
@font-face
	{font-family:Tunga;
	panose-1:0 0 4 0 0 0 0 0 0 0;}
@font-face
	{font-family:"Estrangelo Edessa";
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"Cambria Math";
	panose-1:2 4 5 3 5 4 6 3 2 4;}
@font-face
	{font-family:"Yu Gothic";
	panose-1:2 11 4 0 0 0 0 0 0 0;}
@font-face
	{font-family:DengXian;
	panose-1:2 1 6 0 3 1 1 1 1 1;}
@font-face
	{font-family:Calibri;
	panose-1:2 15 5 2 2 2 4 3 2 4;}
@font-face
	{font-family:"Calibri Light";
	panose-1:2 15 3 2 2 2 4 3 2 4;}
@font-face
	{font-family:"Palatino Linotype";
	panose-1:2 4 5 2 5 5 5 3 3 4;}
@font-face
	{font-family:Verdana;
	panose-1:2 11 6 4 3 5 4 4 2 4;}
@font-face
	{font-family:"Arial Unicode MS";
	panose-1:2 11 6 4 2 2 2 2 2 4;}
@font-face
	{font-family:"Segoe UI Emoji";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:Cambria;
	panose-1:2 4 5 3 5 4 6 3 2 4;}
@font-face
	{font-family:"Segoe UI";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:Tahoma;
	panose-1:2 11 6 4 3 5 4 4 2 4;}
@font-face
	{font-family:"Segoe UI Symbol";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:BISansCond;}
@font-face
	{font-family:Marlett;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"Arial Black";
	panose-1:2 11 10 4 2 1 2 2 2 4;}
@font-face
	{font-family:"Bahnschrift Light";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Bahnschrift SemiLight";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:Bahnschrift;
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Bahnschrift SemiBold";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Bahnschrift Light SemiCondensed";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Bahnschrift SemiLight SemiConde";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Bahnschrift SemiCondensed";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Bahnschrift SemiBold SemiConden";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Bahnschrift Light Condensed";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Bahnschrift SemiLight Condensed";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Bahnschrift Condensed";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Bahnschrift SemiBold Condensed";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:Candara;
	panose-1:2 14 5 2 3 3 3 2 2 4;}
@font-face
	{font-family:"Candara Light";
	panose-1:2 14 5 2 3 3 3 2 2 4;}
@font-face
	{font-family:"Comic Sans MS";
	panose-1:3 15 7 2 3 3 2 2 2 4;}
@font-face
	{font-family:Consolas;
	panose-1:2 11 6 9 2 2 4 3 2 4;}
@font-face
	{font-family:Constantia;
	panose-1:2 3 6 2 5 3 6 3 3 3;}
@font-face
	{font-family:Corbel;
	panose-1:2 11 5 3 2 2 4 2 2 4;}
@font-face
	{font-family:"Corbel Light";
	panose-1:2 11 3 3 2 2 4 2 2 4;}
@font-face
	{font-family:Ebrima;
	panose-1:2 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"Franklin Gothic Medium";
	panose-1:2 11 6 3 2 1 2 2 2 4;}
@font-face
	{font-family:Gabriola;
	panose-1:4 4 6 5 5 16 2 2 13 2;}
@font-face
	{font-family:Gadugi;
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:Georgia;
	panose-1:2 4 5 2 5 4 5 2 3 3;}
@font-face
	{font-family:Impact;
	panose-1:2 11 8 6 3 9 2 5 2 4;}
@font-face
	{font-family:"Ink Free";
	panose-1:3 8 4 2 0 5 0 0 0 0;}
@font-face
	{font-family:"Javanese Text";
	panose-1:2 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"Leelawadee UI";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Leelawadee UI Semilight";
	panose-1:2 11 4 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Lucida Console";
	panose-1:2 11 6 9 4 5 4 2 2 4;}
@font-face
	{font-family:"Lucida Sans Unicode";
	panose-1:2 11 6 2 3 5 4 2 2 4;}
@font-face
	{font-family:"Malgun Gothic";
	panose-1:2 11 5 3 2 0 0 2 0 4;}
@font-face
	{font-family:"\@Malgun Gothic";}
@font-face
	{font-family:"Malgun Gothic Semilight";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"\@Malgun Gothic Semilight";}
@font-face
	{font-family:"Microsoft Himalaya";
	panose-1:1 1 1 0 1 1 1 1 1 1;}
@font-face
	{font-family:"Microsoft JhengHei";
	panose-1:2 11 6 4 3 5 4 4 2 4;}
@font-face
	{font-family:"\@Microsoft JhengHei";}
@font-face
	{font-family:"Microsoft JhengHei UI";
	panose-1:2 11 6 4 3 5 4 4 2 4;}
@font-face
	{font-family:"\@Microsoft JhengHei UI";}
@font-face
	{font-family:"Microsoft JhengHei Light";
	panose-1:2 11 3 4 3 5 4 4 2 4;}
@font-face
	{font-family:"\@Microsoft JhengHei Light";}
@font-face
	{font-family:"Microsoft JhengHei UI Light";
	panose-1:2 11 3 4 3 5 4 4 2 4;}
@font-face
	{font-family:"\@Microsoft JhengHei UI Light";}
@font-face
	{font-family:"Microsoft New Tai Lue";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Microsoft PhagsPa";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Microsoft Sans Serif";
	panose-1:2 11 6 4 2 2 2 2 2 4;}
@font-face
	{font-family:"Microsoft Tai Le";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Microsoft YaHei";
	panose-1:2 11 5 3 2 2 4 2 2 4;}
@font-face
	{font-family:"\@Microsoft YaHei";}
@font-face
	{font-family:"Microsoft YaHei UI";
	panose-1:2 11 5 3 2 2 4 2 2 4;}
@font-face
	{font-family:"\@Microsoft YaHei UI";}
@font-face
	{font-family:"Microsoft YaHei Light";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"\@Microsoft YaHei Light";}
@font-face
	{font-family:"Microsoft YaHei UI Light";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"\@Microsoft YaHei UI Light";}
@font-face
	{font-family:"Microsoft Yi Baiti";
	panose-1:3 0 5 0 0 0 0 0 0 0;}
@font-face
	{font-family:MingLiU-ExtB;
	panose-1:2 2 5 0 0 0 0 0 0 0;}
@font-face
	{font-family:"\@MingLiU-ExtB";}
@font-face
	{font-family:PMingLiU-ExtB;
	panose-1:2 2 5 0 0 0 0 0 0 0;}
@font-face
	{font-family:"\@PMingLiU-ExtB";}
@font-face
	{font-family:MingLiU_HKSCS-ExtB;
	panose-1:2 2 5 0 0 0 0 0 0 0;}
@font-face
	{font-family:"\@MingLiU_HKSCS-ExtB";}
@font-face
	{font-family:"Mongolian Baiti";
	panose-1:3 0 5 0 0 0 0 0 0 0;}
@font-face
	{font-family:"\@MS Gothic";
	panose-1:2 11 6 9 7 2 5 8 2 4;}
@font-face
	{font-family:"MS UI Gothic";
	panose-1:2 11 6 0 7 2 5 8 2 4;}
@font-face
	{font-family:"\@MS UI Gothic";}
@font-face
	{font-family:"MS PGothic";
	panose-1:2 11 6 0 7 2 5 8 2 4;}
@font-face
	{font-family:"\@MS PGothic";}
@font-face
	{font-family:"MV Boli";
	panose-1:2 0 5 0 3 2 0 9 0 0;}
@font-face
	{font-family:"Myanmar Text";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Nirmala UI";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Nirmala UI Semilight";
	panose-1:2 11 4 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Segoe MDL2 Assets";
	panose-1:5 10 1 2 1 1 1 1 1 1;}
@font-face
	{font-family:"Segoe Print";
	panose-1:2 0 6 0 0 0 0 0 0 0;}
@font-face
	{font-family:"Segoe Script";
	panose-1:3 11 5 4 2 0 0 0 0 3;}
@font-face
	{font-family:"Segoe UI Black";
	panose-1:2 11 10 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Segoe UI Historic";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Segoe UI Light";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Segoe UI Semibold";
	panose-1:2 11 7 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Segoe UI Semilight";
	panose-1:2 11 4 2 4 2 4 2 2 3;}
@font-face
	{font-family:"\@SimSun";
	panose-1:2 1 6 0 3 1 1 1 1 1;}
@font-face
	{font-family:NSimSun;
	panose-1:2 1 6 9 3 1 1 1 1 1;}
@font-face
	{font-family:"\@NSimSun";}
@font-face
	{font-family:SimSun-ExtB;
	panose-1:2 1 6 9 6 1 1 1 1 1;}
@font-face
	{font-family:"\@SimSun-ExtB";}
@font-face
	{font-family:"Sitka Small";
	panose-1:2 0 5 5 0 0 0 2 0 4;}
@font-face
	{font-family:"Sitka Text";
	panose-1:2 0 5 5 0 0 0 2 0 4;}
@font-face
	{font-family:"Sitka Subheading";
	panose-1:2 0 5 5 0 0 0 2 0 4;}
@font-face
	{font-family:"Sitka Heading";
	panose-1:2 0 5 5 0 0 0 2 0 4;}
@font-face
	{font-family:"Sitka Display";
	panose-1:2 0 5 5 0 0 0 2 0 4;}
@font-face
	{font-family:"Sitka Banner";
	panose-1:2 0 5 5 0 0 0 2 0 4;}
@font-face
	{font-family:"Trebuchet MS";
	panose-1:2 11 6 3 2 2 2 2 2 4;}
@font-face
	{font-family:Webdings;
	panose-1:5 3 1 2 1 5 9 6 7 3;}
@font-face
	{font-family:"\@Yu Gothic";
	panose-1:2 11 4 0 0 0 0 0 0 0;}
@font-face
	{font-family:"Yu Gothic UI";
	panose-1:2 11 5 0 0 0 0 0 0 0;}
@font-face
	{font-family:"\@Yu Gothic UI";}
@font-face
	{font-family:"Yu Gothic UI Semibold";
	panose-1:2 11 7 0 0 0 0 0 0 0;}
@font-face
	{font-family:"\@Yu Gothic UI Semibold";}
@font-face
	{font-family:"Yu Gothic Light";
	panose-1:2 11 3 0 0 0 0 0 0 0;}
@font-face
	{font-family:"\@Yu Gothic Light";}
@font-face
	{font-family:"Yu Gothic UI Light";
	panose-1:2 11 3 0 0 0 0 0 0 0;}
@font-face
	{font-family:"\@Yu Gothic UI Light";}
@font-face
	{font-family:"Yu Gothic Medium";
	panose-1:2 11 5 0 0 0 0 0 0 0;}
@font-face
	{font-family:"\@Yu Gothic Medium";}
@font-face
	{font-family:"Yu Gothic UI Semilight";
	panose-1:2 11 4 0 0 0 0 0 0 0;}
@font-face
	{font-family:"\@Yu Gothic UI Semilight";}
@font-face
	{font-family:"HoloLens MDL2 Assets";
	panose-1:5 10 1 2 1 1 1 1 1 1;}
@font-face
	{font-family:"Agency FB";
	panose-1:2 11 5 3 2 2 2 2 2 4;}
@font-face
	{font-family:Algerian;
	panose-1:4 2 7 5 4 10 2 6 7 2;}
@font-face
	{font-family:"Book Antiqua";
	panose-1:2 4 6 2 5 3 5 3 3 4;}
@font-face
	{font-family:"Arial Narrow";
	panose-1:2 11 6 6 2 2 2 3 2 4;}
@font-face
	{font-family:"Arial Rounded MT Bold";
	panose-1:2 15 7 4 3 5 4 3 2 4;}
@font-face
	{font-family:"Baskerville Old Face";
	panose-1:2 2 6 2 8 5 5 2 3 3;}
@font-face
	{font-family:"Bauhaus 93";
	panose-1:4 3 9 5 2 11 2 2 12 2;}
@font-face
	{font-family:"Bell MT";
	panose-1:2 2 5 3 6 3 5 2 3 3;}
@font-face
	{font-family:"Bernard MT Condensed";
	panose-1:2 5 8 6 6 9 5 2 4 4;}
@font-face
	{font-family:"Bodoni MT";
	panose-1:2 7 6 3 8 6 6 2 2 3;}
@font-face
	{font-family:"Bodoni MT Black";
	panose-1:2 7 10 3 8 6 6 2 2 3;}
@font-face
	{font-family:"Bodoni MT Condensed";
	panose-1:2 7 6 6 8 6 6 2 2 3;}
@font-face
	{font-family:"Bodoni MT Poster Compressed";
	panose-1:2 7 7 6 8 6 1 5 2 4;}
@font-face
	{font-family:"Bookman Old Style";
	panose-1:2 5 6 4 5 5 5 2 2 4;}
@font-face
	{font-family:"Bradley Hand ITC";
	panose-1:3 7 4 2 5 3 2 3 2 3;}
@font-face
	{font-family:"Britannic Bold";
	panose-1:2 11 9 3 6 7 3 2 2 4;}
@font-face
	{font-family:"Berlin Sans FB";
	panose-1:2 14 6 2 2 5 2 2 3 6;}
@font-face
	{font-family:"Berlin Sans FB Demi";
	panose-1:2 14 8 2 2 5 2 2 3 6;}
@font-face
	{font-family:Broadway;
	panose-1:4 4 9 5 8 11 2 2 5 2;}
@font-face
	{font-family:"Brush Script MT";
	panose-1:3 6 8 2 4 4 6 7 3 4;}
@font-face
	{font-family:"Bookshelf Symbol 7";
	panose-1:5 1 1 1 1 1 1 1 1 1;}
@font-face
	{font-family:"Californian FB";
	panose-1:2 7 4 3 6 8 11 3 2 4;}
@font-face
	{font-family:"Calisto MT";
	panose-1:2 4 6 3 5 5 5 3 3 4;}
@font-face
	{font-family:Castellar;
	panose-1:2 10 4 2 6 4 6 1 3 1;}
@font-face
	{font-family:"Century Schoolbook";
	panose-1:2 4 6 4 5 5 5 2 3 4;}
@font-face
	{font-family:Centaur;
	panose-1:2 3 5 4 5 2 5 2 3 4;}
@font-face
	{font-family:Chiller;
	panose-1:4 2 4 4 3 16 7 2 6 2;}
@font-face
	{font-family:"Colonna MT";
	panose-1:4 2 8 5 6 2 2 3 2 3;}
@font-face
	{font-family:"Cooper Black";
	panose-1:2 8 9 4 4 3 11 2 4 4;}
@font-face
	{font-family:"Copperplate Gothic Bold";
	panose-1:2 14 7 5 2 2 6 2 4 4;}
@font-face
	{font-family:"Copperplate Gothic Light";
	panose-1:2 14 5 7 2 2 6 2 4 4;}
@font-face
	{font-family:"Curlz MT";
	panose-1:4 4 4 4 5 7 2 2 2 2;}
@font-face
	{font-family:Dubai;
	panose-1:2 11 5 3 3 4 3 3 2 4;}
@font-face
	{font-family:"Dubai Light";
	panose-1:2 11 3 3 3 4 3 3 2 4;}
@font-face
	{font-family:"Dubai Medium";
	panose-1:2 11 6 3 3 4 3 3 2 4;}
@font-face
	{font-family:Elephant;
	panose-1:2 2 9 4 9 5 5 2 3 3;}
@font-face
	{font-family:"Engravers MT";
	panose-1:2 9 7 7 8 5 5 2 3 4;}
@font-face
	{font-family:"Eras Bold ITC";
	panose-1:2 11 9 7 3 5 4 2 2 4;}
@font-face
	{font-family:"Eras Demi ITC";
	panose-1:2 11 8 5 3 5 4 2 8 4;}
@font-face
	{font-family:"Eras Light ITC";
	panose-1:2 11 4 2 3 5 4 2 8 4;}
@font-face
	{font-family:"Eras Medium ITC";
	panose-1:2 11 6 2 3 5 4 2 8 4;}
@font-face
	{font-family:"Felix Titling";
	panose-1:4 6 5 5 6 2 2 2 10 4;}
@font-face
	{font-family:Forte;
	panose-1:3 6 9 2 4 5 2 7 2 3;}
@font-face
	{font-family:"Franklin Gothic Book";
	panose-1:2 11 5 3 2 1 2 2 2 4;}
@font-face
	{font-family:"Franklin Gothic Demi";
	panose-1:2 11 7 3 2 1 2 2 2 4;}
@font-face
	{font-family:"Franklin Gothic Demi Cond";
	panose-1:2 11 7 6 3 4 2 2 2 4;}
@font-face
	{font-family:"Franklin Gothic Heavy";
	panose-1:2 11 9 3 2 1 2 2 2 4;}
@font-face
	{font-family:"Franklin Gothic Medium Cond";
	panose-1:2 11 6 6 3 4 2 2 2 4;}
@font-face
	{font-family:"Freestyle Script";
	panose-1:3 8 4 2 3 2 5 11 4 4;}
@font-face
	{font-family:"French Script MT";
	panose-1:3 2 4 2 4 6 7 4 6 5;}
@font-face
	{font-family:"Footlight MT Light";
	panose-1:2 4 6 2 6 3 10 2 3 4;}
@font-face
	{font-family:Garamond;
	panose-1:2 2 4 4 3 3 1 1 8 3;}
@font-face
	{font-family:Gigi;
	panose-1:4 4 5 4 6 16 7 2 13 2;}
@font-face
	{font-family:"Gill Sans MT";
	panose-1:2 11 5 2 2 1 4 2 2 3;}
@font-face
	{font-family:"Gill Sans MT Condensed";
	panose-1:2 11 5 6 2 1 4 2 2 3;}
@font-face
	{font-family:"Gill Sans Ultra Bold Condensed";
	panose-1:2 11 10 6 2 1 4 2 2 3;}
@font-face
	{font-family:"Gill Sans Ultra Bold";
	panose-1:2 11 10 2 2 1 4 2 2 3;}
@font-face
	{font-family:"Gloucester MT Extra Condensed";
	panose-1:2 3 8 8 2 6 1 1 1 1;}
@font-face
	{font-family:"Gill Sans MT Ext Condensed Bold";
	panose-1:2 11 9 2 2 1 4 2 2 3;}
@font-face
	{font-family:"Century Gothic";
	panose-1:2 11 5 2 2 2 2 2 2 4;}
@font-face
	{font-family:"Goudy Old Style";
	panose-1:2 2 5 2 5 3 5 2 3 3;}
@font-face
	{font-family:"Goudy Stout";
	panose-1:2 2 9 4 7 3 11 2 4 1;}
@font-face
	{font-family:"Harlow Solid Italic";
	panose-1:4 3 6 4 2 15 2 2 13 2;}
@font-face
	{font-family:Harrington;
	panose-1:4 4 5 5 5 10 2 2 7 2;}
@font-face
	{font-family:Haettenschweiler;
	panose-1:2 11 7 6 4 9 2 6 2 4;}
@font-face
	{font-family:"High Tower Text";
	panose-1:2 4 5 2 5 5 6 3 3 3;}
@font-face
	{font-family:"Imprint MT Shadow";
	panose-1:4 2 6 5 6 3 3 3 2 2;}
@font-face
	{font-family:"Informal Roman";
	panose-1:3 6 4 2 3 4 6 11 2 4;}
@font-face
	{font-family:"Blackadder ITC";
	panose-1:4 2 5 5 5 16 7 2 13 2;}
@font-face
	{font-family:"Edwardian Script ITC";
	panose-1:3 3 3 2 4 7 7 13 8 4;}
@font-face
	{font-family:"Kristen ITC";
	panose-1:3 5 5 2 4 2 2 3 2 2;}
@font-face
	{font-family:Jokerman;
	panose-1:4 9 6 5 6 13 6 2 7 2;}
@font-face
	{font-family:"Juice ITC";
	panose-1:4 4 4 3 4 10 2 2 2 2;}
@font-face
	{font-family:"Kunstler Script";
	panose-1:3 3 4 2 2 6 7 13 13 6;}
@font-face
	{font-family:"Wide Latin";
	panose-1:2 10 10 7 5 5 5 2 4 4;}
@font-face
	{font-family:"Lucida Bright";
	panose-1:2 4 6 2 5 5 5 2 3 4;}
@font-face
	{font-family:"Lucida Calligraphy";
	panose-1:3 1 1 1 1 1 1 1 1 1;}
@font-face
	{font-family:"Lucida Fax";
	panose-1:2 6 6 2 5 5 5 2 2 4;}
@font-face
	{font-family:"Lucida Handwriting";
	panose-1:3 1 1 1 1 1 1 1 1 1;}
@font-face
	{font-family:"Lucida Sans";
	panose-1:2 11 6 2 3 5 4 2 2 4;}
@font-face
	{font-family:"Lucida Sans Typewriter";
	panose-1:2 11 5 9 3 5 4 3 2 4;}
@font-face
	{font-family:Magneto;
	panose-1:4 3 8 5 5 8 2 2 13 2;}
@font-face
	{font-family:"Maiandra GD";
	panose-1:2 14 5 2 3 3 8 2 2 4;}
@font-face
	{font-family:"Matura MT Script Capitals";
	panose-1:3 2 8 2 6 6 2 7 2 2;}
@font-face
	{font-family:Mistral;
	panose-1:3 9 7 2 3 4 7 2 4 3;}
@font-face
	{font-family:"Modern No\. 20";
	panose-1:2 7 7 4 7 5 5 2 3 3;}
@font-face
	{font-family:"Monotype Corsiva";
	panose-1:3 1 1 1 1 2 1 1 1 1;}
@font-face
	{font-family:"Niagara Engraved";
	panose-1:4 2 5 2 7 7 3 3 2 2;}
@font-face
	{font-family:"Niagara Solid";
	panose-1:4 2 5 2 7 7 2 2 2 2;}
@font-face
	{font-family:"OCR A Extended";
	panose-1:2 1 5 9 2 1 2 1 3 3;}
@font-face
	{font-family:"Old English Text MT";
	panose-1:3 4 9 2 4 5 8 3 8 6;}
@font-face
	{font-family:Onyx;
	panose-1:4 5 6 2 8 7 2 2 2 3;}
@font-face
	{font-family:"MS Outlook";
	panose-1:5 1 1 0 1 0 0 0 0 0;}
@font-face
	{font-family:"Palace Script MT";
	panose-1:3 3 3 2 2 6 7 12 11 5;}
@font-face
	{font-family:Papyrus;
	panose-1:3 7 5 2 6 5 2 3 2 5;}
@font-face
	{font-family:Parchment;
	panose-1:3 4 6 2 4 7 8 4 8 4;}
@font-face
	{font-family:Perpetua;
	panose-1:2 2 5 2 6 4 1 2 3 3;}
@font-face
	{font-family:"Perpetua Titling MT";
	panose-1:2 2 5 2 6 5 5 2 8 4;}
@font-face
	{font-family:Playbill;
	panose-1:4 5 6 3 10 6 2 2 2 2;}
@font-face
	{font-family:"Poor Richard";
	panose-1:2 8 5 2 5 5 5 2 7 2;}
@font-face
	{font-family:Pristina;
	panose-1:3 6 4 2 4 4 6 8 2 4;}
@font-face
	{font-family:"Rage Italic";
	panose-1:3 7 5 2 4 5 7 7 3 4;}
@font-face
	{font-family:Ravie;
	panose-1:4 4 8 5 5 8 9 2 6 2;}
@font-face
	{font-family:"MS Reference Sans Serif";
	panose-1:2 11 6 4 3 5 4 4 2 4;}
@font-face
	{font-family:"MS Reference Specialty";
	panose-1:5 0 5 0 0 0 0 0 0 0;}
@font-face
	{font-family:"Rockwell Condensed";
	panose-1:2 6 6 3 5 4 5 2 1 4;}
@font-face
	{font-family:Rockwell;
	panose-1:2 6 6 3 2 2 5 2 4 3;}
@font-face
	{font-family:"Rockwell Extra Bold";
	panose-1:2 6 9 3 4 5 5 2 4 3;}
@font-face
	{font-family:"Script MT Bold";
	panose-1:3 4 6 2 4 6 7 8 9 4;}
@font-face
	{font-family:"Showcard Gothic";
	panose-1:4 2 9 4 2 1 2 2 6 4;}
@font-face
	{font-family:"Snap ITC";
	panose-1:4 4 10 7 6 10 2 2 2 2;}
@font-face
	{font-family:Stencil;
	panose-1:4 4 9 5 13 8 2 2 4 4;}
@font-face
	{font-family:"Tw Cen MT";
	panose-1:2 11 6 2 2 1 4 2 6 3;}
@font-face
	{font-family:"Tw Cen MT Condensed";
	panose-1:2 11 6 6 2 1 4 2 2 3;}
@font-face
	{font-family:"Tw Cen MT Condensed Extra Bold";
	panose-1:2 11 8 3 2 2 2 2 2 4;}
@font-face
	{font-family:"Tempus Sans ITC";
	panose-1:4 2 4 4 3 13 7 2 2 2;}
@font-face
	{font-family:"Viner Hand ITC";
	panose-1:3 7 5 2 3 5 2 2 2 3;}
@font-face
	{font-family:Vivaldi;
	panose-1:3 2 6 2 5 5 6 9 8 4;}
@font-face
	{font-family:"Vladimir Script";
	panose-1:3 5 4 2 4 4 7 7 3 5;}
@font-face
	{font-family:"Wingdings 2";
	panose-1:5 2 1 2 1 5 7 7 7 7;}
@font-face
	{font-family:"Wingdings 3";
	panose-1:5 4 1 2 1 8 7 7 7 7;}
@font-face
	{font-family:AngsanaUPC;}
@font-face
	{font-family:CordiaUPC;}
@font-face
	{font-family:Abadi;}
@font-face
	{font-family:"Abadi Extra Light";}
@font-face
	{font-family:Aharoni;}
@font-face
	{font-family:Aldhabi;}
@font-face
	{font-family:Aparajita;}
@font-face
	{font-family:"Arabic Typesetting";}
@font-face
	{font-family:"Arial Nova";}
@font-face
	{font-family:"Arial Nova Cond";}
@font-face
	{font-family:"Arial Nova Cond Light";}
@font-face
	{font-family:"Arial Nova Light";}
@font-face
	{font-family:"Avenir Next LT Pro";}
@font-face
	{font-family:"Avenir Next LT Pro Light";}
@font-face
	{font-family:BatangChe;}
@font-face
	{font-family:Bembo;}
@font-face
	{font-family:Biome;}
@font-face
	{font-family:"Biome Light";}
@font-face
	{font-family:"Browallia New";}
@font-face
	{font-family:BrowalliaUPC;}
@font-face
	{font-family:Cavolini;}
@font-face
	{font-family:Dante;}
@font-face
	{font-family:DaunPenh;}
@font-face
	{font-family:David;}
@font-face
	{font-family:Daytona;}
@font-face
	{font-family:"Daytona Condensed";}
@font-face
	{font-family:"Daytona Condensed Light";}
@font-face
	{font-family:"Daytona Light";}
@font-face
	{font-family:"DengXian Light";}
@font-face
	{font-family:DilleniaUPC;}
@font-face
	{font-family:DokChampa;}
@font-face
	{font-family:DotumChe;}
@font-face
	{font-family:"Elephant Pro";}
@font-face
	{font-family:EucrosiaUPC;}
@font-face
	{font-family:Euphemia;}
@font-face
	{font-family:FangSong;}
@font-face
	{font-family:FrankRuehl;}
@font-face
	{font-family:FreesiaUPC;}
@font-face
	{font-family:"Georgia Pro";}
@font-face
	{font-family:"Georgia Pro Black";}
@font-face
	{font-family:"Georgia Pro Cond";}
@font-face
	{font-family:"Georgia Pro Cond Black";}
@font-face
	{font-family:"Georgia Pro Cond Light";}
@font-face
	{font-family:"Georgia Pro Cond Semibold";}
@font-face
	{font-family:"Georgia Pro Light";}
@font-face
	{font-family:"Georgia Pro Semibold";}
@font-face
	{font-family:"Gill Sans Nova";}
@font-face
	{font-family:"Gill Sans Nova Cond";}
@font-face
	{font-family:"Gill Sans Nova Cond Lt";}
@font-face
	{font-family:"Gill Sans Nova Cond Ultra Bold";}
@font-face
	{font-family:"Gill Sans Nova Cond XBd";}
@font-face
	{font-family:"Gill Sans Nova Light";}
@font-face
	{font-family:"Gill Sans Nova Ultra Bold";}
@font-face
	{font-family:Gisha;}
@font-face
	{font-family:Grotesque;}
@font-face
	{font-family:"Grotesque Light";}
@font-face
	{font-family:GulimChe;}
@font-face
	{font-family:Gungsuh;}
@font-face
	{font-family:GungsuhChe;}
@font-face
	{font-family:"Hadassah Friedlaender";}
@font-face
	{font-family:HGGothicE;}
@font-face
	{font-family:HGMaruGothicMPRO;}
@font-face
	{font-family:HGMinchoE;}
@font-face
	{font-family:HGPGothicE;}
@font-face
	{font-family:HGPMinchoE;}
@font-face
	{font-family:HGPSoeiKakugothicUB;}
@font-face
	{font-family:HGSGothicE;}
@font-face
	{font-family:HGSMinchoE;}
@font-face
	{font-family:HGSoeiKakugothicUB;}
@font-face
	{font-family:HGSSoeiKakugothicUB;}
@font-face
	{font-family:IrisUPC;}
@font-face
	{font-family:"Iskoola Pota";}
@font-face
	{font-family:JasmineUPC;}
@font-face
	{font-family:KaiTi;}
@font-face
	{font-family:Kalinga;}
@font-face
	{font-family:Kartika;}
@font-face
	{font-family:"Khmer UI";}
@font-face
	{font-family:Kigelia;}
@font-face
	{font-family:"Kigelia Arabic";}
@font-face
	{font-family:"Kigelia Arabic Light";}
@font-face
	{font-family:"Kigelia Light";}
@font-face
	{font-family:KodchiangUPC;}
@font-face
	{font-family:Kokila;}
@font-face
	{font-family:"Lao UI";}
@font-face
	{font-family:Leelawadee;}
@font-face
	{font-family:"Levenim MT";}
@font-face
	{font-family:LilyUPC;}
@font-face
	{font-family:"Mangal Pro";}
@font-face
	{font-family:Meiryo;}
@font-face
	{font-family:"Meiryo UI";}
@font-face
	{font-family:"Microsoft GothicNeo";}
@font-face
	{font-family:"Microsoft GothicNeo Light";}
@font-face
	{font-family:"Microsoft Uighur";}
@font-face
	{font-family:MingLiU_HKSCS;}
@font-face
	{font-family:Miriam;}
@font-face
	{font-family:"Miriam Fixed";}
@font-face
	{font-family:"Modern Love";}
@font-face
	{font-family:"Modern Love Caps";}
@font-face
	{font-family:"Modern Love Grunge";}
@font-face
	{font-family:MoolBoran;}
@font-face
	{font-family:"MS PMincho";}
@font-face
	{font-family:"MT Extra";}
@font-face
	{font-family:Narkisim;}
@font-face
	{font-family:"Neue Haas Grotesk Text Pro";}
@font-face
	{font-family:"News Gothic MT";}
@font-face
	{font-family:Nyala;}
@font-face
	{font-family:OCRB;}
@font-face
	{font-family:"Plantagenet Cherokee";}
@font-face
	{font-family:Posterama;}
@font-face
	{font-family:"Quire Sans";}
@font-face
	{font-family:"Quire Sans Light";}
@font-face
	{font-family:"Quire Sans Pro Light";}
@font-face
	{font-family:"Rockwell Light";}
@font-face
	{font-family:"Rockwell Nova";}
@font-face
	{font-family:"Rockwell Nova Cond";}
@font-face
	{font-family:"Rockwell Nova Cond Light";}
@font-face
	{font-family:"Rockwell Nova Extra Bold";}
@font-face
	{font-family:"Rockwell Nova Light";}
@font-face
	{font-family:Rod;}
@font-face
	{font-family:"Sabon Next LT";}
@font-face
	{font-family:"Sagona Book";}
@font-face
	{font-family:"Sagona ExtraLight";}
@font-face
	{font-family:"Sakkal Majalla";}
@font-face
	{font-family:"Sanskrit Text";}
@font-face
	{font-family:Selawik;}
@font-face
	{font-family:"Selawik Light";}
@font-face
	{font-family:"Selawik Semibold";}
@font-face
	{font-family:"Shonar Bangla";}
@font-face
	{font-family:"Simplified Arabic";}
@font-face
	{font-family:"Simplified Arabic Fixed";}
@font-face
	{font-family:"Sitka Banner Semibold";}
@font-face
	{font-family:"Sitka Display Semibold";}
@font-face
	{font-family:"Sitka Heading Semibold";}
@font-face
	{font-family:"Sitka Small Semibold";}
@font-face
	{font-family:"Sitka Subheading Semibold";}
@font-face
	{font-family:"Sitka Text Semibold";}
@font-face
	{font-family:"Source Sans Pro";}
@font-face
	{font-family:"Source Sans Pro Black";}
@font-face
	{font-family:"Source Sans Pro ExtraLight";}
@font-face
	{font-family:"Source Sans Pro Light";}
@font-face
	{font-family:"Source Sans Pro SemiBold";}
@font-face
	{font-family:"Speak Pro";}
@font-face
	{font-family:"Speak Pro Light";}
@font-face
	{font-family:STCaiyun;}
@font-face
	{font-family:STFangsong;}
@font-face
	{font-family:STHupo;}
@font-face
	{font-family:STKaiti;}
@font-face
	{font-family:STXihei;}
@font-face
	{font-family:STXingkai;}
@font-face
	{font-family:STXinwei;}
@font-face
	{font-family:STZhongsong;}
@font-face
	{font-family:"TH SarabunPSK";}
@font-face
	{font-family:"The Hand";}
@font-face
	{font-family:"The Hand Black";}
@font-face
	{font-family:"The Hand Extrablack";}
@font-face
	{font-family:"The Hand Light";}
@font-face
	{font-family:"The Serif Hand";}
@font-face
	{font-family:"The Serif Hand Black";}
@font-face
	{font-family:"The Serif Hand Extrablack";}
@font-face
	{font-family:"The Serif Hand Light";}
@font-face
	{font-family:"Tisa Offc Serif Pro";}
@font-face
	{font-family:"Tisa Offc Serif Pro Thin";}
@font-face
	{font-family:"Trade Gothic Next";}
@font-face
	{font-family:"Trade Gothic Next Cond";}
@font-face
	{font-family:"Trade Gothic Next Cond Hv";}
@font-face
	{font-family:"Trade Gothic Next Heavy";}
@font-face
	{font-family:"Trade Gothic Next Light";}
@font-face
	{font-family:"Traditional Arabic";}
@font-face
	{font-family:"UD Digi Kyokasho N-B";}
@font-face
	{font-family:"UD Digi Kyokasho N-R";}
@font-face
	{font-family:"UD Digi Kyokasho NK-B";}
@font-face
	{font-family:"UD Digi Kyokasho NK-R";}
@font-face
	{font-family:"UD Digi Kyokasho NP-B";}
@font-face
	{font-family:"UD Digi Kyokasho NP-R";}
@font-face
	{font-family:Univers;}
@font-face
	{font-family:"Univers Condensed";}
@font-face
	{font-family:"Univers Condensed Light";}
@font-face
	{font-family:"Univers Light";}
@font-face
	{font-family:"Urdu Typesetting";}
@font-face
	{font-family:Utsaah;}
@font-face
	{font-family:Vani;}
@font-face
	{font-family:"Verdana Pro";}
@font-face
	{font-family:"Verdana Pro Black";}
@font-face
	{font-family:"Verdana Pro Cond";}
@font-face
	{font-family:"Verdana Pro Cond Black";}
@font-face
	{font-family:"Verdana Pro Cond Light";}
@font-face
	{font-family:"Verdana Pro Cond SemiBold";}
@font-face
	{font-family:"Verdana Pro Light";}
@font-face
	{font-family:"Verdana Pro SemiBold";}
@font-face
	{font-family:Vijaya;}
@font-face
	{font-family:"Walbaum Display";}
@font-face
	{font-family:"Walbaum Display Heavy";}
@font-face
	{font-family:"Walbaum Display Light";}
@font-face
	{font-family:"Walbaum Display SemiBold";}
@font-face
	{font-family:"Walbaum Heading";}
@font-face
	{font-family:"Walbaum Text";}
@font-face
	{font-family:"Yu Mincho";}
@font-face
	{font-family:"Yu Mincho Demibold";}
@font-face
	{font-family:"Yu Mincho Light";}
@font-face
	{font-family:"TimesNewRoman\,Italic";
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:TimesNewRoman;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"Arial\,Italic";
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:TimesNewRomanPSMT;}
@font-face
	{font-family:"Times New Roman Bold";
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:PraxisCom-Regular;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"Arial Bold";
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:EUAlbertina;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:Times;
	panose-1:2 2 6 3 5 4 5 2 3 4;}
@font-face
	{font-family:"\@TimesNewRoman\,Italic";
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"\@Arial\,Italic";
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"\@MS Mincho";
	panose-1:2 2 6 9 4 2 5 8 3 4;}
@font-face
	{font-family:"\@Batang";
	panose-1:2 3 6 0 0 1 1 1 1 1;}
@font-face
	{font-family:"\@BatangChe";}
@font-face
	{font-family:"\@Gungsuh";}
@font-face
	{font-family:"\@GungsuhChe";}
@font-face
	{font-family:"\@DengXian Light";}
@font-face
	{font-family:"\@Gulim";
	panose-1:2 11 6 0 0 1 1 1 1 1;}
@font-face
	{font-family:"\@GulimChe";}
@font-face
	{font-family:"\@Dotum";
	panose-1:2 11 6 0 0 1 1 1 1 1;}
@font-face
	{font-family:"\@DotumChe";}
@font-face
	{font-family:"\@Meiryo";}
@font-face
	{font-family:"\@Meiryo UI";}
@font-face
	{font-family:"\@MingLiU";
	panose-1:2 1 6 9 0 1 1 1 1 1;}
@font-face
	{font-family:"\@PMingLiU";
	panose-1:2 1 6 1 0 1 1 1 1 1;}
@font-face
	{font-family:"\@MingLiU_HKSCS";}
@font-face
	{font-family:"\@MS PMincho";}
@font-face
	{font-family:"\@STXingkai";}
@font-face
	{font-family:"\@STZhongsong";}
@font-face
	{font-family:"\@Yu Mincho";}
@font-face
	{font-family:"\@Arial Unicode MS";
	panose-1:2 11 6 4 2 2 2 2 2 4;}
@font-face
	{font-family:Times-Roman;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:CourierNewPSMT;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"SAS Monospace";}
@font-face
	{font-family:"Bookshelf Symbol 3";}
@font-face
	{font-family:Goudy;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:Garamond-Italic;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
 /* Style Definitions */
 p.MsoNormal, li.MsoNormal, div.MsoNormal
	{margin:0in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
h1
	{margin:0in;
	page-break-after:avoid;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
h6
	{margin-top:12.0pt;
	margin-right:0in;
	margin-bottom:3.0pt;
	margin-left:0in;
	text-align:justify;
	font-size:11.0pt;
	font-family:"Arial",sans-serif;
	font-weight:normal;
	font-style:italic;}
p.MsoFootnoteText, li.MsoFootnoteText, div.MsoFootnoteText
	{margin:0in;
	text-align:justify;
	font-size:10.0pt;
	font-family:"Times New Roman",serif;}
p.MsoCommentText, li.MsoCommentText, div.MsoCommentText
	{margin:0in;
	line-height:13.0pt;
	font-size:10.0pt;
	font-family:"Times New Roman",serif;}
p.MsoHeader, li.MsoHeader, div.MsoHeader
	{margin:0in;
	font-size:10.0pt;
	font-family:"Arial",sans-serif;}
p.MsoFooter, li.MsoFooter, div.MsoFooter
	{mso-style-link:"Footer Char";
	margin:0in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoCaption, li.MsoCaption, div.MsoCaption
	{margin:0in;
	text-align:center;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
span.MsoFootnoteReference
	{vertical-align:super;}
p.MsoEndnoteText, li.MsoEndnoteText, div.MsoEndnoteText
	{margin:0in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoBodyText, li.MsoBodyText, div.MsoBodyText
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:0in;
	font-size:10.0pt;
	font-family:"Times New Roman",serif;}
p.MsoDate, li.MsoDate, div.MsoDate
	{margin:0in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoBodyText2, li.MsoBodyText2, div.MsoBodyText2
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:28.35pt;
	punctuation-wrap:simple;
	text-autospace:none;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
a:link, span.MsoHyperlink
	{color:#4013F2;
	text-decoration:none none;}
a:visited, span.MsoHyperlinkFollowed
	{color:purple;
	text-decoration:underline;}
p.MsoDocumentMap, li.MsoDocumentMap, div.MsoDocumentMap
	{margin:0in;
	background:navy;
	font-size:10.0pt;
	font-family:"Tahoma",sans-serif;}
p.MsoPlainText, li.MsoPlainText, div.MsoPlainText
	{mso-style-link:"Plain Text Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:0in;
	font-size:10.0pt;
	font-family:"Courier New";}
p.MsoCommentSubject, li.MsoCommentSubject, div.MsoCommentSubject
	{margin:0in;
	font-size:10.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
p.MsoAcetate, li.MsoAcetate, div.MsoAcetate
	{margin:0in;
	font-size:8.0pt;
	font-family:"Tahoma",sans-serif;}
p.MsoRMPane, li.MsoRMPane, div.MsoRMPane
	{margin:0in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListParagraph, li.MsoListParagraph, div.MsoListParagraph
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:35.4pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
span.PlainTextChar
	{mso-style-name:"Plain Text Char";
	mso-style-link:"Plain Text";
	font-family:"Courier New";}
p.SubSectionHeadings, li.SubSectionHeadings, div.SubSectionHeadings
	{mso-style-name:"Sub Section Headings";
	margin:0in;
	page-break-after:avoid;
	font-size:10.0pt;
	font-family:"Helvetica",sans-serif;
	font-style:italic;}
p.Body, li.Body, div.Body
	{mso-style-name:Body;
	mso-style-link:"Body Char";
	margin:0in;
	text-align:justify;
	text-indent:.2in;
	font-size:10.0pt;
	font-family:"Helvetica",sans-serif;}
span.BodyChar
	{mso-style-name:"Body Char";
	mso-style-link:Body;
	font-family:"Helvetica",sans-serif;}
p.AllText, li.AllText, div.AllText
	{mso-style-name:AllText;
	margin-top:6.0pt;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:0in;
	text-align:justify;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
span.AllTextChar
	{mso-style-name:"AllText Char";}
p.NormalArial, li.NormalArial, div.NormalArial
	{mso-style-name:"Normal + Arial\,11 pt\,Justified\,Left\:  0\.5\0022\,After\:  11 pt";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:.5in;
	text-align:justify;
	font-size:11.0pt;
	font-family:"Arial",sans-serif;}
span.NormalArialChar
	{mso-style-name:"Normal + Arial Char\,11 pt Char\,Justified Char\,Left\:  0\.5\0022 Char\,After\:  11 pt Char";
	font-family:"Arial",sans-serif;}
span.t101
	{mso-style-name:t101;
	font-family:"Arial",sans-serif;
	font-variant:normal !important;
	font-weight:normal;
	font-style:normal;}
p.BalloonText2, li.BalloonText2, div.BalloonText2
	{mso-style-name:"Balloon Text2";
	margin:0in;
	font-size:8.0pt;
	font-family:"Tahoma",sans-serif;}
p.BalloonText1, li.BalloonText1, div.BalloonText1
	{mso-style-name:"Balloon Text1";
	margin:0in;
	font-size:8.0pt;
	font-family:"Tahoma",sans-serif;}
p.CommentSubject1, li.CommentSubject1, div.CommentSubject1
	{mso-style-name:"Comment Subject1";
	margin:0in;
	font-size:10.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
p.CommentSubject2, li.CommentSubject2, div.CommentSubject2
	{mso-style-name:"Comment Subject2";
	margin:0in;
	font-size:10.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
p.Standard, li.Standard, div.Standard
	{mso-style-name:Standard;
	margin:0in;
	text-autospace:none;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.BodytextAgency, li.BodytextAgency, div.BodytextAgency
	{mso-style-name:"Body text \(Agency\)";
	mso-style-link:"Body text \(Agency\) Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:7.0pt;
	margin-left:0in;
	line-height:14.0pt;
	font-size:9.0pt;
	font-family:"Verdana",sans-serif;}
span.BodytextAgencyChar
	{mso-style-name:"Body text \(Agency\) Char";
	mso-style-link:"Body text \(Agency\)";
	font-family:"Verdana",sans-serif;}
p.Default, li.Default, div.Default
	{mso-style-name:Default;
	margin:0in;
	text-autospace:none;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;
	color:black;}
p.TitleA, li.TitleA, div.TitleA
	{mso-style-name:"Title A";
	margin:0in;
	text-align:center;
	text-autospace:none;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
p.TitleB, li.TitleB, div.TitleB
	{mso-style-name:"Title B";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:28.35pt;
	text-indent:-28.35pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
span.FooterChar
	{mso-style-name:"Footer Char";
	mso-style-link:Footer;}
span.msoIns
	{mso-style-name:"";
	text-decoration:underline;
	color:teal;}
span.msoDel
	{mso-style-name:"";
	text-decoration:line-through;
	color:red;}
 /* Page Definitions */
 @page WordSection1
	{size:595.35pt 842.0pt;
	margin:56.7pt 70.9pt 56.7pt 70.9pt;}
div.WordSection1
	{page:WordSection1;}
 /* List Definitions */
 ol
	{margin-bottom:0in;}
ul
	{margin-bottom:0in;}
-->
</style>

</head>

<body lang=EN-US link="#4013F2" vlink=purple style='word-wrap:break-word'>

<div class=WordSection1>

<p class=MsoNormal style='text-autospace:none'><a name="OLE_LINK6"><b><span
lang=EN-GB style='color:black'>&nbsp;</span></b></a></p>

<p class=MsoNormal style='text-autospace:none'><b><span lang=EN-GB
style='color:black'>&nbsp;</span></b></p>

<p class=MsoNormal style='text-autospace:none'><b><span lang=EN-GB
style='color:black'>&nbsp;</span></b></p>

<p class=MsoNormal style='text-autospace:none'><b><span lang=EN-GB
style='color:black'>&nbsp;</span></b></p>

<p class=MsoNormal style='text-autospace:none'><b><span lang=EN-GB
style='color:black'>&nbsp;</span></b></p>

<p class=MsoNormal style='text-autospace:none'><b><span lang=EN-GB
style='color:black'>&nbsp;</span></b></p>

<p class=MsoNormal style='text-autospace:none'><b><span lang=EN-GB
style='color:black'>&nbsp;</span></b></p>

<p class=MsoNormal style='text-autospace:none'><b><span lang=EN-GB
style='color:black'>&nbsp;</span></b></p>

<p class=MsoNormal style='text-autospace:none'><b><span lang=EN-GB
style='color:black'>&nbsp;</span></b></p>

<p class=MsoNormal style='text-autospace:none'><b><span lang=EN-GB
style='color:black'>&nbsp;</span></b></p>

<p class=MsoNormal style='text-autospace:none'><b><span lang=EN-GB
style='color:black'>&nbsp;</span></b></p>

<p class=MsoNormal style='text-autospace:none'><b><span lang=EN-GB
style='color:black'>&nbsp;</span></b></p>

<p class=MsoNormal style='text-autospace:none'><b><span lang=EN-GB
style='color:black'>&nbsp;</span></b></p>

<p class=MsoNormal style='text-autospace:none'><b><span lang=EN-GB
style='color:black'>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center;text-autospace:none'><b><span
lang=EN-GB style='color:black'>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center;text-autospace:none'><b><span
lang=EN-GB style='color:black'>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center;text-autospace:none'><b><span
lang=EN-GB style='color:black'>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center;text-autospace:none'><b><span
lang=EN-GB style='color:black'>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center;text-autospace:none'><b><span
lang=EN-GB style='color:black'>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center;text-autospace:none'><b><span
lang=EN-GB style='color:black'>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center;text-autospace:none'><b><span
lang=EN-GB style='color:black'>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center;text-autospace:none'><b><span
lang=EN-GB style='color:black'>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center;text-autospace:none'><b><span
lang=EN-GB style='color:black'>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center;text-autospace:none'><b><span
lang=EN-GB style='color:black'>ANNEX I</span></b></p>

<p class=MsoNormal align=center style='text-align:center;text-autospace:none'><b><span
lang=EN-GB style='color:black'>&nbsp;</span></b></p>

<p class=TitleA><span lang=EN-GB>SUMMARY OF PRODUCT CHARACTERISTICS</span></p>

<b><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif;
color:black'><br clear=all style='page-break-before:always'>
</span></b>

<p class=MsoNormal style='text-autospace:none'><b><span lang=EN-GB
style='color:black'>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; NAME OF THE
MEDICINAL PRODUCT</span></b></p>

<p class=MsoNormal style='margin-right:7.9pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:7.9pt'><span lang=EN-GB>Gardasil,
suspension for injection.</span></p>

<p class=MsoNormal style='margin-right:7.9pt'><span lang=EN-GB>Gardasil,
suspension for injection in a pre-filled syringe.</span></p>

<p class=MsoNormal style='margin-right:7.9pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Human Papillomavirus Vaccine [Types&nbsp;6,
11, 16, 18] (Recombinant, adsorbed). </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><b><span lang=EN-GB
style='color:black'>2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; QUALITATIVE AND
QUANTITATIVE COMPOSITION</span></b></p>

<p class=MsoNormal style='text-autospace:none'><b><span lang=EN-GB
style='color:black'>&nbsp;</span></b></p>

<p class=MsoNormal><span lang=EN-GB>1 dose (0.5&nbsp;ml) contains
approximately:</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Human Papillomavirus<sup>1</sup> Type 6 L1
protein<span class=MsoFootnoteReference>2,3</span>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
20&nbsp;micrograms</span></p>

<p class=MsoNormal><span lang=EN-GB>Human Papillomavirus<sup>1</sup> Type 11 L1
protein<sup>2,3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</sup>40&nbsp;micrograms</span></p>

<p class=MsoNormal><span lang=EN-GB>Human Papillomavirus<sup>1</sup> Type 16 L1
protein<span class=MsoFootnoteReference>2,3</span>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
40&nbsp;micrograms</span></p>

<p class=MsoNormal><span lang=EN-GB>Human Papillomavirus<sup>1</sup> Type 18 L1
protein<sup>2,3</sup>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 20&nbsp;micrograms.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><sup><span lang=EN-GB>1</span></sup><span lang=EN-GB>Human
Papillomavirus = HPV.</span></p>

<p class=MsoNormal><sup><span lang=EN-GB>2</span></sup><span lang=EN-GB>L1
protein in the form of virus-like particles produced in yeast cells (<i>Saccharomyces
cerevisiae</i> CANADE&nbsp;3C&#8209;5 (Strain&nbsp;1895)) by recombinant DNA
technology. </span></p>

<p class=MsoNormal><sup><span lang=EN-GB>3</span></sup><span lang=EN-GB>adsorbed
on amorphous alumin<span style='color:black'>i</span>um hydroxyphosphate
sulphate adjuvant (0.225&nbsp;milligrams Al).</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>For<span
style='color:black'> a full list</span> of excipients, see section&nbsp;6.1.</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid'><b><span lang=EN-GB>3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; PHARMACEUTICAL <span
style='text-transform:uppercase'>form</span></span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid'><span lang=EN-GB style='text-transform:uppercase'>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:7.9pt'><span lang=EN-GB>Gardasil, suspension
for injection.</span></p>

<p class=MsoNormal style='margin-right:7.9pt'><span lang=EN-GB>Gardasil,
suspension for injection in a pre-filled syringe.</span></p>

<p class=MsoNormal style='margin-right:7.9pt'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>Prior to
agitation, Gardasil may appear as a clear liquid with a white precipitate.
After thorough agitation, it is a white, cloudy liquid.</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB
style='text-transform:uppercase'>4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Clinical
particulars</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB
style='text-transform:uppercase'>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid'><b><span lang=EN-GB>4.1&nbsp;&nbsp;&nbsp;&nbsp; Therapeutic indications</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><span
lang=EN-GB>Gardasil is a vaccine for use from the age of 9&nbsp;years for the
prevention of:</span></p>

<p class=MsoNormal style='margin-left:27.0pt;text-indent:-27.0pt;text-autospace:
none'><span lang=EN-GB>&#8211;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>premalignant genital lesions (cervical, vulvar
and vaginal), premalignant anal lesions, cervical cancers and anal cancers causally
related to certain oncogenic Human Papillomavirus (HPV) types</span></p>

<p class=MsoNormal style='margin-left:27.0pt;text-indent:-27.0pt;text-autospace:
none'><span lang=EN-GB>&#8211;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>genital warts (condyloma acuminata) causally
related to specific HPV types. </span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
style='color:black'>See sections&nbsp;4.4 and 5.1 for important information o</span><span
lang=EN-GB>n the data that support this indication.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>The use of
Gardasil should be in accordance with official recommendations.</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><b><span
lang=EN-GB style='color:black'>4.2&nbsp;&nbsp;&nbsp;&nbsp; Posology and method
of administration</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>Posology</span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><i><span lang=EN-GB>Individuals
9 to and including 13&nbsp;years of age </span></i></p>

<p class=MsoNormal><span lang=EN-GB>Gardasil can be administered according to a
2-dose schedule (0.5&nbsp;ml at 0, 6&nbsp;months) (see section&nbsp;5.1). </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>If the second vaccine dose is administered
earlier than 6&nbsp;months after the first dose, a third dose should always be
administered.</span></p>

<p class=Default><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Default><span lang=EN-GB style='font-size:11.0pt'>Alternatively,
Gardasil can be administered according to a 3-dose (0.5&nbsp;ml at 0, 2,
6&nbsp;months) schedule. The second dose should be administered at least one
month after the first dose and the third dose should be administered at least
3&nbsp;months after the second dose. All three doses should be given within a
1-year period. </span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><i><span lang=EN-GB>Individuals
14&nbsp;years of age and older</span></i></p>

<p class=MsoNormal><span lang=EN-GB>Gardasil should be administered according
to a 3-dose (0.5&nbsp;ml at 0, 2, 6&nbsp;months) schedule.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>The second dose should be administered at
least one month after the first dose and the third dose should be administered
at least 3&nbsp;months after the second dose. All three doses should be given
within a 1-year period.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>The use of Gardasil should be in accordance
with official recommendations.</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><i><span
lang=EN-GB>Paediatric population</span></i></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>The safety and
efficacy of </span><span lang=EN-GB>Gardasil in children below 9&nbsp;years of
age have not been established. No data are available (see section&nbsp;5.1).</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>It is recommended that individuals who
receive a first dose of Gardasil complete the vaccination course with Gardasil
(see section&nbsp;4.4).</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
style='color:black'>The need for a booster dose has not been established<i>.</i></span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>Method of
administration</span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>The vaccine should be administered by
intramuscular injection. The preferred site is the deltoid area of the upper
arm or in the higher anterolateral area of the thigh.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Gardasil must not be injected
intravascularly. Neither subcutaneous nor intradermal administration has been
studied.<b> </b>These methods of administration are not recommended (see
section&nbsp;6.6).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid'><b><span lang=EN-GB>4.3&nbsp;&nbsp;&nbsp;&nbsp; Contraindications</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-right:.9pt'><span lang=EN-GB>Hypersensitivity
to the active substances or to any of the excipients. </span></p>

<p class=MsoNormal style='margin-right:.9pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:.9pt'><span lang=EN-GB>Individuals who
develop symptoms indicative of hypersensitivity after receiving a dose of
Gardasil should not receive further doses of Gardasil.</span></p>

<p class=MsoNormal style='margin-right:.9pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:.9pt'><span lang=EN-GB>Administration of
</span><span lang=EN-GB>Gardasil should be postponed in individuals suffering
from an acute severe febrile illness. However, the presence of a minor
infection, such as a mild upper respiratory tract infection or low-grade fever,
is not a contraindication for immunisation.</span></p>

<p class=MsoNormal style='margin-right:.9pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><b><span
lang=EN-GB>4.4&nbsp;&nbsp;&nbsp;&nbsp; </span></b><b><span lang=EN-GB
style='color:black'>Special warnings and precautions for use</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>The decision to
vaccinate an individual should take into account the risk for previous HPV
exposure and potential benefit from vaccination.</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>As with all injectable vaccines, appropriate
medical treatment should always be readily available in case of rare
anaphylactic reactions following the administration of the vaccine.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=Body align=left style='text-align:left;text-indent:0in'><span
lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>Syncope
(fainting), sometimes associated with falling, can occur following, or even
before, any vaccination, especially in adolescents as a psychogenic response to
the needle injection. This can be accompanied by several neurological signs
such as transient visual disturbance, paraesthesia, and tonic-clonic limb
movements during recovery. Therefore, vaccinees should be observed for
approximately 15&nbsp;minutes after vaccine administration. It is important
that procedures are in place to avoid injury from faints.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>As with any vaccine, vaccination with </span><span
lang=EN-GB>Gardasil may not result in protection in all vaccine recipients. </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Gardasil </span><span lang=EN-GB>will only
protect against diseases that are caused by HPV types&nbsp;6, 11, 16 and 18 and
to a <a name="OLE_LINK2"></a><a name="OLE_LINK5">limited extent against
diseases caused by certain related HPV types (See section&nbsp;5.1). </a></span><span
lang=EN-GB>Therefore, appropriate precautions against sexually transmitted
diseases should continue to be used.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Gardasil is for prophylactic use only and
has no effect on active HPV infections or established clinical disease.
Gardasil has not been shown to have a therapeutic effect. The vaccine is
therefore, not indicated for treatment of cervical cancer, high-grade cervical,
vulvar, and vaginal dysplastic lesions or genital warts. It is also not
intended to prevent progression of other established HPV-related lesions.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Gardasil does not prevent lesions due to a
vaccine HPV type in individuals infected with that HPV type at the time of
vaccination (see section&nbsp;5.1).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>The use of Gardasil in
adult women should take into consideration the variability of HPV type
prevalence in different geographical areas. </span></p>

<p class=MsoNormal><span lang=EN-GB style='background:yellow'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Vaccination is not a substitute for routine
cervical screening. <a name="OLE_LINK4">Since no vaccine is 100% effective and </a></span><span
lang=EN-GB style='color:black'>Gardasil </span><span lang=EN-GB>will not
provide protection against every HPV type, or against existing HPV infections,
routine cervical screening remains critically important and should follow local
recommendations</span><span lang=EN-GB>.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Safety and immunogenicity of the vaccine
have been assessed in individuals aged from 7 to 12&nbsp;years who are known to
be infected with human immunodeficiency virus (HIV) (see section&nbsp;5.1).
Individuals with impaired immune responsiveness, due to either the use of
potent immunosuppressive therapy, a genetic defect, or other causes, may not
respond to the vaccine.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>This vaccine should be given with caution
to individuals with thrombocytopaenia or any coagulation disorder because
bleeding may occur following an intramuscular administration in these
individuals.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>Long-term follow-up
studies were conducted to determine the duration of protection. (see
section&nbsp;5.1).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>There are no safety, immunogenicity or
efficacy data to support change during vaccination with Gardasil to other HPV
vaccines which do not cover the same HPV types. Therefore, it is important that
the same vaccine should be prescribed for the whole dose regimen.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>4.5&nbsp;&nbsp;&nbsp;&nbsp; Interaction
with other medicinal products and other forms of interaction</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>In all clinical
trials, individuals who had received immunoglobulin or blood-derived products
during the 6&nbsp;months prior to the first vaccine dose were excluded. </span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>Use with
other vaccines </span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Administration of </span><span lang=EN-GB>Gardasil
at the same time (but, for injected vaccines, at a different injection site) as
hepatitis B (recombinant) vaccine did not interfere with the immune response to
the HPV types. The seroprotection rates (proportion of individuals reaching
seroprotective level anti-HBs <u>&gt;</u>10&nbsp;mIU/ml) were unaffected (96.5%
for concomitant vaccination and 97.5% for hepatitis B vaccine only). Anti-HBs
geometric mean antibody titres were lower on co-administration, but the
clinical significance of this observation is not known.<b><i> </i></b></span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>Gardasil may be
administered concomitantly with a combined booster vaccine containing
diphtheria (d) and tetanus (T) with either pertussis [acellular, component]
(ap) and/or poliomyelitis [inactivated] (IPV) (dTap, dT-IPV, dTap-IPV vaccines)
with no significant interference with antibody response to any of the
components of either vaccine. However, a trend of lower anti-HPV GMTs was
observed in the concomitant group. The clinical significance of this
observation is not known.&nbsp; This is based on the results from a clinical
trial in which a combined dTap-IPV vaccine was administered concomitantly with
the first dose of Gardasil. (see section&nbsp;4.8).</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>The concomitant
administration of Gardasil with vaccines other than the ones above has not been
studied.</span></p>

<p class=MsoNormal style='text-autospace:none'><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><u><span
lang=EN-GB>Use with hormonal contraceptives</span></u></p>

<p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><i><span
lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>In clinical
studies, 57.5% of women aged 16 to 26&nbsp;years and 31.2% of women aged 24 to
45&nbsp;years who received Gardasil used hormonal contraceptives during the
vaccination period. Use of hormonal contraceptives did not appear to affect the
immune response to <span style='color:black'>Gardasil.</span></span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>4.6&nbsp;&nbsp;&nbsp;&nbsp; Fertility,
pregnancy and lactation</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>Pregnancy</span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal><span lang=EN-GB>Specific studies of the vaccine in pregnant
women were not conducted. During the clinical development program, 3,819 women
(vaccine&nbsp;=&nbsp;1,894 vs. placebo&nbsp;=&nbsp;1,925) reported at least one
pregnancy. There were no significant differences in types of anomalies or
proportion of pregnancies with an adverse outcome in Gardasil and placebo
treated individuals. These data on pregnant women (more than 1000 exposed
outcomes) indicate no malformative nor feto/ neonatal toxicity.</span></p>

<p class=MsoNormal><span lang=EN-GB style='background:#E6E6E6'>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
style='color:black'>The data on </span><span lang=EN-GB>Gardasil<span
style='color:black'> administered during pregnancy did not indicate any safety
signal. However, these data are insufficient to recommend use of </span><span
style='color:black'>Gardasil during pregnancy. Vaccination should be postponed
until completion of pregnancy. </span></span></p>

<p class=MsoNormal><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>Breast-feeding</span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal><span lang=EN-GB>In breast-feeding mothers given Gardasil or
placebo during the vaccination period of the clinical trials the rates of
adverse reactions in the mother and the breast-fed infant were comparable
between the vaccination and the placebo groups. In addition, vaccine immunogenicity
was comparable among breast-feeding mothers and women who did not breast-feed
during the vaccine administration.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>Therefore, </span><span
lang=EN-GB>Gardasil can be used during breast-feeding.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>Fertility</span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal><span lang=EN-GB>Animal studies do not indicate direct or
indirect harmful effects with respect to reproductive toxicity (see
section&nbsp;5.3). No effects on male fertility were observed in rats (see
section&nbsp;5.3).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><b><span
lang=EN-GB style='color:black'>4.7&nbsp;&nbsp;&nbsp;&nbsp; Effects on ability
to drive and use machines</span></b></p>

<p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><b><span
lang=EN-GB style='color:black'>&nbsp;</span></b></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>No studies on the
effects on the ability to drive and use machines have been performed.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><b><span
lang=EN-GB style='color:black'>4.8&nbsp;&nbsp;&nbsp;&nbsp; Undesirable effects</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><b><i><span
lang=EN-GB>A. Summary of the safety profile</span></i></b></p>

<p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><b><i><span
lang=EN-GB>&nbsp;</span></i></b></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>In 7 clinical
trials (6 placebo-controlled), individuals were administered Gardasil or
placebo on the day of enrolment and approximately 2 and 6&nbsp;months thereafter.
<span style='color:black'>Few individuals (0.2%) discontinued due to adverse
reactions. Safety was evaluated in either the entire study population (6
studies) or in a predefined subset (one study) of the study population using
vaccination report card (VRC)-aided surveillance for 14&nbsp;days after each
injection of </span>Gardasil<span style='color:black'> or placebo. The
individuals who were monitored using VRC-aided surveillance included 10,088 individuals
(6,995 females 9 to 45&nbsp;years of age and 3,093 males 9 to 26&nbsp;years of
age at enrolment) who received </span>Gardasil<span style='color:black'> and
7,995 individuals (5,692 females and 2,303 males)</span><span style='color:
blue'> </span><span style='color:black'>who received placebo. </span></span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>The most common adverse
reactions observed were injection-site adverse reactions (77.1% of vaccinees
within 5&nbsp;days following any vaccination visit) and </span><span
lang=EN-GB style='color:black'>headache (16.6% of the vaccinees)</span><span
lang=EN-GB style='color:black'>. </span><span lang=EN-GB style='color:black'>These
adverse reactions usually were mild or moderate in intensity.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><b><i><span
lang=EN-GB>B. Tabulated summary of adverse reactions</span></i></b></p>

<p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><b><i><span
lang=EN-GB>&nbsp;</span></i></b></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>Clinical
Trials</span></b></p>

<p class=MsoNormal style='margin-right:-.05in'><span lang=EN-GB>Table&nbsp;1
presents vaccine-related adverse reactions which were observed among recipients
of Gardasil at a frequency of at least 1.0% and also at a greater frequency
than observed among placebo recipients. They are ranked under headings of
frequency using the following convention:</span></p>

<p class=MsoNormal style='margin-right:-.05in'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.05in'><span lang=EN-GB>[Very Common
(&#8805;1/10); Common (&#8805;1/100 to </span><span lang=EN-GB
style='font-family:Symbol'>&lt;</span><span lang=EN-GB>1/10); Uncommon
(&#8805;1/1,000 to </span><span lang=EN-GB style='font-family:Symbol'>&lt;</span><span
lang=EN-GB>1/100); Rare (&#8805;1/10,000 to </span><span lang=EN-GB
style='font-family:Symbol'>&lt;</span><span lang=EN-GB>1/1,000); Very Rare (</span><span
lang=EN-GB style='font-family:Symbol'>&lt;</span><span lang=EN-GB>1/10,000)]</span></p>

<p class=MsoNormal style='text-autospace:none'><b><i><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></i></b></p>

<p class=Standard style='page-break-after:avoid'><b><span lang=EN-GB
style='font-size:11.0pt'>Post-Marketing Experience</span></b></p>

<p class=MsoNormal style='margin-right:-.05in'><span lang=EN-GB>Table&nbsp;1
also includes additional adverse events which have been spontaneously reported
during the post-marketing use of Gardasil<sup><span style='position:relative;
top:-5.0pt'> </span></sup>worldwide. Because these events are reported
voluntarily from a population of uncertain size, it is not always possible to
reliably estimate their frequency or establish a causal relationship to vaccine
exposure. Consequently, the frequency of these adverse events is qualified as
&quot;not known&quot;.</span></p>

<p class=MsoNormal style='margin-left:.25in'><b><span lang=EN-GB
style='color:black'>&nbsp;</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><i><span lang=EN-GB
style='color:black'>Table&nbsp;1: Adverse Events Following Administration of
Gardasil from Clinical Trials and Post-Marketing Surveillance</span></i></p>

<div align=center>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0 width="100%"
 style='width:100.0%;border-collapse:collapse;border:none'>
 <tr style='height:26.45pt'>
  <td width="34%" valign=top style='width:34.44%;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:26.45pt'>
  <p class=MsoNormal style='margin-right:-.05in'><b><span lang=EN-GB
  style='color:black'>System Organ Class</span></b></p>
  </td>
  <td width="16%" valign=top style='width:16.78%;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt;height:26.45pt'>
  <p class=MsoNormal style='margin-right:-.05in'><b><span lang=EN-GB
  style='color:black'>Frequency</span></b></p>
  </td>
  <td width="48%" valign=top style='width:48.78%;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt;height:26.45pt'>
  <p class=MsoNormal style='margin-right:-.05in'><b><span lang=EN-GB
  style='color:black'>Adverse Events</span></b></p>
  </td>
  <td style='height:26.45pt;border:none' width=0 height=35></td>
 </tr>
 <tr style='height:12.75pt'>
  <td width="34%" valign=top style='width:34.44%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:12.75pt'>
  <p class=MsoNormal align=center style='margin-right:-.05in;text-align:center'><span
  lang=EN-GB style='color:black'>Infections and infestations</span></p>
  </td>
  <td width="16%" valign=top style='width:16.78%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:12.75pt'>
  <p class=MsoNormal align=center style='margin-right:-.05in;text-align:center'><span
  lang=EN-GB style='color:black'>Not known</span></p>
  </td>
  <td width="48%" valign=top style='width:48.78%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:12.75pt'>
  <p class=MsoNormal style='margin-right:-.05in'><span lang=EN-GB
  style='color:black'>Injection-site cellulitis *</span></p>
  </td>
  <td style='height:12.75pt;border:none' width=0 height=17></td>
 </tr>
 <tr style='height:12.75pt'>
  <td width="34%" rowspan=2 valign=top style='width:34.44%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:12.75pt'>
  <p class=MsoNormal align=center style='margin-right:-.05in;text-align:center'><span
  lang=EN-GB style='color:black'>Blood and lymphatic system disorders</span></p>
  </td>
  <td width="16%" rowspan=2 valign=top style='width:16.78%;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:12.75pt'>
  <p class=MsoNormal align=center style='margin-right:-.05in;text-align:center'><span
  lang=EN-GB style='color:black'>Not known</span></p>
  </td>
  <td width="48%" rowspan=2 valign=top style='width:48.78%;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:12.75pt'>
  <p class=MsoNormal style='margin-right:-.05in'><span lang=EN-GB
  style='color:black'>Idiopathic thrombocytopenic purpura*, lymphadenopathy*</span></p>
  </td>
  <td style='height:12.75pt;border:none' width=0 height=17></td>
 </tr>
 <tr style='height:12.75pt'>
  <td style='height:12.75pt;border:none' width=0 height=17></td>
 </tr>
 <tr>
  <td width="34%" valign=top style='width:34.44%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='margin-right:-.05in;text-align:center'><span
  lang=EN-GB style='color:black'>Immune system disorders</span></p>
  </td>
  <td width="16%" valign=top style='width:16.78%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='margin-right:-.05in;text-align:center'><span
  lang=EN-GB style='color:black'>Not known</span></p>
  </td>
  <td width="48%" valign=top style='width:48.78%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-right:-.05in'><span lang=EN-GB
  style='color:black'>Hypersensitivity reactions including
  anaphylactic/anaphylactoid reactions*</span></p>
  </td>
  <td style='border:none' width=0><p class='MsoNormal'>&nbsp;</td>
 </tr>
 <tr>
  <td width="34%" rowspan=2 valign=top style='width:34.44%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='margin-right:-.05in;text-align:center'><span
  lang=EN-GB style='color:black'>Nervous system disorders</span></p>
  </td>
  <td width="16%" valign=top style='width:16.78%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='margin-right:-.05in;text-align:center'><span
  lang=EN-GB style='color:black'>Very common</span></p>
  </td>
  <td width="48%" valign=top style='width:48.78%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-right:-.05in'><span lang=EN-GB
  style='color:black'>Headache</span></p>
  </td>
  <td style='border:none' width=0><p class='MsoNormal'>&nbsp;</td>
 </tr>
 <tr>
  <td width="16%" valign=top style='width:16.78%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='margin-right:-.05in;text-align:center'><span
  lang=EN-GB style='color:black'>Not known</span></p>
  </td>
  <td width="48%" valign=top style='width:48.78%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-right:-.05in'><span lang=EN-GB
  style='color:black'>Acute disseminated encephalomyelitis*, Dizziness<sup>1 </sup>*,
  Guillain-Barr&eacute; syndrome*, syncope sometimes accompanied by
  tonic-clonic movements*</span></p>
  </td>
  <td style='border:none' width=0><p class='MsoNormal'>&nbsp;</td>
 </tr>
 <tr>
  <td width="34%" rowspan=2 valign=top style='width:34.44%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='margin-right:-.05in;text-align:center'><span
  lang=EN-GB style='color:black'>Gastrointestinal disorders</span></p>
  </td>
  <td width="16%" valign=top style='width:16.78%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='margin-right:-.05in;text-align:center'><span
  lang=EN-GB style='color:black'>Common</span></p>
  </td>
  <td width="48%" valign=top style='width:48.78%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-right:-.05in'><span lang=EN-GB
  style='color:black'>Nausea</span></p>
  </td>
  <td style='border:none' width=0><p class='MsoNormal'>&nbsp;</td>
 </tr>
 <tr>
  <td width="16%" valign=top style='width:16.78%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='margin-right:-.05in;text-align:center'><span
  lang=EN-GB style='color:black'>Not known</span></p>
  </td>
  <td width="48%" valign=top style='width:48.78%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-right:-.05in'><span lang=EN-GB
  style='color:black'>Vomiting*</span></p>
  </td>
  <td style='border:none' width=0><p class='MsoNormal'>&nbsp;</td>
 </tr>
 <tr>
  <td width="34%" rowspan=2 valign=top style='width:34.44%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='margin-right:-.05in;text-align:center'><span
  lang=EN-GB style='color:black'>Musculoskeletal and Connective Tissue
  Disorders</span></p>
  </td>
  <td width="16%" valign=top style='width:16.78%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='margin-right:-.05in;text-align:center'><span
  lang=EN-GB style='color:black'>Common</span></p>
  </td>
  <td width="48%" valign=top style='width:48.78%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-right:-.05in'><span lang=EN-GB
  style='color:black'>Pain in extremity</span></p>
  </td>
  <td style='border:none' width=0><p class='MsoNormal'>&nbsp;</td>
 </tr>
 <tr>
  <td width="16%" valign=top style='width:16.78%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='margin-right:-.05in;text-align:center'><span
  lang=EN-GB style='color:black'>Not known</span></p>
  </td>
  <td width="48%" valign=top style='width:48.78%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-right:-.05in'><span lang=EN-GB
  style='color:black'>Arthralgia*, Myalgia*</span></p>
  </td>
  <td style='border:none' width=0><p class='MsoNormal'>&nbsp;</td>
 </tr>
 <tr style='height:17.6pt'>
  <td width="34%" rowspan=3 valign=top style='width:34.44%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:17.6pt'>
  <p class=MsoNormal align=center style='margin-right:-.05in;text-align:center'><span
  lang=EN-GB style='color:black'>General disorders and administration site
  conditions</span></p>
  </td>
  <td width="16%" valign=top style='width:16.78%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:17.6pt'>
  <p class=MsoNormal align=center style='margin-right:-.05in;text-align:center'><span
  lang=EN-GB style='color:black'>Very common</span></p>
  </td>
  <td width="48%" valign=top style='width:48.78%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:17.6pt'>
  <p class=MsoNormal style='margin-right:-.05in'><span lang=EN-GB
  style='color:black'>At the injection site: erythema, pain, swelling</span></p>
  </td>
  <td style='height:17.6pt;border:none' width=0 height=23></td>
 </tr>
 <tr style='height:26.25pt'>
  <td width="16%" valign=top style='width:16.78%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:26.25pt'>
  <p class=MsoNormal align=center style='margin-right:-.05in;text-align:center'><span
  lang=EN-GB style='color:black'>Common</span></p>
  </td>
  <td width="48%" valign=top style='width:48.78%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:26.25pt'>
  <p class=MsoNormal style='margin-right:-.05in'><span lang=EN-GB
  style='color:black'>Pyrexia</span></p>
  <p class=MsoNormal style='margin-right:-.05in'><span lang=EN-GB
  style='color:black'>At the injection site: hematoma, pruritus</span></p>
  </td>
  <td style='height:26.25pt;border:none' width=0 height=35></td>
 </tr>
 <tr style='height:17.7pt'>
  <td width="16%" valign=top style='width:16.78%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:17.7pt'>
  <p class=MsoNormal align=center style='margin-right:-.05in;text-align:center'><span
  lang=EN-GB style='color:black'>Not known</span></p>
  </td>
  <td width="48%" valign=top style='width:48.78%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:17.7pt'>
  <p class=MsoNormal style='margin-right:-.05in'><span lang=EN-GB
  style='color:black'>Asthenia*, chills*, fatigue*, malaise*</span></p>
  </td>
  <td style='height:17.7pt;border:none' width=0 height=24></td>
 </tr>
 <tr style='height:35.3pt'>
  <td width="100%" colspan=3 valign=top style='width:100.0%;border:none;
  padding:0in 5.4pt 0in 5.4pt;height:35.3pt'>
  <p class=MsoNormal style='margin-left:2.05pt'><span lang=EN-GB
  style='font-size:10.0pt;color:black'>* Post Marketing adverse events
  (frequency cannot be estimated from the available data).</span></p>
  <p class=MsoNormal style='margin-top:0in;margin-right:-.05in;margin-bottom:
  0in;margin-left:2.05pt;margin-bottom:.0001pt'><sup><span lang=EN-GB
  style='font-size:10.0pt;color:black'>1 </span></sup><span lang=EN-GB
  style='font-size:10.0pt;color:black'>During clinical trials, dizziness was
  observed as a common adverse reaction in females. In males, dizziness was not
  observed at a greater frequency in vaccine recipients than in placebo
  recipients.</span></p>
  </td>
  <td style='height:35.3pt;border:none' width=0 height=47></td>
 </tr>
</table>

</div>

<p class=MsoPlainText style='margin-bottom:0in'><b><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></b></p>

<p class=MsoPlainText style='margin-bottom:0in'><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif'>In addition, in
clinical trials adverse reactions that were judged to be vaccine- or
placebo-related by the study investigator were observed at frequencies lower
than 1%: </span></p>

<p class=MsoPlainText style='margin-bottom:0in'><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoPlainText style='margin-bottom:0in;page-break-after:avoid'><u><span
lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>Respiratory,
thoracic and mediastinal disorders:</span></u></p>

<p class=MsoPlainText style='margin-bottom:0in'><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif'>Very rare:
bronchospasm.</span></p>

<p class=MsoPlainText style='margin-bottom:0in'><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoPlainText style='margin-bottom:0in;page-break-after:avoid'><u><span
lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>Skin
and subcutaneous tissue disorders:</span></u></p>

<p class=MsoPlainText style='margin-bottom:0in'><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif'>Rare: urticaria.</span></p>

<p class=MsoPlainText style='margin-bottom:0in'><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif'>Nine cases (0.06%)
of urticaria were reported in the <span style='color:black'>Gardasil</span>
group and 20 cases (0.15%) were seen in the adjuvant-containing placebo group.</span></p>

<p class=MsoPlainText style='margin-bottom:0in'><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoPlainText style='margin-bottom:0in'><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif'>In the clinical
studies, individuals in the Safety Population reported any new medical
conditions during the follow-up. Among 15,706 individuals who received Gardasil
and 13,617 individuals who received placebo, there were<span style='color:black'>
39</span> cases of non-specific arthritis/arthropathy reported, <span
style='color:black'>24</span> in the Gardasil group and <span style='color:
black'>15</span> in the placebo group. </span></p>

<p class=MsoPlainText style='margin-bottom:0in'><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoPlainText style='margin-bottom:0in'><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif;color:black'>In a
clinical trial of 843 healthy adolescent males and females 11-17&nbsp;years of
age, administration of the first dose of Gardasil concomitantly with a combined
diphtheria, tetanus, pertussis [acellular, component] and poliomyelitis
[inactivated] booster vaccine showed that there was more injection-site
swelling and headache reported following concomitant administration. The differences
observed were &lt;&nbsp;10% and in the majority of subjects, the adverse events
were reported as mild to moderate in intensity.</span></p>

<p class=MsoPlainText style='margin-bottom:0in'><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif;color:black'>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><u><span
lang=EN-GB>Reporting of suspected adverse reactions</span></u></p>

<p class=MsoPlainText style='margin-bottom:0in'><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif'>Reporting
suspected adverse reactions after authorisation of the medicinal product is important.
It allows continued monitoring of the benefit/risk balance of the medicinal
product. Healthcare professionals are asked to report any suspected adverse
reactions via <span style='color:black;background:#BFBFBF'>the national
reporting system listed in </span><u><span style='color:blue;background:#BFBFBF'><a
href="http://www.ema.europa.eu/docs/en_GB/document_library/Template_or_form/2013/03/WC500139752.doc"><u><span
style='color:blue'>Appendix V</span></u></a></span></u>.</span></p>

<p class=MsoPlainText style='margin-bottom:0in'><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif;color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid'><b><span lang=EN-GB>4.9&nbsp;&nbsp;&nbsp;&nbsp; Overdose</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>There have been reports of administration
of higher than recommended doses of Gardasil. </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>In general, the adverse event profile
reported with overdose was comparable to recommended single doses of Gardasil.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid'><b><span lang=EN-GB>5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; PHARMACOLOGICAL
PROPERTIES</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid'><a name="OLE_LINK7"><b><span lang=EN-GB>5.1&nbsp;&nbsp;&nbsp;&nbsp; Pharmacodynamic
properties</span></b></a></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Pharmacotherapeutic group: Viral Vaccine,
ATC code: J07BM01</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><i><span lang=EN-GB>Mechanism
of Action </span></i></p>

<p class=MsoNormal style='page-break-after:avoid'><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal><span lang=EN-GB>Gardasil is an adjuvanted non-infectious
recombinant quadrivalent vaccine prepared from the highly purified virus-like
particles (VLPs) of the major capsid L1 protein of HPV types 6, 11, 16 and 18.</span><span
lang=EN-GB> The VLPs contain no viral DNA, they cannot infect cells, reproduce
or cause disease. HPV only infects humans, but animal studies with analogous
papillomaviruses suggest that the efficacy of LI VLP vaccines is mediated by
the development of a humoral immune response. </span></p>

<p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>HPV&nbsp;16 and
HPV&nbsp;18 are estimated to be responsible for approximately 70% of cervical
cancers and 75-80% of anal cancers; 80% of adenocarcinoma in situ (AIS); 45-70%
of high-grade cervical intraepithelial neoplasia (CIN&nbsp;2/3); 25% of low
grade cervical intraepithelial neoplasia (</span><span lang=EN-GB>CIN&nbsp;1</span><span
lang=EN-GB>); approximately 70% of HPV related high-<span style='color:black'>grade
vulvar (VIN&nbsp;2/3) and vaginal (VaIN&nbsp;2/3) intraepithelial neoplasia and
80% of HPV related high-grade anal (AIN 2/3) intraepithelial neoplasia.
HPV&nbsp;6 and 11 are responsible for approximately 90% of genital warts and
10% of low grade cervical intraepithelial neoplasia (CIN&nbsp;1). CIN&nbsp;3
and AIS have been accepted as immediate precursors of invasive cervical cancer.</span></span></p>

<p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal><span lang=EN-GB>The term &quot;premalignant genital
lesions&quot; in section</span><span lang=EN-GB style='color:black'>&nbsp;</span><span
lang=EN-GB>4.1 corresponds to high-grade cervical intraepithelial neoplasia
(CIN&nbsp;2/3), high-grade vulvar intraepithelial neoplasia (VIN&nbsp;2/3) and
high-grade vaginal intraepithelial neoplasia (VaIN&nbsp;2/3).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>The term &quot;</span><span lang=EN-GB>premalignant
anal lesions&quot; in section&nbsp;4.1 corresponds to high-grade anal
intraepithelial neoplasia (AIN&nbsp;2/3).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
style='color:black'>The indication is based on the demonstration of efficacy of
Gardasil in females 16 to 45 &nbsp;years of age and in males 16 to 26&nbsp;years
of age and on the demonstration of immunogenicity of Gardasil in 9- to 15-year
old children and adolescents.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><i><span lang=EN-GB>Clinical
Studies</span></i></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>Efficacy
in women 16 through 26&nbsp;years</span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>The efficacy of Gardasil </span><span
lang=EN-GB>in 16- through 26&nbsp;year-old women was assessed in 4
placebo-controlled, double-blind, randomised Phase II and III clinical studies
including a total of 20,541 women, who were enrolled and vaccinated without
pre-screening for the presence of HPV infection.&nbsp; </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>The primary efficacy endpoints included
HPV&nbsp;6-, 11-, 16-, or 18-related vulvar and vaginal lesions (genital warts,
VIN, VaIN) and CIN of any grade and cervical cancers (Protocol 013, FUTURE I),
HPV&nbsp;16- or 18-related CIN&nbsp;2/3 and AIS and cervical cancers (Protocol
015, FUTURE II), HPV&nbsp;6-, 11&#8209;, 16-, or 18-related persistent
infection </span><span lang=EN-GB>and disease (Protocol 007), and HPV&nbsp;16-related
persistent infection (Protocol 005). The primary analyses of efficacy, with respect
to vaccine HPV types (HPV&nbsp;6, 11, 16, and 18), were conducted in the
per-protocol efficacy (PPE) population (i.e. all 3 vaccinations within 1 year
of enrollment, no major protocol deviations and na&iuml;ve to the relevant HPV
type(s) prior to dose 1 and through 1 month Postdose 3 (Month 7)).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>Efficacy results are
presented for the combined analysis of study protocols. The efficacy for
HPV&nbsp;16/18 related CIN&nbsp;2/3 or AIS is based on data from protocols 005
(16-related endpoints only), 007, 013, and 015. The efficacy for all other
endpoints is based on protocols 007, 013, and 015. The median duration of
follow-up for these studies was 4.0, 3.0, 3.0, and 3.0 years for Protocol 005,
Protocol 007, Protocol 013, and Protocol 015, respectively. The median duration
of follow-up for the combined protocols (005, 007, 013, and 015) was 3.6&nbsp;years.
Results of individual studies support the results from the combined analysis.
Gardasil was efficacious against HPV disease caused by each of the four vaccine
HPV types. At end of study, individuals enrolled in the two Phase-III studies (Protocol-013
and Protocol-015), were followed for up to 4&nbsp;years (median 3.7&nbsp;years).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Cervical Intraepithelial Neoplasia (CIN)
Grade 2/3 (moderate to high-grade dysplasia) </span><span lang=EN-GB>and
adenocarcinoma in situ<b> </b>(AIS) were used in the clinical trials as a
surrogate marker for cervical cancer.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>In the
long-term extension study of Protocol 015, 2,536&nbsp;women 16-23 years old
during vaccination with Gardasil in the base study were followed. In the PPE
population no cases of HPV diseases (HPV types 6/11/16/18 related high grade
CIN) were observed up to approximately 14&nbsp;years (median follow-up of 11.9&nbsp;years).
In this study, a durable protection was statistically demonstrated to
approximately 12&nbsp;years.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>Efficacy </span></u><u><span
lang=EN-GB>in women na&iuml;ve to the relevant vaccine HPV type(s)</span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal><span lang=EN-GB>Efficacy was measured starting after the
Month 7 visit. Overall, 73% of women were na&iuml;ve (PCR negative and
seronegative) to all 4 HPV types at enrolment.</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>The efficacy results
for relevant endpoints analysed at 2&nbsp;years post-enrolment and at end of
study (median duration of follow-up&nbsp;=&nbsp;3.6 years) in the per-protocol
population are presented in the Table&nbsp;2.</span></p>

<p class=MsoNormal style='margin-right:-2.0pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>In a supplemental analysis, the efficacy of
Gardasil was evaluated against HPV&nbsp;16/18-related CIN&nbsp;3 and AIS.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><i><span lang=EN-GB>Table&nbsp;2:
Analysis of efficacy of Gardasil against high grade cervical lesions in the PPE
population</span></i></p>

<div align=center>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0 width="100%"
 style='width:100.0%;border-collapse:collapse;border:none'>
 <tr style='page-break-inside:avoid'>
  <td width="23%" valign=top style='width:23.28%;border:solid windowtext 1.0pt;
  border-bottom:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>&nbsp;</span></b></p>
  </td>
  <td width="12%" valign=top style='width:12.82%;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB>Gardasil</span></b></p>
  </td>
  <td width="11%" valign=top style='width:11.68%;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB>Placebo</span></b></p>
  </td>
  <td width="12%" rowspan=2 style='width:12.84%;border-top:solid windowtext 1.0pt;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 2.25pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB>% Efficacy</span></b></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB>at 2 years</span></b></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB>(95% CI)</span></b></p>
  </td>
  <td width="12%" valign=top style='width:12.84%;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB>Gardasil</span></b></p>
  </td>
  <td width="11%" valign=top style='width:11.8%;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB>Placebo</span></b></p>
  </td>
  <td width="14%" rowspan=2 style='width:14.72%;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB>% Efficacy***</span></b></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB>at end of study</span></b></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB>(95% CI)</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="23%" valign=top style='width:23.28%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>&nbsp;</span></b></p>
  </td>
  <td width="12%" valign=top style='width:12.82%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <div style='border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 1.0pt 0in'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid;border:none;padding:0in'><b><span lang=EN-GB>Number of cases</span></b></p>
  </div>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB>Number of</span></b></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB>individuals*</span></b></p>
  </td>
  <td width="11%" valign=top style='width:11.68%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <div style='border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 1.0pt 0in'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid;border:none;padding:0in'><b><span lang=EN-GB>Number of cases</span></b></p>
  </div>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB>Number of</span></b></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB>individuals*</span></b></p>
  </td>
  <td width="12%" valign=top style='width:12.84%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <div style='border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 1.0pt 0in'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid;border:none;padding:0in'><b><span lang=EN-GB>Number of cases</span></b></p>
  </div>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB>Number of</span></b></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB>individuals*</span></b></p>
  </td>
  <td width="11%" valign=top style='width:11.8%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <div style='border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 1.0pt 0in'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid;border:none;padding:0in'><b><span lang=EN-GB>Number of cases</span></b></p>
  </div>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB>Number of</span></b></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB>individuals*</span></b></p>
  </td>
 </tr>
 <tr style='height:27.25pt'>
  <td width="23%" valign=top style='width:23.28%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:27.25pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB>HPV 16/18-related CIN 2/3 or AIS</span></b></p>
  </td>
  <td width="12%" valign=top style='width:12.82%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:27.25pt'>
  <div style='border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 1.0pt 0in'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid;border:none;padding:0in'><span lang=EN-GB>0</span></p>
  </div>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>8487</span></p>
  </td>
  <td width="11%" valign=top style='width:11.68%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:27.25pt'>
  <div style='border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 1.0pt 0in'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid;border:none;padding:0in'><span lang=EN-GB>53</span></p>
  </div>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>8460</span></p>
  </td>
  <td width="12%" valign=top style='width:12.84%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 2.25pt;
  padding:0in 5.4pt 0in 5.4pt;height:27.25pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>100.0</span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>(92.9, 100.0)</span></p>
  </td>
  <td width="12%" valign=top style='width:12.84%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:27.25pt'>
  <div style='border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 1.0pt 0in'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid;border:none;padding:0in'><span lang=EN-GB>2**</span></p>
  </div>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>8493</span></p>
  </td>
  <td width="11%" valign=top style='width:11.8%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:27.25pt'>
  <div style='border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 1.0pt 0in'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid;border:none;padding:0in'><span lang=EN-GB>112</span></p>
  </div>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>8464</span></p>
  </td>
  <td width="14%" valign=top style='width:14.72%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:27.25pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>98.2</span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>(93.5, 99.8)</span></p>
  </td>
 </tr>
 <tr style='height:27.25pt'>
  <td width="23%" valign=top style='width:23.28%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:27.25pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB>HPV 16/18-related CIN 3</span></b></p>
  </td>
  <td width="12%" valign=top style='width:12.82%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:27.25pt'>
  <div style='border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 1.0pt 0in'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid;border:none;padding:0in'><span lang=EN-GB>0</span></p>
  </div>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>8487</span></p>
  </td>
  <td width="11%" valign=top style='width:11.68%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:27.25pt'>
  <div style='border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 1.0pt 0in'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid;border:none;padding:0in'><span lang=EN-GB>29</span></p>
  </div>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>8460</span></p>
  </td>
  <td width="12%" valign=top style='width:12.84%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 2.25pt;
  padding:0in 5.4pt 0in 5.4pt;height:27.25pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>100</span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>(86.5, 100.0)</span></p>
  </td>
  <td width="12%" valign=top style='width:12.84%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:27.25pt'>
  <div style='border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 1.0pt 0in'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid;border:none;padding:0in'><span lang=EN-GB>2**</span></p>
  </div>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>8493</span></p>
  </td>
  <td width="11%" valign=top style='width:11.8%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:27.25pt'>
  <div style='border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 1.0pt 0in'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid;border:none;padding:0in'><span lang=EN-GB>64</span></p>
  </div>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>8464</span></p>
  </td>
  <td width="14%" valign=top style='width:14.72%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:27.25pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>96.9</span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>(88.4, 99.6)</span></p>
  </td>
 </tr>
 <tr style='height:27.25pt'>
  <td width="23%" valign=top style='width:23.28%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:27.25pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB>HPV 16/18-related AIS</span></b></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB>&nbsp;</span></b></p>
  </td>
  <td width="12%" valign=top style='width:12.82%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:27.25pt'>
  <div style='border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 1.0pt 0in'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid;border:none;padding:0in'><span lang=EN-GB>0</span></p>
  </div>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>8487</span></p>
  </td>
  <td width="11%" valign=top style='width:11.68%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:27.25pt'>
  <div style='border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 1.0pt 0in'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid;border:none;padding:0in'><span lang=EN-GB>6</span></p>
  </div>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>8460</span></p>
  </td>
  <td width="12%" valign=top style='width:12.84%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 2.25pt;
  padding:0in 5.4pt 0in 5.4pt;height:27.25pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>100</span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>(14.8, 100.0)</span></p>
  </td>
  <td width="12%" valign=top style='width:12.84%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:27.25pt'>
  <div style='border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 1.0pt 0in'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid;border:none;padding:0in'><span lang=EN-GB>0</span></p>
  </div>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>8493</span></p>
  </td>
  <td width="11%" valign=top style='width:11.8%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:27.25pt'>
  <div style='border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 1.0pt 0in'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid;border:none;padding:0in'><span lang=EN-GB>7</span></p>
  </div>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>8464</span></p>
  </td>
  <td width="14%" valign=top style='width:14.72%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:27.25pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>100</span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>(30.6, 100.0)</span></p>
  </td>
 </tr>
</table>

</div>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
style='font-size:10.0pt'>*Number of individuals with at least one follow-up
visit after Month 7</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB
style='font-size:10.0pt'>**</span></b><span lang=EN-GB style='font-size:10.0pt'>Based
on virologic evidence, the first CIN&nbsp;3 case in a patient chronically
infected with HPV&nbsp;52 is likely to be causally related to HPV&nbsp;52. In
only 1 of 11 specimens HPV&nbsp;16 was found (at Month&nbsp;32.5) and was not
detected in tissue excised during LEEP (Loop Electro-Excision Procedure). In
the second CIN&nbsp;3 case observed in </span><span lang=EN-GB
style='font-size:10.0pt'>a patient infected with HPV&nbsp;51 at Day 1 (in 2 of
9 specimens); HPV&nbsp;16 was detected at a Month&nbsp;51 biopsy (in 1 of 9
specimens) and HPV&nbsp;56 was detected in 3 of 9 specimens at Month&nbsp;52 in
tissue excised during LEEP. </span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
style='font-size:10.0pt'>***Patients were followed for up to 4&nbsp;years
(median 3.6&nbsp;years)</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>Note: Point estimates
and confidence intervals are adjusted for person-time of follow-up.</span></p>

<p class=MsoNormal><b><u><span lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></b></p>

<p class=MsoNormal><span lang=EN-GB>At end of study and in the combined
protocols, </span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>the efficacy of Gardasil against HPV&nbsp;6-,
11-, 16-, 18-related CIN 1 was 95.9 % (95% CI: 91.4, 98.4), </span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>the efficacy of Gardasil against HPV&nbsp;6-,
11-, 16-, 18-related CIN (1, 2, 3) or AIS was 96.0% (95% CI: 92.3, 98.2), </span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>the efficacy of Gardasil against HPV&nbsp;6-,
11-, 16-, 18-related VIN2/3 and VaIN 2/3 was 100% (95% CI: 67.2, 100) and 100%
(95% CI: 55.4, 100), respectively,</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>the efficacy of Gardasil against HPV&nbsp;6-,
11-, 16-, 18-related genital warts was 99.0% (95% CI: 96.2, 99.9).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>In Protocol 012 the efficacy of Gardasil
against the 6 month definition of persistent infection</span><span lang=EN-GB>
[samples positive on two or more consecutive visits 6&nbsp;months apart (&plusmn;</span><span
lang=EN-GB>1&nbsp;month</span><span lang=EN-GB>) or longer] related to HPV&nbsp;16
was 98.7% (95% CI: 95.1, 99.8) and 100.0% (95% CI: 93.2, 100.0) for HPV&nbsp;18
respectively, after a follow-up of up to 4&nbsp;years (mean of
3.6&nbsp;years).&nbsp; For the 12&nbsp;month definition of persistent infection,
efficacy against HPV&nbsp;16 was 100.0 % (95% CI: 93.9, 100.0) and 100.0% (95%
CI: 79.9, 100.0) for HPV&nbsp;18 respectively<b>.</b></span></p>

<p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>Efficacy
in women with evidence of HPV&nbsp;6, 11, 16, or 18 infection or disease at day
1</span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal><span lang=EN-GB>There was </span><span lang=EN-GB>no
evidence of protection from disease caused by vaccine HPV types for which women
were PCR positive at day 1. Women who were already infected with one or more
vaccine-related HPV types prior to vaccination were protected from clinical
disease caused by the remaining vaccine HPV types.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>Efficacy </span></u><u><span
lang=EN-GB>in women with and without prior infection or disease due to
HPV&nbsp;6, 11, 16, or 18</span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>The modified intention to treat (ITT)
population included women regardless of baseline HPV status at Day 1, who
received at least one vaccination and in whom case counting started at 1 month
Postdose 1. This population approximates to the general population of women
with respect to prevalence of HPV infection</span><b><span lang=EN-GB> </span></b><span
lang=EN-GB>or disease at enrolment. The results are summarised in Table&nbsp;3.</span></p>

<p class=MsoNormal><u><span lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><i><span lang=EN-GB>Table&nbsp;3:
Efficacy of Gardasil in high grade cervical lesions in the modified
ITT-population including women regardless of baseline HPV status </span></i></p>

<div align=center>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0 width="100%"
 style='width:100.0%;border-collapse:collapse;border:none'>
 <tr style='page-break-inside:avoid'>
  <td width="19%" rowspan=2 valign=top style='width:19.54%;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>&nbsp;</span></b></p>
  </td>
  <td width="16%" valign=top style='width:16.6%;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB>Gardasil</span></b></p>
  </td>
  <td width="12%" valign=top style='width:12.92%;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB>Placebo</span></b></p>
  </td>
  <td width="13%" rowspan=2 style='width:13.36%;border-top:solid windowtext 1.0pt;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 2.25pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB>% Efficacy**</span></b></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB>at 2 years</span></b></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB>(95% CI)</span></b></p>
  </td>
  <td width="12%" valign=top style='width:12.3%;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB>Gardasil</span></b></p>
  </td>
  <td width="12%" valign=top style='width:12.3%;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB>Placebo</span></b></p>
  </td>
  <td width="12%" rowspan=2 style='width:12.98%;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB>% Efficacy**</span></b></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB>at end of study</span></b></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB>(95% CI)</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="16%" valign=top style='width:16.6%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <div style='border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 1.0pt 0in'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid;border:none;padding:0in'><b><span lang=EN-GB>Number of</span></b></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid;border:none;padding:0in'><b><span lang=EN-GB>cases</span></b></p>
  </div>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB>Number of</span></b></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB>individuals*</span></b></p>
  </td>
  <td width="12%" valign=top style='width:12.92%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <div style='border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 1.0pt 0in'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid;border:none;padding:0in'><b><span lang=EN-GB>Number of cases</span></b></p>
  </div>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB>Number of</span></b></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB>individuals*</span></b></p>
  </td>
  <td width="12%" valign=top style='width:12.3%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <div style='border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 1.0pt 0in'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid;border:none;padding:0in'><b><span lang=EN-GB>Number of cases</span></b></p>
  </div>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB>Number of</span></b></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB>individuals*</span></b></p>
  </td>
  <td width="12%" valign=top style='width:12.3%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <div style='border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 1.0pt 0in'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid;border:none;padding:0in'><b><span lang=EN-GB>Number of cases</span></b></p>
  </div>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB>Number of</span></b></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB>individuals*</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="19%" valign=top style='width:19.54%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><b><span
  lang=EN-GB>HPV 16- or HPV 18-related CIN 2/3 or AIS</span></b></p>
  </td>
  <td width="16%" valign=top style='width:16.6%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <div style='border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 1.0pt 0in'>
  <p class=MsoNormal align=center style='text-align:center;border:none;
  padding:0in'><span lang=EN-GB>122</span></p>
  </div>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>9831</span></p>
  </td>
  <td width="12%" valign=top style='width:12.92%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <div style='border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 1.0pt 0in'>
  <p class=MsoNormal align=center style='text-align:center;border:none;
  padding:0in'><span lang=EN-GB>201</span></p>
  </div>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>9896</span></p>
  </td>
  <td width="13%" valign=top style='width:13.36%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 2.25pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>39.0</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>(23.3,
  51.7)</span></p>
  </td>
  <td width="12%" valign=top style='width:12.3%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <div style='border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 1.0pt 0in'>
  <p class=MsoNormal align=center style='text-align:center;border:none;
  padding:0in'><span lang=EN-GB>146</span></p>
  </div>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>9836</span></p>
  </td>
  <td width="12%" valign=top style='width:12.3%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <div style='border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 1.0pt 0in'>
  <p class=MsoNormal align=center style='text-align:center;border:none;
  padding:0in'><span lang=EN-GB>303</span></p>
  </div>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>9904</span></p>
  </td>
  <td width="12%" valign=top style='width:12.98%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>51.8</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>(41.1,
  60.7)</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:28.15pt'>
  <td width="19%" valign=top style='width:19.54%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:28.15pt'>
  <p class=MsoNormal align=center style='text-align:center'><b><span
  lang=EN-GB>HPV 16/18-related CIN 3</span></b></p>
  </td>
  <td width="16%" valign=top style='width:16.6%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:28.15pt'>
  <div style='border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 1.0pt 0in'>
  <p class=MsoNormal align=center style='text-align:center;border:none;
  padding:0in'><span lang=EN-GB>83</span></p>
  </div>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>9831</span></p>
  </td>
  <td width="12%" valign=top style='width:12.92%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:28.15pt'>
  <div style='border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 1.0pt 0in'>
  <p class=MsoNormal align=center style='text-align:center;border:none;
  padding:0in'><span lang=EN-GB>127</span></p>
  </div>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>9896</span></p>
  </td>
  <td width="13%" valign=top style='width:13.36%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 2.25pt;
  padding:0in 5.4pt 0in 5.4pt;height:28.15pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>34.3</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>(12.7,
  50.8)</span></p>
  </td>
  <td width="12%" valign=top style='width:12.3%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:28.15pt'>
  <div style='border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 1.0pt 0in'>
  <p class=MsoNormal align=center style='text-align:center;border:none;
  padding:0in'><span lang=EN-GB>103</span></p>
  </div>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>9836</span></p>
  </td>
  <td width="12%" valign=top style='width:12.3%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:28.15pt'>
  <div style='border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 1.0pt 0in'>
  <p class=MsoNormal align=center style='text-align:center;border:none;
  padding:0in'><span lang=EN-GB>191</span></p>
  </div>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>9904</span></p>
  </td>
  <td width="12%" valign=top style='width:12.98%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:28.15pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>46.0</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>(31.0,
  57.9)</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:27.85pt'>
  <td width="19%" valign=top style='width:19.54%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:27.85pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB>HPV 16/18-related AIS</span></b></p>
  </td>
  <td width="16%" valign=top style='width:16.6%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:27.85pt'>
  <div style='border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 1.0pt 0in'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid;border:none;padding:0in'><span lang=EN-GB>5</span></p>
  </div>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>9831</span></p>
  </td>
  <td width="12%" valign=top style='width:12.92%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:27.85pt'>
  <div style='border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 1.0pt 0in'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid;border:none;padding:0in'><span lang=EN-GB>11</span></p>
  </div>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>9896</span></p>
  </td>
  <td width="13%" valign=top style='width:13.36%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 2.25pt;
  padding:0in 5.4pt 0in 5.4pt;height:27.85pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>54.3</span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>(&lt;0, 87.6)</span></p>
  </td>
  <td width="12%" valign=top style='width:12.3%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:27.85pt'>
  <div style='border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 1.0pt 0in'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid;border:none;padding:0in'><span lang=EN-GB>6</span></p>
  </div>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>9836</span></p>
  </td>
  <td width="12%" valign=top style='width:12.3%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:27.85pt'>
  <div style='border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 1.0pt 0in'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid;border:none;padding:0in'><span lang=EN-GB>15</span></p>
  </div>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>9904</span></p>
  </td>
  <td width="12%" valign=top style='width:12.98%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:27.85pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>60.0</span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>(&lt;0, 87.3)</span></p>
  </td>
 </tr>
</table>

</div>

<div style='border:none;border-top:solid windowtext 1.0pt;padding:1.0pt 0in 0in 0in'>

<p class=MsoNormal style='page-break-after:avoid;border:none;padding:0in'><span
lang=EN-GB style='font-size:10.0pt'>*Number of individuals with at least one
follow-up visit after 30 days after Day 1</span></p>

<p class=MsoNormal style='page-break-after:avoid;border:none;padding:0in'><span
lang=EN-GB style='font-size:10.0pt'>**Percent efficacy is calculated from the combined
protocols. The efficacy for HPV&nbsp;16/18 related CIN&nbsp;2/3 or AIS is based
on data from protocols 005 (16-related endpoints only), 007, 013, and 015. Patients
were followed for up to 4&nbsp;years (median 3.6&nbsp;years). </span></p>

<p class=MsoNormal style='border:none;padding:0in'><span lang=EN-GB
style='font-size:10.0pt'>Note: point estimates and confidence intervals are adjusted
for person-time of follow-up.</span></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Efficacy against HPV&nbsp;6-, 11-, 16-,
18-related VIN&nbsp;2/3 was 73.3% (95% CI: 40.3, 89.4), against HPV&nbsp;6-,
11-, 16-, 18-related VaIN&nbsp;2/3 was 85.7% (95% CI: 37.6, 98.4), and against
HPV&nbsp;6-, 11-, 16-, 18-related genital warts was 80.3% (95% CI: 73.9, 85.3)
in the combined protocols at end of study.</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Overall 12% of the combined study
population had an abnormal Pap test suggestive of CIN at Day 1.</span><span
lang=EN-GB> Among women with an abnormal Pap test at Day 1 who were na&iuml;ve
to the relevant vaccine HPV types at Day 1, efficacy of the vaccine remained
high. Among women with an abnormal Pap test at Day 1 who were already infected
with the relevant vaccine HPV types at Day 1, no vaccine efficacy was observed.</span></p>

<p class=MsoNormal><u><span lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><u><span
lang=EN-GB>Protection Against the Overall Burden of Cervical HPV disease in 16-
Through 26-Year-Old Women</span></u></p>

<p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>The impact of
Gardasil against the overall risk for cervical, HPV disease (i.e., disease
caused by any HPV type) was evaluated starting 30 days after the first dose in
17,599 individuals enrolled in the two Phase III efficacy trials (Protocols 013
and 015). Among women who were na&iuml;ve to 14 common HPV types and had a
negative Pap test at Day 1, administration of Gardasil reduced the incidence of
CIN&nbsp;2/3 or AIS caused by vaccine- or non-vaccine HPV types by 42.7% (95%
CI: 23.7, 57.3) </span><span lang=EN-GB>and of genital warts by 82.8% (95% CI:
74.3, 88.8) at end of study.</span></p>

<p class=MsoNormal><u><span lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal><span lang=EN-GB>In the modified ITT population, the benefit
of the vaccine with respect to the overall incidence of CIN&nbsp;2/3 or AIS
(caused by any HPV type) and of genital warts was much lower, with a reduction
of 18.4% (95% CI: 7.0, 28.4) and 62.5% (95% CI: 54.0, 69.5), respectively, as
Gardasil does not impact the course of infections or disease that are present
at vaccination onset.</span></p>

<p class=MsoNormal><u><span lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>Impact on
Definitive Cervical Therapy Procedures </span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>The impact of Gardasil on rates of
Definitive Cervical Therapy Procedures regardless of causal HPV types was
evaluated in 18,150 individuals enrolled in Protocol 007, Protocols 013 and
015. <span class=BodyChar><span style='font-family:"Times New Roman",serif'>In
the </span></span>HPV na&iuml;ve population (na&iuml;ve to 14 common HPV types
and had a negative Pap test at Day 1), <span class=BodyChar><span
style='font-family:"Times New Roman",serif'>Gardasil reduced the proportion of
women who experienced a definitive cervical therapy procedure (Loop
Electro-Excision Procedure or Cold-Knife Conization) </span></span>by 41.9%
(95% CI: 27.7, 53.5)<span class=BodyChar><span style='font-family:"Times New Roman",serif'>
at end of study. In the ITT population the corresponding reduction was 23.9% (</span></span>95%
CI: <span class=BodyChar><span style='font-family:"Times New Roman",serif'>15.2,
31.7).</span></span></span></p>

<p class=MsoNormal><u><span lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><u><span
lang=EN-GB>Cross-protective efficacy</span></u></p>

<p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><u><span
lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>The efficacy of
Gardasil against CIN (any grade) and CIN&nbsp;2/3 or AIS caused by 10
non-vaccine HPV types (HPV 31, 33, 35, 39, 45, 51, 52, 56, 58, 59) structurally
related to HPV&nbsp;16 or HPV&nbsp;18 was evaluated in the combined Phase III
efficacy database (N&nbsp;=&nbsp;17,599) after a median follow-up of 3.7&nbsp;years
(at end of study). Efficacy against disease endpoints caused by pre-specified
combinations of non-vaccine HPV types was measured. The studies were not
powered to assess efficacy against disease caused by individual HPV types.</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>The primary
analysis was done in type-specific populations that required women to be
negative for the type being analyzed, but who could be positive for other HPV
types (96% of the overall population)</span><span lang=EN-GB>.</span><span
lang=EN-GB> The primary time point analysis after 3&nbsp;years did not reach
statistical significance for all pre-specified endpoints. The final
end-of-study results for the combined incidence of CIN&nbsp;2/3 or AIS in this
population after a median follow-up of 3.7&nbsp;years are shown in Table&nbsp;4.</span><span
lang=EN-GB> For composite endpoints, statistically significant efficacy against
disease was demonstrated against HPV types phylogenetically related to
HPV&nbsp;16 (primarily HPV&nbsp;31) whereas no statistically significant
efficacy was observed for HPV types phylogenetically related to HPV&nbsp;18
(including HPV&nbsp;45). For the 10 individual HPV types, statistical significance
was only reached for HPV&nbsp;31.</span></p>

<p class=MsoNormal style='text-autospace:none'><b><span lang=EN-GB
style='color:black'>&nbsp;</span></b></p>

<p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><a
name="OLE_LINK14"></a><a name="OLE_LINK15"><i><span lang=EN-GB>Table&nbsp;4:
Results for CIN&nbsp;2/3 or AIS in Type-Specific HPV-Na&iuml;ve Individuals<sup>&#8224;
</sup>(end of study results)</span></i></a></p>

<div align=center>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0 width="100%"
 style='width:100.0%;border-collapse:collapse;border:none'>
 <tr>
  <td width="100%" colspan=5 valign=top style='width:100.0%;border:solid windowtext 1.0pt;
  background:#E6E6E6;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Na&iuml;ve
  to &#8805; 1 HPV Type</span></p>
  </td>
 </tr>
 <tr>
  <td width="27%" rowspan=2 valign=bottom style='width:27.76%;border:solid windowtext 1.0pt;
  border-top:none;background:#E6E6E6;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='color:black'>Composite Endpoint</span></p>
  </td>
  <td width="16%" valign=bottom style='width:16.08%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  background:#E6E6E6;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='color:black'>Gardasil</span></p>
  </td>
  <td width="16%" valign=bottom style='width:16.38%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  background:#E6E6E6;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='color:black'>Placebo</span></p>
  </td>
  <td width="19%" rowspan=2 valign=bottom style='width:19.9%;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  background:#E6E6E6;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='color:black'>% Efficacy</span></p>
  </td>
  <td width="19%" rowspan=2 valign=bottom style='width:19.9%;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  background:#E6E6E6;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='color:black'>95% CI</span></p>
  </td>
 </tr>
 <tr>
  <td width="16%" valign=bottom style='width:16.08%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  background:#E6E6E6;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='color:black'>cases</span></p>
  </td>
  <td width="16%" valign=bottom style='width:16.38%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  background:#E6E6E6;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='color:black'>cases</span></p>
  </td>
 </tr>
 <tr>
  <td width="27%" valign=top style='width:27.76%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>(HPV 31/45)<sup> &#8225;</sup></span></p>
  </td>
  <td width="16%" valign=top style='width:16.08%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>34</span></p>
  </td>
  <td width="16%" valign=top style='width:16.38%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>60</span></p>
  </td>
  <td width="19%" valign=top style='width:19.9%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>43.2%</span></p>
  </td>
  <td width="19%" valign=top style='width:19.9%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>12.1, 63.9</span></p>
  </td>
 </tr>
 <tr>
  <td width="27%" valign=top style='width:27.76%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>(HPV 31/33/45/52/58)<sup> &sect;</sup></span></p>
  </td>
  <td width="16%" valign=top style='width:16.08%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>111</span></p>
  </td>
  <td width="16%" valign=top style='width:16.38%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>150</span></p>
  </td>
  <td width="19%" valign=top style='width:19.9%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>25.8%</span></p>
  </td>
  <td width="19%" valign=top style='width:19.9%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>4.6, 42.5</span></p>
  </td>
 </tr>
 <tr>
  <td width="27%" valign=top style='width:27.76%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>10 non-vaccine HPV Types<sup>&#9553;</sup></span></p>
  </td>
  <td width="16%" valign=top style='width:16.08%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>162</span></p>
  </td>
  <td width="16%" valign=top style='width:16.38%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>211</span></p>
  </td>
  <td width="19%" valign=top style='width:19.9%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>23.0%</span></p>
  </td>
  <td width="19%" valign=top style='width:19.9%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>5.1, 37.7</span></p>
  </td>
 </tr>
 <tr>
  <td width="27%" valign=top style='width:27.76%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>HPV-16 related types<i><u> </u></i>(A9 species)</span></p>
  </td>
  <td width="16%" valign=top style='width:16.08%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>111</span></p>
  </td>
  <td width="16%" valign=top style='width:16.38%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>157</span></p>
  </td>
  <td width="19%" valign=top style='width:19.9%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>29.1%</span></p>
  </td>
  <td width="19%" valign=top style='width:19.9%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>9.1, 44.9</span></p>
  </td>
 </tr>
 <tr>
  <td width="27%" valign=top style='width:27.76%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='margin-left:12.0pt;text-align:center;
  page-break-after:avoid'><span lang=EN-GB>HPV 31</span></p>
  </td>
  <td width="16%" valign=top style='width:16.08%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>23</span></p>
  </td>
  <td width="16%" valign=top style='width:16.38%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>52</span></p>
  </td>
  <td width="19%" valign=top style='width:19.9%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>55.6%</span></p>
  </td>
  <td width="19%" valign=top style='width:19.9%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>26.2, 74.1<sup>&#8224;</sup></span></p>
  </td>
 </tr>
 <tr>
  <td width="27%" valign=top style='width:27.76%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='margin-left:12.0pt;text-align:center;
  page-break-after:avoid'><span lang=EN-GB>HPV 33</span></p>
  </td>
  <td width="16%" valign=top style='width:16.08%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>29</span></p>
  </td>
  <td width="16%" valign=top style='width:16.38%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>36</span></p>
  </td>
  <td width="19%" valign=top style='width:19.9%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>19.1%</span></p>
  </td>
  <td width="19%" valign=top style='width:19.9%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>&lt;0, 52.1<sup>&#8224;</sup></span></p>
  </td>
 </tr>
 <tr>
  <td width="27%" valign=top style='width:27.76%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='margin-left:12.0pt;text-align:center;
  page-break-after:avoid'><span lang=EN-GB>HPV 35</span></p>
  </td>
  <td width="16%" valign=top style='width:16.08%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>13</span></p>
  </td>
  <td width="16%" valign=top style='width:16.38%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>15</span></p>
  </td>
  <td width="19%" valign=top style='width:19.9%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>13.0%</span></p>
  </td>
  <td width="19%" valign=top style='width:19.9%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>&lt;0, 61.9<sup>&#8224;</sup></span></p>
  </td>
 </tr>
 <tr>
  <td width="27%" valign=top style='width:27.76%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='margin-left:12.0pt;text-align:center;
  page-break-after:avoid'><span lang=EN-GB>HPV 52</span></p>
  </td>
  <td width="16%" valign=top style='width:16.08%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>44</span></p>
  </td>
  <td width="16%" valign=top style='width:16.38%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>52</span></p>
  </td>
  <td width="19%" valign=top style='width:19.9%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>14.7%</span></p>
  </td>
  <td width="19%" valign=top style='width:19.9%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>&lt;0, 44.2<sup>&#8224;</sup></span></p>
  </td>
 </tr>
 <tr>
  <td width="27%" valign=top style='width:27.76%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='margin-left:12.0pt;text-align:center;
  page-break-after:avoid'><span lang=EN-GB>HPV 58</span></p>
  </td>
  <td width="16%" valign=top style='width:16.08%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>24</span></p>
  </td>
  <td width="16%" valign=top style='width:16.38%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>35</span></p>
  </td>
  <td width="19%" valign=top style='width:19.9%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>31.5%</span></p>
  </td>
  <td width="19%" valign=top style='width:19.9%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>&lt;0, 61.0<sup>&#8224;</sup></span></p>
  </td>
 </tr>
 <tr>
  <td width="27%" valign=top style='width:27.76%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>HPV-18 related types&nbsp;&nbsp; &nbsp;&nbsp;(A7
  species)</span></p>
  </td>
  <td width="16%" valign=top style='width:16.08%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>34</span></p>
  </td>
  <td width="16%" valign=top style='width:16.38%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>46</span></p>
  </td>
  <td width="19%" valign=top style='width:19.9%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>25.9%</span></p>
  </td>
  <td width="19%" valign=top style='width:19.9%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>&lt;0, 53.9</span></p>
  </td>
 </tr>
 <tr>
  <td width="27%" valign=top style='width:27.76%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='margin-left:12.0pt;text-align:center;
  page-break-after:avoid'><span lang=EN-GB>HPV 39</span></p>
  </td>
  <td width="16%" valign=top style='width:16.08%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>15</span></p>
  </td>
  <td width="16%" valign=top style='width:16.38%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>24</span></p>
  </td>
  <td width="19%" valign=top style='width:19.9%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>37.5%</span></p>
  </td>
  <td width="19%" valign=top style='width:19.9%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>&lt;0, 69.5<sup>&#8224;</sup></span></p>
  </td>
 </tr>
 <tr>
  <td width="27%" valign=top style='width:27.76%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='margin-left:12.0pt;text-align:center;
  page-break-after:avoid'><span lang=EN-GB>HPV 45</span></p>
  </td>
  <td width="16%" valign=top style='width:16.08%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>11</span></p>
  </td>
  <td width="16%" valign=top style='width:16.38%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>11</span></p>
  </td>
  <td width="19%" valign=top style='width:19.9%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>0.0%</span></p>
  </td>
  <td width="19%" valign=top style='width:19.9%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>&lt;0, 60.7<sup>&#8224;</sup></span></p>
  </td>
 </tr>
 <tr>
  <td width="27%" valign=top style='width:27.76%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='margin-left:12.0pt;text-align:center;
  page-break-after:avoid'><span lang=EN-GB>HPV 59</span></p>
  </td>
  <td width="16%" valign=top style='width:16.08%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>9</span></p>
  </td>
  <td width="16%" valign=top style='width:16.38%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>15</span></p>
  </td>
  <td width="19%" valign=top style='width:19.9%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>39.9%</span></p>
  </td>
  <td width="19%" valign=top style='width:19.9%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>&lt;0, 76.8<sup>&#8224;</sup></span></p>
  </td>
 </tr>
 <tr>
  <td width="27%" valign=top style='width:27.76%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>A5 species (HPV 51)</span></p>
  </td>
  <td width="16%" valign=top style='width:16.08%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>34</span></p>
  </td>
  <td width="16%" valign=top style='width:16.38%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>41</span></p>
  </td>
  <td width="19%" valign=top style='width:19.9%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>16.3%</span></p>
  </td>
  <td width="19%" valign=top style='width:19.9%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>&lt;0, 48.5<sup>&#8224;</sup></span></p>
  </td>
 </tr>
 <tr>
  <td width="27%" valign=top style='width:27.76%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>A6&nbsp; species (HPV 56)</span></p>
  </td>
  <td width="16%" valign=top style='width:16.08%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>34</span></p>
  </td>
  <td width="16%" valign=top style='width:16.38%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>30</span></p>
  </td>
  <td width="19%" valign=top style='width:19.9%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>-13.7%</span></p>
  </td>
  <td width="19%" valign=top style='width:19.9%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>&lt;0, 32.5<sup>&#8224;</sup></span></p>
  </td>
 </tr>
 <tr>
  <td width="100%" colspan=5 valign=top style='width:100.0%;border:none;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:.3in;text-indent:-.3in;page-break-after:
  avoid;text-autospace:none'><sup><span lang=EN-GB style='font-size:10.0pt'>&#8224;</span></sup><span
  lang=EN-GB style='font-size:10.0pt'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The
  studies were not powered to assess efficacy against disease caused by
  individual HPV types.</span></p>
  </td>
 </tr>
 <tr>
  <td width="100%" colspan=5 valign=top style='width:100.0%;border:none;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:.3in;text-indent:-.3in;page-break-after:
  avoid;text-autospace:none'><sup><span lang=EN-GB style='font-size:10.0pt'>&#8225;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></sup><span
  lang=EN-GB style='font-size:10.0pt'>Efficacy was based on reductions in
  HPV&nbsp;31-related CIN&nbsp;2/3 or AIS</span></p>
  </td>
 </tr>
 <tr>
  <td width="100%" colspan=5 valign=top style='width:100.0%;border:none;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:.3in;text-indent:-.3in;page-break-after:
  avoid;text-autospace:none'><sup><span lang=EN-GB style='font-size:10.0pt'>&sect;</span></sup><span
  lang=EN-GB style='font-size:10.0pt'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Efficacy
  was based on reductions in HPV&nbsp;31-, 33-, 52-, and 58-related CIN&nbsp;2/3
  or AIS</span></p>
  </td>
 </tr>
 <tr>
  <td width="100%" colspan=5 valign=top style='width:100.0%;border:none;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:21.55pt;text-indent:-21.55pt;
  text-autospace:none'><sup><span lang=EN-GB style='font-size:10.0pt'>&#9553; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></sup><span
  lang=EN-GB style='font-size:10.0pt'>Includes assay-identified non-vaccine HPV
  types 31, 33, 35, 39, 45, 51, 52, 56, 58, and 59.<sup>&nbsp; </sup></span></p>
  </td>
 </tr>
</table>

</div>

<p class=MsoNormal style='text-autospace:none'><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='page-break-after:avoid;background:white'><a
name="OLE_LINK9"></a><a name="OLE_LINK17"><u><span lang=EN-GB style='color:
black'>Efficacy in </span></u></a><a name="OLE_LINK18"></a><a name="OLE_LINK19"><u><span
lang=EN-GB style='color:black'>women 24 through 45 years</span></u></a></p>

<p class=MsoNormal style='page-break-after:avoid;background:white'><b><span
lang=EN-GB style='color:black'>&nbsp;</span></b></p>

<p class=MsoNormal style='background:white'><span lang=EN-GB style='color:black'>The
efficacy of Gardasil in 24- through 45&nbsp;year-old women was assessed in 1
placebo-controlled, double-blind, randomised Phase III clinical study (Protocol
019, FUTURE III) including a total of 3,817 women, who were enrolled and
vaccinated without pre-screening for the presence of HPV infection.</span><span
lang=EN-GB style='color:black'> </span></p>

<p class=MsoNormal style='background:white'><b><span lang=EN-GB
style='color:black'>&nbsp;</span></b></p>

<p class=MsoNormal><span lang=EN-GB style='color:black;background:white'>The
primary efficacy endpoints included the combined incidence of HPV&nbsp;6-, 11-,
16- or 18-related and the combined incidence of HPV&nbsp;16- or HPV&nbsp;18-related
persistent infection (6&nbsp;month definition), genital warts, vulvar and
vaginal lesions, CIN of any grade, AIS, and cervical cancers. </span><span
lang=EN-GB style='color:black;background:white'>The median duration of
follow-up for this study was 4.0&nbsp;years.</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black;background:white'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>In the long-term extension study of
Protocol 019, 685 women 24-45&nbsp;years old during vaccination with Gardasil
in the base study were followed. In the PPE population, no cases of HPV
diseases (HPV types 6/11/16/18 related CIN any grade<i> </i>and Genital Warts)
were observed through 10.1&nbsp;years (median follow-up of 8.7&nbsp;years).</span></p>

<p class=MsoNormal style='text-autospace:none'><u><span lang=EN-GB
style='color:black'><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><u><span
lang=EN-GB style='color:black'>Efficacy in women na&iuml;ve to the relevant
vaccine HPV type(s)</span></u></p>

<p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
style='color:black'>The primary analyses of efficacy were conducted in the
per-protocol efficacy (PPE) population (i.e. all 3 vaccinations within 1&nbsp;year
of enrolment, no major protocol deviations and na&iuml;ve to the relevant HPV
type(s) prior to dose 1 and through 1 month Postdose 3 (Month 7)). Efficacy was
measured starting after the Month 7 visit. Overall, 67% of individuals were
na&iuml;ve (PCR negative and seronegative) to all 4 HPV types at enrolment.</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
style='color:black'>The efficacy of Gardasil against the combined incidence of
HPV&nbsp;6-, 11-, 16-, or 18-related persistent infection, genital warts,
vulvar and vaginal lesions, CIN of any grade, AIS, and cervical cancers was
88.7% (95% CI: 78.1, 94.8). </span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
style='color:black;background:white'>The efficacy of Gardasil against the
combined incidence</span><span lang=EN-GB style='color:black'> of HPV&nbsp;16-
or 18-related </span><span lang=EN-GB style='color:black'>persistent infection,
genital warts, vulvar and vaginal lesions, CIN of any grade, AIS, and cervical
cancers</span><span lang=EN-GB style='color:black'> was 84.7% (95% CI: 67.5,
93.7).</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB
style='color:black'>Efficacy in women with and without prior infection or disease
due to HPV&nbsp;6, 11, 16, or 18</span></u></p>

<p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
style='color:black'>The Full Analysis Set population (also known as the ITT
population) included women regardless of baseline HPV status at Day 1, who
received at least one vaccination and in whom case counting started at Day 1.
This population approximates to the general population of women with respect to
prevalence of HPV infection or disease at enrolment.</span></p>

<p class=MsoNormal style='text-autospace:none'><u><span lang=EN-GB
style='color:black'><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
style='color:black'>The efficacy of Gardasil against the combined incidence of
HPV&nbsp;6-, 11-, 16-, or 18-related persistent infection, genital warts,
vulvar and vaginal lesions, CIN of any grade, AIS, and cervical cancers was
47.2% (95% CI: 33.5, 58.2).</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>The efficacy of
Gardasil against the combined incidence of HPV&nbsp;16- or 18-related
persistent infection, genital warts, vulvar and vaginal lesions, CIN of any
grade, AIS, and cervical cancers was 41.6% (95% CI: 24.3, 55.2). </span></p>

<p class=MsoNormal><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB
style='color:black'>Efficacy in women (16 to 45&nbsp;years) with evidence of a
prior infection with a vaccine HPV type (seropositive) that was no longer
detectable at vaccination onset (PCR negative)</span></u></p>

<p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>In post hoc analyses of
individuals (who received at least one vaccination) with evidence of a prior
infection with a vaccine HPV type (seropositive) no longer detectable (PCR
negative) at vaccination onset, the efficacy of Gardasil to prevent conditions
due to the recurrence of the same HPV type was 100% (95% CI: 62.8, 100.0; 0 vs.
12 cases </span><span lang=EN-GB style='color:black'>[n&nbsp;=&nbsp;2572 from pooled
studies in young women]</span><span lang=EN-GB style='color:black'>) against
HPV 6-, 11-, 16-, and 18-related CIN&nbsp;2/3, VIN&nbsp;2/3, VaIN&nbsp;2/3, and
genital warts in women 16 to 26&nbsp;years. Efficacy was 68.2% (95% CI: 17.9,
89.5; 6 vs. 20 cases </span><span lang=EN-GB style='color:black'>[n&nbsp;=&nbsp;832
from studies in young and adult women combined]</span><span lang=EN-GB
style='color:black'>) against HPV&nbsp;16- and 18-related persistent infection
in women 16 to 45&nbsp;years.</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><u><span
lang=EN-GB style='color:black'>Efficacy in men 16 through 26&nbsp;years</span></u></p>

<p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><b><u><span
lang=EN-GB style='color:black'><span style='text-decoration:none'>&nbsp;</span></span></u></b></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>Efficacy was evaluated
against HPV&nbsp;6-, 11-, 16-, 18-related external genital warts,
penile/perineal/perianal intraepithelial neoplasia (PIN) grades 1/2/3, and
persistent infection.</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>The efficacy of
Gardasil in 16- through 26&nbsp;year-old men was assessed in 1
placebo-controlled, double-blind, randomised Phase III clinical study (Protocol
020) including a total of 4,055 men who were enrolled and vaccinated without
pre-screening for the presence of HPV infection. The median duration of
follow-up was 2.9&nbsp;years.</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>In a subset of 598 men
(GARDASIL&nbsp;=&nbsp;299; placebo&nbsp;=&nbsp;299) in Protocol 020 who
self-identified as having sex with men (MSM) efficacy against anal
intraepithelial neoplasia (AIN grades 1/2/3) and anal cancer, and intra-anal
persistent infection was evaluated.</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>MSM are at higher risk
of anal HPV infection compared to the general population; the absolute benefit
of vaccination in terms of prevention of anal cancer in the general population is
expected to be very low.</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>HIV infection was an
exclusion criterion (see also section&nbsp;4.4).</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB
style='color:black'>Efficacy in Men na&iuml;ve to the relevant vaccine HPV
types</span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>The primary analyses of
efficacy, with respect to vaccine HPV types (HPV&nbsp;6, 11, 16, 18), were
conducted in the per-protocol efficacy (PPE) population (i.e. all 3 vaccinations
within 1 year of enrolment, no major protocol deviations and na&iuml;ve to the
relevant HPV type(s) prior to dose 1 and through 1 month Postdose 3 (Month 7)).
Efficacy was measured starting after the Month 7 visit. Overall, 83% of men
(87% of heterosexual subjects and 61% of MSM subjects)<i> </i>were na&iuml;ve
(PCR negative and seronegative) to all 4 HPV types at enrolment.</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Anal Intraepithelial Neoplasia (AIN) Grade
2/3 (moderate to high-grade dysplasia) was used in the clinical trials as a
surrogate marker for anal cance<span style='color:black'>r.</span></span></p>

<p class=MsoNormal><s><span lang=EN-GB style='color:black'><span
 style='text-decoration:none'>&nbsp;</span></span></s></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>The efficacy results
for relevant endpoints analysed at end of study (median duration of follow-up
2.4&nbsp;years) in the per-protocol population are presented in the Table&nbsp;5.
</span><span lang=EN-GB>&nbsp;Efficacy against PIN grades 1/2/3 was not
demonstrated.</span></p>

<p class=MsoNormal><b><i><span lang=EN-GB style='color:black'>&nbsp;</span></i></b></p>

<p class=MsoNormal style='page-break-after:avoid'><i><span lang=EN-GB
style='color:black'>Table&nbsp;5: Efficacy of Gardasil against external genital
lesions in the PPE* population of 16-26&nbsp;year old men </span></i></p>

<div align=center>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0 width=643
 style='border-collapse:collapse;border:none'>
 <tr>
  <td width=170 rowspan=2 valign=top style='width:127.85pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='color:black'>&nbsp;</span></p>
  <p class=MsoNormal align=center style='text-align:center'><b><span
  lang=EN-GB style='color:black'>Endpoint</span></b></p>
  </td>
  <td width=158 colspan=2 valign=top style='width:118.55pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><b><span
  lang=EN-GB style='color:black'>Gardasil</span></b></p>
  </td>
  <td width=161 colspan=2 valign=top style='width:120.5pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><b><span
  lang=EN-GB style='color:black'>Placebo</span></b></p>
  </td>
  <td width=154 rowspan=2 valign=top style='width:115.5pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><b><span
  lang=EN-GB style='color:black'>% Efficacy (95%CI)</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=64 valign=top style='width:47.65pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='color:black'>N</span></p>
  </td>
  <td width=95 valign=top style='width:70.9pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='color:black'>Number of cases</span></p>
  </td>
  <td width=66 valign=top style='width:49.6pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='color:black'>N</span></p>
  </td>
  <td width=95 valign=top style='width:70.9pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='color:black'>Number of cases</span></p>
  </td>
 </tr>
 <tr>
  <td width=643 colspan=6 valign=top style='width:6.7in;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='color:black'>HPV 6/11/16/18-related external genital lesions</span></p>
  </td>
 </tr>
 <tr>
  <td width=170 valign=top style='width:127.85pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='margin-left:9.05pt;text-align:center'><span
  lang=EN-GB style='color:black'>External genital lesions</span></p>
  </td>
  <td width=64 valign=top style='width:47.65pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='color:black'>1394</span></p>
  </td>
  <td width=95 valign=top style='width:70.9pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='color:black'>3</span></p>
  </td>
  <td width=66 valign=top style='width:49.6pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='color:black'>1404</span></p>
  </td>
  <td width=95 valign=top style='width:70.9pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='color:black'>32</span></p>
  </td>
  <td width=154 valign=top style='width:115.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='color:black'>90.6 (70.1. 98.2)</span></p>
  </td>
 </tr>
 <tr>
  <td width=170 valign=top style='width:127.85pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='margin-left:9.0pt;text-align:center'><span
  lang=EN-GB style='color:black'>Genital warts</span></p>
  </td>
  <td width=64 valign=top style='width:47.65pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='color:black'>1394</span></p>
  </td>
  <td width=95 valign=top style='width:70.9pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='color:black'>3</span></p>
  </td>
  <td width=66 valign=top style='width:49.6pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='color:black'>1404</span></p>
  </td>
  <td width=95 valign=top style='width:70.9pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='color:black'>28</span></p>
  </td>
  <td width=154 valign=top style='width:115.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='color:black'>89.3 (65.3, 97.9)</span></p>
  </td>
 </tr>
 <tr>
  <td width=170 valign=top style='width:127.85pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='margin-left:9.0pt;text-align:center'><span
  lang=EN-GB style='color:black'>PIN1/2/3</span></p>
  </td>
  <td width=64 valign=top style='width:47.65pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='color:black'>1394</span></p>
  </td>
  <td width=95 valign=top style='width:70.9pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='color:black'>0</span></p>
  </td>
  <td width=66 valign=top style='width:49.6pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='color:black'>1404</span></p>
  </td>
  <td width=95 valign=top style='width:70.9pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='color:black'>4</span></p>
  </td>
  <td width=154 valign=top style='width:115.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='color:black'>100.0 (-52.1, 100.0)</span></p>
  </td>
 </tr>
</table>

</div>

<p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt;color:black'>*The
individuals in the PPE population received all 3 vaccinations within 1 year of enrolment,
had no major protocol deviations, and were na&iuml;ve to the relevant HPV
type(s) prior to dose 1 and through 1 month Postdose 3 (Month 7).</span></p>

<p class=MsoNormal><s><span lang=EN-GB style='color:black'><span
 style='text-decoration:none'>&nbsp;</span></span></s></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>At end of study
analysis for anal lesions in the MSM population (median duration of follow-up
was 2.15 years), the preventive effect against HPV&nbsp;6-, 11-, 16-, 18-related
AIN 2/3 was 74.9% (95 % CI: 8.8, 95.4; 3/194 versus 13/208) and against
HPV&nbsp;16- or 18-related AIN 2/3 86.6% (95 % CI: 0.0, 99.7; 1/194 versus
8/208). </span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>The duration of protection against anal
cancer is currently unknown. In the long-term extension study of Protocol 020, 917
men 16-26 years old during vaccination with Gardasil in the base study were
followed. In the PPE population, no cases of HPV types 6/11 related genital
warts, HPV 6/11/16/18 external genital lesions or HPV 6/11/16/18 high grade AIN
in MSM were observed through 11.5&nbsp;years (median follow-up of 9.5&nbsp;years).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB
style='color:black'>Efficacy in men with or without prior infection or disease
due to HPV&nbsp;6, 11, 16, or 18</span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB
style='color:black'><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>The Full Analysis Set
population included men regardless of baseline HPV status at Day 1, who
received at least one vaccination and in whom case counting started at Day 1.
This population approximates to the general population of men with respect to
prevalence of HPV infection or disease at enrolment.</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>The efficacy of
GARDASIL against HPV&nbsp;6-, 11-, 16-, 18-related external genital warts was
68.1% (95% CI: 48.8, 79.3). </span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>The efficacy of
GARDASIL against HPV&nbsp;6-, 11-, 16-, 18-related AIN&nbsp;2/3 and
HPV&nbsp;16- or 18-related AIN&nbsp;2/3, in the MSM substudy, was 54.2% (95%
CI: 18.0, 75.3; 18/275 versus 39/276) and 57.5% (95% CI: -1.8, 83.9; 8/275
versus 19/276 cases), respectively.</span></p>

<p class=MsoNormal><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB
style='color:black'>Protection Against the Overall Burden of HPV disease in 16-
Through 26-Year-Old Men</span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>The impact of Gardasil
against the overall risk for external genital lesions was evaluated after the
first dose in 2,545 individuals enrolled in the Phase III efficacy trial
(Protocol 020). Among men who were na&iuml;ve to 14 common HPV types,
administration of Gardasil reduced the incidence of external genital lesions
caused by vaccine- or non-vaccine HPV types by 81.5% (95% CI: 58.0, 93.0). In
the Full Analysis Set (FAS) population, the benefit of the vaccine with respect
to the overall incidence of EGL was lower, with a reduction of 59.3% (95% CI:
40.0, 72.9), as Gardasil does not impact the course of infections or disease
that are present at vaccination onset. </span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB
style='color:black'>Impact on Biopsy and Definitive Therapy Procedures </span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>The impact of Gardasil
on rates of biopsy and treatment of EGL regardless of causal HPV types was
evaluated in 2,545 individuals enrolled in Protocol 020. In the HPV na&iuml;ve
population (na&iuml;ve to 14 common HPV types), Gardasil reduced the proportion
of men who had a biopsy by 54.2% (95% CI: 28.3, 71.4) and who were treated by
47.7% (95% CI: 18.4, 67.1) at end of study. In the FAS population, the
corresponding reduction was 45.7% (95% CI: 29.0, 58.7) and 38.1% (95% CI: 19.4,
52.6).</span></p>

<p class=MsoNormal><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal style='page-break-after:avoid'><i><span lang=EN-GB>Immunogenicity</span></i></p>

<p class=MsoNormal style='page-break-after:avoid'><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>Assays to
Measure Immune Response</span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal><span lang=EN-GB>No minimum antibody level associated with
protection has been identified for HPV vaccines.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>The immunogenicity of Gardasil was assessed
in 20,132 (Gardasil n&nbsp;=&nbsp;10,723; placebo n&nbsp;=&nbsp;9,409) girls
and women 9 to 26&nbsp;years of age, 5,417 (Gardasil n&nbsp;=&nbsp;3,109;
placebo n&nbsp;=&nbsp;2,308) boys and men 9 to 26&nbsp;years of age and 3,819
women 24 to 45&nbsp;years of age (Gardasil n&nbsp;=&nbsp;1,911, placebo
n&nbsp;=&nbsp;1,908).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Type-specific immunoassays, competitive
Luminex-based immunoassay (cLIA), with type-specific standards were used to
assess immunogenicity to each vaccine type. This assay measures antibodies
against a single neutralizing epitope for each individual HPV type.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>Immune
Responses to Gardasil at 1&nbsp;month post dose 3 </span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>In the clinical studies in women 16 to
26&nbsp;years of age,<b> </b></span><span lang=EN-GB>99.8%, 99.8%, 99.8%, and
99.5% of individuals who received Gardasil became anti-HPV&nbsp;6,
anti-HPV&nbsp;11, anti-HPV&nbsp;16, and anti-HPV&nbsp;18-seropositive,
respectively, by 1 month Postdose 3. <span style='color:black'>In the clinical
study in women<b> </b>24 to 45&nbsp;years, 98.4%, 98.1%, 98.8%, and 97.4% of
individuals who received Gardasil became anti-HPV&nbsp;6, anti-</span></span><span
lang=EN-GB>HPV&nbsp;11</span><span lang=EN-GB style='color:black'>,
anti-HPV&nbsp;16, and anti-HPV&nbsp;18 seropositive, respectively, by 1 month
Postdose 3. In the clinical study in men<b> </b>16 to 26&nbsp;years, 98.9%,
99.2%, 98.8%, and 97.4% of individuals who received Gardasil became anti-HPV&nbsp;6,
anti-HPV&nbsp;11, anti-HPV&nbsp;16, and anti-HPV&nbsp;18 seropositive,
respectively, by 1&nbsp;month Postdose 3. </span><span lang=EN-GB>Gardasil
induced high anti-HPV Geometric Mean Titres (GMTs) 1 month Postdose 3 in all
age groups tested.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>As expected for women 24 to 45&nbsp;years
of age (Protocol 019), the observed antibody titres were lower than that seen
in women 16 to 26&nbsp;years.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Anti-HPV levels in placebo individuals who
had cleared an HPV infection (seropositive and PCR negative) were substantially
lower than those induced by the vaccine. Furthermore, anti-HPV levels (GMTs) in
vaccinated individuals remained at or above serostatus cut-off during the
long-term follow-up of the </span><span lang=EN-GB>Phase III studies (see below
under <i>Persistence of Immune Response of Gardasil</i>).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>Bridging
the Efficacy of </span></u><u><span lang=EN-GB>Gardasil from Women to Girls </span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>A clinical
study (Protocol 016) compared the immunogenicity of Gardasil in 10- to 15-year-old
girls to those in 16- to 23&nbsp;year old women. In the vaccine group, 99.1 to
100% became seropositive to all vaccine serotypes by 1 month Postdose 3<b><i>.</i></b></span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>Table&nbsp;6
compares the 1 month Postdose 3 anti-HPV&nbsp;6, 11, 16, and 18 GMTs in 9- to
15&nbsp;year-old girls with those in 16- to 26-year old women. </span></p>

<p class=MsoNormal style='text-autospace:none'><b><i><span lang=EN-GB>&nbsp;</span></i></b></p>

<p class=MsoNormal style='page-break-after:avoid'><i><span lang=EN-GB>Table&nbsp;6:
Immunogenicity bridging between 9- to 15-year-old girls and 16- to 26-year-old
women (</span></i><i><span lang=EN-GB>per-protocol population) based on titres
as measured by cLIA</span></i></p>

<div align=center>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0 width="100%"
 style='width:100.0%;border-collapse:collapse;border:none'>
 <tr style='page-break-inside:avoid'>
  <td width="9%" rowspan=2 style='width:9.8%;border:solid windowtext 1.0pt;
  padding:0in 2.9pt 0in 2.9pt'>
  <p class=MsoNormal style='margin-left:1.0in'><b><span lang=EN-GB>&nbsp;</span></b></p>
  </td>
  <td width="44%" colspan=2 style='width:44.64%;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 2.9pt 0in 2.9pt'>
  <p class=MsoNormal align=center style='text-align:center'><b><span
  lang=EN-GB>9- to 15-Year-Old Girls</span></b></p>
  <p class=MsoNormal align=center style='text-align:center'><b><span
  lang=EN-GB>(Protocols 016 and 018)</span></b></p>
  </td>
  <td width="45%" colspan=3 style='width:45.56%;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 2.9pt 0in 2.9pt'>
  <p class=MsoNormal align=center style='text-align:center'><b><span
  lang=EN-GB>16- to 26-Year-Old Women</span></b></p>
  <p class=MsoNormal align=center style='text-align:center'><b><span
  lang=EN-GB>(Protocols 013 and 015)</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="9%" style='width:9.96%;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 2.9pt 0in 2.9pt'>
  <p class=MsoNormal align=center style='text-align:center'><b><span
  lang=EN-GB>n</span></b></p>
  </td>
  <td width="34%" style='width:34.68%;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 2.9pt 0in 2.9pt'>
  <p class=MsoNormal align=center style='text-align:center'><b><span
  lang=EN-GB>GMT (95% CI)</span></b></p>
  </td>
  <td width="12%" style='width:12.36%;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 2.9pt 0in 2.9pt'>
  <p class=MsoNormal align=center style='text-align:center'><b><span
  lang=EN-GB>n</span></b></p>
  </td>
  <td width="33%" colspan=2 style='width:33.2%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 2.9pt 0in 2.9pt'>
  <p class=MsoNormal align=center style='text-align:center'><b><span
  lang=EN-GB>GMT (95% CI)</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="9%" style='width:9.8%;border:solid windowtext 1.0pt;border-top:
  none;padding:0in 2.9pt 0in 2.9pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>HPV
  6</span></p>
  </td>
  <td width="9%" style='width:9.96%;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 2.9pt 0in 2.9pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>915</span></p>
  </td>
  <td width="34%" style='width:34.68%;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 2.9pt 0in 2.9pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>929
  (874, 987)</span></p>
  </td>
  <td width="12%" style='width:12.36%;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 2.9pt 0in 2.9pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>2631</span></p>
  </td>
  <td width="33%" colspan=2 style='width:33.2%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 2.9pt 0in 2.9pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>543
  (526, 560)</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="9%" style='width:9.8%;border:solid windowtext 1.0pt;border-top:
  none;padding:0in 2.9pt 0in 2.9pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>HPV
  11</span></p>
  </td>
  <td width="9%" style='width:9.96%;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 2.9pt 0in 2.9pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>915</span></p>
  </td>
  <td width="34%" style='width:34.68%;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 2.9pt 0in 2.9pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>1303
  (1223, 1388)</span></p>
  </td>
  <td width="12%" style='width:12.36%;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 2.9pt 0in 2.9pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>2655</span></p>
  </td>
  <td width="33%" colspan=2 style='width:33.2%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 2.9pt 0in 2.9pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>762
  (735, 789)</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="9%" style='width:9.8%;border:solid windowtext 1.0pt;border-top:
  none;padding:0in 2.9pt 0in 2.9pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>HPV
  16</span></p>
  </td>
  <td width="9%" style='width:9.96%;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 2.9pt 0in 2.9pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>913</span></p>
  </td>
  <td width="34%" style='width:34.68%;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 2.9pt 0in 2.9pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>4909
  (4548, 5300)</span></p>
  </td>
  <td width="12%" style='width:12.36%;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 2.9pt 0in 2.9pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>2570</span></p>
  </td>
  <td width="33%" colspan=2 style='width:33.2%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 2.9pt 0in 2.9pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>2294
  (2185, 2408)</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="9%" style='width:9.8%;border:solid windowtext 1.0pt;border-top:
  none;padding:0in 2.9pt 0in 2.9pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>HPV
  18</span></p>
  </td>
  <td width="9%" style='width:9.96%;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 2.9pt 0in 2.9pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>920</span></p>
  </td>
  <td width="34%" style='width:34.68%;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 2.9pt 0in 2.9pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>1040
  (965, 1120)</span></p>
  </td>
  <td width="12%" style='width:12.36%;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 2.9pt 0in 2.9pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>2796</span></p>
  </td>
  <td width="33%" colspan=2 style='width:33.2%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 2.9pt 0in 2.9pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>462
  (444, 480)</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="99%" colspan=5 style='width:99.22%;border:none;padding:0in 2.9pt 0in 2.9pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>GMT- Geometric
  mean titre in mMU/ml (mMU&nbsp;=&nbsp;milli-Merck units)</span></p>
  </td>
  <td style='border:none;padding:0in 0in 0in 0in' width="0%"><p class='MsoNormal'>&nbsp;</td>
 </tr>
 <tr height=0>
  <td width=69 style='border:none'></td>
  <td width=70 style='border:none'></td>
  <td width=245 style='border:none'></td>
  <td width=87 style='border:none'></td>
  <td width=229 style='border:none'></td>
  <td width=6 style='border:none'></td>
 </tr>
</table>

</div>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>Anti-HPV
responses at Month 7 among 9- to 15-year-old girls were non-inferior to
anti-HPV responses in 16- to 26-year-old women for whom efficacy was
established in the Phase III studies. Immunogenicity was related to age and
Month 7 anti-HPV levels were significantly higher in younger individuals below
12&nbsp;years of age than in those above that age.</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>On the basis of
this immunogenicity bridging, the efficacy of Gardasil in 9- to 15-year-old
girls is inferred.</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>In the long-term
extension study of Protocol 018, 369 girls 9-15 years old during vaccination
with Gardasil in the base study were followed. In the PPE population, no cases
of HPV diseases (HPV types 6/11/16/18 related CIN any grade and Genital Warts)
were observed through 10.7&nbsp;years (median follow-up of 10.0&nbsp;years).</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>Bridging
the Efficacy of </span></u><u><span lang=EN-GB>Gardasil from Men to Boys </span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal><span lang=EN-GB>Three clinical studies (Protocols 016, 018
and 020) were used to compare the immunogenicity of Gardasil in 9- to
15-year-old boys to 16- to 26-year-old men. In the vaccine group, 97.4 to 99.9%
became seropositive to all vaccine serotypes by 1 month Postdose 3<b><i>.</i></b></span></p>

<p class=MsoNormal><b><i><span lang=EN-GB>&nbsp;</span></i></b></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>Table&nbsp;7
compares the 1 month Postdose 3 anti-HPV&nbsp;6, 11, 16, and 18 GMTs in 9- to
15-year-old boys with those in 16- to 26-year-old men. </span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><i><span lang=EN-GB>Table&nbsp;7:
Immunogenicity bridging between 9- to 15-year-old boys and 16- to 26-year-old
men (</span></i><i><span lang=EN-GB>per-protocol population) based on titres as
measured by cLIA</span></i></p>

<div align=center>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0 width="100%"
 style='width:100.0%;border-collapse:collapse;border:none'>
 <thead>
  <tr style='page-break-inside:avoid'>
   <td width="14%" rowspan=2 style='width:14.96%;border:solid windowtext 1.0pt;
   padding:0in 2.9pt 0in 2.9pt'>
   <p class=MsoNormal align=center style='margin-left:1.0in;text-align:center'><b><span
   lang=EN-GB>&nbsp;</span></b></p>
   </td>
   <td width="39%" colspan=2 style='width:39.76%;border:solid windowtext 1.0pt;
   border-left:none;padding:0in 2.9pt 0in 2.9pt'>
   <p class=MsoNormal align=center style='text-align:center'><b><span
   lang=EN-GB>9- to 15-Year-Old Boys</span></b></p>
   <p class=MsoNormal align=center style='text-align:center'><b><span
   lang=EN-GB>&nbsp;</span></b></p>
   </td>
   <td width="45%" colspan=2 style='width:45.28%;border:solid windowtext 1.0pt;
   border-left:none;padding:0in 2.9pt 0in 2.9pt'>
   <p class=MsoNormal align=center style='text-align:center'><b><span
   lang=EN-GB>16- to 26-Year-Old Men</span></b></p>
   <p class=MsoNormal align=center style='text-align:center'><b><span
   lang=EN-GB>&nbsp;</span></b></p>
   </td>
  </tr>
  <tr style='page-break-inside:avoid'>
   <td width="12%" style='width:12.5%;border-top:none;border-left:none;
   border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   padding:0in 2.9pt 0in 2.9pt'>
   <p class=MsoNormal align=center style='text-align:center'><b><span
   lang=EN-GB>n</span></b></p>
   </td>
   <td width="27%" style='width:27.26%;border-top:none;border-left:none;
   border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   padding:0in 2.9pt 0in 2.9pt'>
   <p class=MsoNormal align=center style='text-align:center'><b><span
   lang=EN-GB>GMT (95% CI)</span></b></p>
   </td>
   <td width="17%" style='width:17.04%;border-top:none;border-left:none;
   border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   padding:0in 2.9pt 0in 2.9pt'>
   <p class=MsoNormal align=center style='text-align:center'><b><span
   lang=EN-GB>n</span></b></p>
   </td>
   <td width="28%" style='width:28.24%;border-top:none;border-left:none;
   border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   padding:0in 2.9pt 0in 2.9pt'>
   <p class=MsoNormal align=center style='text-align:center'><b><span
   lang=EN-GB>GMT (95% CI)</span></b></p>
   </td>
  </tr>
 </thead>
 <tr style='page-break-inside:avoid'>
  <td width="14%" style='width:14.96%;border:solid windowtext 1.0pt;border-top:
  none;padding:0in 2.9pt 0in 2.9pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>HPV
  6</span></p>
  </td>
  <td width="12%" style='width:12.5%;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 2.9pt 0in 2.9pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>884</span></p>
  </td>
  <td width="27%" valign=top style='width:27.26%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 2.9pt 0in 2.9pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>1038
  (964, 1117)</span></p>
  </td>
  <td width="17%" style='width:17.04%;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 2.9pt 0in 2.9pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>1093</span></p>
  </td>
  <td width="28%" valign=top style='width:28.24%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 2.9pt 0in 2.9pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>448
  (419, 479)</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="14%" style='width:14.96%;border:solid windowtext 1.0pt;border-top:
  none;padding:0in 2.9pt 0in 2.9pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>HPV
  11</span></p>
  </td>
  <td width="12%" style='width:12.5%;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 2.9pt 0in 2.9pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>885</span></p>
  </td>
  <td width="27%" valign=top style='width:27.26%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 2.9pt 0in 2.9pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>1387
  (1299, 1481)</span></p>
  </td>
  <td width="17%" style='width:17.04%;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 2.9pt 0in 2.9pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>1093</span></p>
  </td>
  <td width="28%" valign=top style='width:28.24%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 2.9pt 0in 2.9pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>624
  (588, 662)</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="14%" style='width:14.96%;border:solid windowtext 1.0pt;border-top:
  none;padding:0in 2.9pt 0in 2.9pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>HPV
  16</span></p>
  </td>
  <td width="12%" style='width:12.5%;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 2.9pt 0in 2.9pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>882</span></p>
  </td>
  <td width="27%" valign=top style='width:27.26%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 2.9pt 0in 2.9pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>6057
  (5601, 6549)</span></p>
  </td>
  <td width="17%" style='width:17.04%;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 2.9pt 0in 2.9pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>1136</span></p>
  </td>
  <td width="28%" valign=top style='width:28.24%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 2.9pt 0in 2.9pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>2403
  (2243, 2575)</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="14%" style='width:14.96%;border:solid windowtext 1.0pt;border-top:
  none;padding:0in 2.9pt 0in 2.9pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>HPV 18</span></p>
  </td>
  <td width="12%" style='width:12.5%;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 2.9pt 0in 2.9pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>887</span></p>
  </td>
  <td width="27%" valign=top style='width:27.26%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 2.9pt 0in 2.9pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>1357 (1249, 1475)</span></p>
  </td>
  <td width="17%" style='width:17.04%;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 2.9pt 0in 2.9pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>1175</span></p>
  </td>
  <td width="28%" valign=top style='width:28.24%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 2.9pt 0in 2.9pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>403 (375, 433)</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="100%" colspan=5 style='width:100.0%;border:none;padding:0in 2.9pt 0in 2.9pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>GMT- Geometric
  mean titre in mMU/ml (mMU&nbsp;=&nbsp;milli-Merck units)</span></p>
  </td>
 </tr>
</table>

</div>

<p class=MsoNormal><b><i><span lang=EN-GB>&nbsp;</span></i></b></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>Anti-HPV
responses at Month 7 among 9- to 15-year-old boys were non-inferior to anti-HPV
responses in 16- to 26-year-old men for whom efficacy was established in the Phase
III studies. Immunogenicity was related to age and Month 7 anti-HPV levels were
significantly higher in younger individuals.</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>On the basis of this immunogenicity bridging,
the efficacy of Gardasil in 9- to 15-year-old boys is inferred.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>In the long-term extension study of
Protocol 018, 326 boys 9-15&nbsp;years old during vaccination with Gardasil in
the base study were followed. In the PPE population, no cases of HPV diseases
(HPV types 6/11/16/18 related External Genital Lesions) were observed through
10.6&nbsp;years (median follow-up of 9.9&nbsp;years).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>Persistence
of Immune Response of Gardasil</span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal><span lang=EN-GB>A subset of individuals enrolled in the
Phase III studies was followed up for a long-term period for safety,
immunogenicity and effectiveness. Total IgG Luminex Immunoassay (IgG LIA) was
used to assess the persistence of immune response in addition to cLIA.</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>In </span><span lang=EN-GB>all populations
(women 9&nbsp;&#8211;&nbsp;45 years, men 9&nbsp;&#8211;&nbsp;26&nbsp;years)</span><span
lang=EN-GB>, peak anti-HPV&nbsp;6, anti-HPV&nbsp;11, anti-HPV&nbsp;16, and
anti-HPV&nbsp;18 GMTs cLIA were observed at Month 7. Afterwards, the GMTs
declined through Month 24&nbsp;-&nbsp;48 and then generally stabilized. The duration
of immunity following a 3-dose series has been observed for up to 14&nbsp;years
post&#8209;vaccination.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Girls and boys vaccinated with Gardasil at
9-15&nbsp;years of age in Protocol 018 base study were followed up in an
extension study. Depending on HPV type, 60-96% and 78-98% of subjects were seropositive
by cLIA and IgG LIA respectively 10&nbsp;years after vaccination (see
Table&nbsp;8).</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><i><span lang=EN-GB>Table&nbsp;8:
Long-term immunogenicity data (</span></i><i><span lang=EN-GB>per-protocol population)
based on percentage of seropositive subjects as measured by cLIA and IgG LIA
(Protocol 018) at 10&nbsp;years, in girls and boys 9-15&nbsp;years of age&nbsp;
</span></i></p>

<p class=MsoNormal style='page-break-after:avoid'><i><span lang=EN-GB>&nbsp;</span></i></p>

<div align=center>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0 width="100%"
 style='width:100.0%;border-collapse:collapse;border:none'>
 <tr style='page-break-inside:avoid'>
  <td width="17%" rowspan=2 style='width:17.08%;border:solid windowtext 1.0pt;
  padding:0in 2.9pt 0in 2.9pt'>
  <p class=MsoNormal align=center style='margin-left:1.0in;text-align:center'><b><span
  lang=EN-GB>&nbsp;</span></b></p>
  </td>
  <td width="39%" colspan=2 style='width:39.7%;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 2.9pt 0in 2.9pt'>
  <p class=MsoNormal align=center style='text-align:center'><b><span
  lang=EN-GB>cLIA</span></b></p>
  <p class=MsoNormal align=center style='text-align:center'><b><span
  lang=EN-GB>&nbsp;</span></b></p>
  </td>
  <td width="43%" colspan=2 style='width:43.22%;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 2.9pt 0in 2.9pt'>
  <p class=MsoNormal align=center style='text-align:center'><b><span
  lang=EN-GB>IgG LIA</span></b></p>
  <p class=MsoNormal align=center style='text-align:center'><b><span
  lang=EN-GB>&nbsp;</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="13%" style='width:13.36%;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 2.9pt 0in 2.9pt'>
  <p class=MsoNormal align=center style='text-align:center'><b><span
  lang=EN-GB>n</span></b></p>
  </td>
  <td width="26%" style='width:26.34%;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 2.9pt 0in 2.9pt'>
  <p class=MsoNormal align=center style='text-align:center'><b><span
  lang=EN-GB>% of seropositive subjects</span></b></p>
  </td>
  <td width="14%" style='width:14.02%;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 2.9pt 0in 2.9pt'>
  <p class=MsoNormal align=center style='text-align:center'><b><span
  lang=EN-GB>n</span></b></p>
  </td>
  <td width="29%" style='width:29.2%;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 2.9pt 0in 2.9pt'>
  <p class=MsoNormal align=center style='text-align:center'><b><span
  lang=EN-GB>% of seropositive subjects</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="17%" style='width:17.08%;border:solid windowtext 1.0pt;border-top:
  none;padding:0in 2.9pt 0in 2.9pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>HPV
  6</span></p>
  </td>
  <td width="13%" style='width:13.36%;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 2.9pt 0in 2.9pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>409</span></p>
  </td>
  <td width="26%" valign=top style='width:26.34%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 2.9pt 0in 2.9pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>89%</span></p>
  </td>
  <td width="14%" style='width:14.02%;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 2.9pt 0in 2.9pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>430</span></p>
  </td>
  <td width="29%" valign=top style='width:29.2%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 2.9pt 0in 2.9pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>93%</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="17%" style='width:17.08%;border:solid windowtext 1.0pt;border-top:
  none;padding:0in 2.9pt 0in 2.9pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>HPV
  11</span></p>
  </td>
  <td width="13%" style='width:13.36%;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 2.9pt 0in 2.9pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>409</span></p>
  </td>
  <td width="26%" valign=top style='width:26.34%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 2.9pt 0in 2.9pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>89%</span></p>
  </td>
  <td width="14%" style='width:14.02%;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 2.9pt 0in 2.9pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>430</span></p>
  </td>
  <td width="29%" valign=top style='width:29.2%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 2.9pt 0in 2.9pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>90%</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="17%" style='width:17.08%;border:solid windowtext 1.0pt;border-top:
  none;padding:0in 2.9pt 0in 2.9pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>HPV
  16</span></p>
  </td>
  <td width="13%" style='width:13.36%;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 2.9pt 0in 2.9pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>403</span></p>
  </td>
  <td width="26%" valign=top style='width:26.34%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 2.9pt 0in 2.9pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>96%</span></p>
  </td>
  <td width="14%" style='width:14.02%;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 2.9pt 0in 2.9pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>426</span></p>
  </td>
  <td width="29%" valign=top style='width:29.2%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 2.9pt 0in 2.9pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>98%</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="17%" style='width:17.08%;border:solid windowtext 1.0pt;border-top:
  none;padding:0in 2.9pt 0in 2.9pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>HPV
  18</span></p>
  </td>
  <td width="13%" style='width:13.36%;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 2.9pt 0in 2.9pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>408</span></p>
  </td>
  <td width="26%" valign=top style='width:26.34%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 2.9pt 0in 2.9pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>60%</span></p>
  </td>
  <td width="14%" style='width:14.02%;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 2.9pt 0in 2.9pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>429</span></p>
  </td>
  <td width="29%" valign=top style='width:29.2%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 2.9pt 0in 2.9pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>78%</span></p>
  </td>
 </tr>
</table>

</div>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>Women vaccinated with
Gardasil at 16-23&nbsp;years of age in Protocol 015 base were followed up in an
extension study. Fourteen years after vaccination, 91%, 91%, 98% and 52% were
anti-HPV&nbsp;6, anti-HPV&nbsp;11, anti-HPV&nbsp;16 and anti-HPV&nbsp;18
seropositive in the cLIA, respectively, and 98%, 98%, 100% and 94% were
anti-HPV&nbsp;6, anti-HPV&nbsp;11, anti-HPV&nbsp;16 and anti-HPV&nbsp;18
seropositive in the IgG LIA, respectively.</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>Women vaccinated with
Gardasil at 24-45&nbsp;years of age in Protocol 019 base study were followed up
in an extension study. Ten years after vaccination, 79%, 85%, 94%, and 36% were
anti-HPV&nbsp;6, anti-HPV&nbsp;11, anti-HPV&nbsp;16 and anti-HPV&nbsp;18
seropositive in the cLIA, respectively, and 86%, 79%, 100% and 83% were
anti-HPV&nbsp;6, anti-HPV&nbsp;11, anti-HPV&nbsp;16 and anti-HPV&nbsp;18
seropositive in the IgG LIA, respectively.</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>Men vaccinated with
Gardasil at 16-26&nbsp;years of age in Protocol 020 base study were followed up
in an extension study. Ten&nbsp;years after vaccination, 79%, 80%, 95% and 40%
were anti-HPV&nbsp;6, anti-HPV&nbsp;11, anti-HPV&nbsp;16 and anti-HPV&nbsp;18
seropositive in the cLIA, respectively, and 92%, 92%, 100% and 92% were
anti-HPV&nbsp;6, anti-HPV&nbsp;11, anti-HPV&nbsp;16 and anti-HPV&nbsp;18
seropositive in the IgG LIA, respectively.</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>In these studies,
individuals who were seronegative for anti-HPV&nbsp;6, anti-HPV&nbsp;11,
anti-HPV&nbsp;16, and anti-HPV&nbsp;18 in the cLIA were still protected against
clinical disease after a follow-up of 14&nbsp;years for 16-23&nbsp;year-old
women, 10&nbsp;years for 24-45&nbsp;year-old women, and 10&nbsp;years for
16-26&nbsp;year-old men.</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>Evidence
of Anamnestic (Immune Memory) Response</span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal><span lang=EN-GB>Evidence of an anamnestic response was seen
in vaccinated women who were seropositive to relevant HPV type(s) prior to
vaccination. In addition, a subset of vaccinated women who received a challenge
dose of Gardasil 5 years after the onset of vaccination, exhibited a rapid and
strong anamnestic response that exceeded the anti-HPV GMTs observed 1 month
Postdose 3. </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>HIV
infected subjects</span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal><span lang=EN-GB>An academic study documenting safety and
immunogenicity of Gardasil has been performed in 126 HIV infected subjects aged
from 7-12&nbsp;years (of which 96 received Gardasil). Seroconversion to all
four antigens occurred in more than ninety-six percent of the subjects. The
GMTs were somewhat lower than reported in non-HIV infected subjects of the same
age in other studies. The clinical relevance of the lower response is unknown.
The safety profile was similar to non-HIV infected subjects in other studies.
The CD4% or plasma HIV RNA was not affected by vaccination. </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>Immune
Responses to Gardasil using a 2-dose schedule in individuals 9-13&nbsp;years of
age</span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal><span lang=EN-GB>A clinical trial showed that among girls
who received 2 doses of HPV vaccine 6&nbsp;months apart, antibody responses to
the 4 HPV types, one month after the last dose were non-inferior to those among
young women who received 3 doses of the vaccine within 6&nbsp;months. </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>At Month 7, in the Per Protocol population,
the immune response in girls aged 9-13&nbsp;years (n&nbsp;=&nbsp;241) who
received 2 doses of Gardasil (at 0, 6&nbsp;months) was non&#8211;inferior and
numerically higher to the immune response in women aged 16-26 years (n&nbsp;=&nbsp;246)
who received 3 doses of Gardasil (at 0, 2, 6&nbsp;months). </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>At 36 month
follow-up, the GMT in girls (2 doses, n&nbsp;=&nbsp;86) remained non-inferior
to the GMT in women (3doses, n&nbsp;=&nbsp;86) for all 4 HPV types.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>In the same study, in girls aged 9-13&nbsp;years,
the immune response after a 2-dose schedule was numerically lower than after a
3-dose schedule (n&nbsp;=&nbsp;248 at Month 7; n&nbsp;=&nbsp;82 at Month 36).
The clinical relevance of these findings is unknown. </span><span lang=EN-GB>A
subset of the study participants from the 2-dose group (n=50) were followed
5-years post-vaccination (Month 60 Postdose 1). Among the girls receiving 2
doses of the vaccine, 96%, 100%, 100%, and 84% remained seropositive to anti-HPV
6, anti-HPV 11, anti-HPV 16, and anti-HPV 18, respectively, in the cLIA.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Duration of protection of a 2-dose schedule
of Gardasil has not been established.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid'><b><span lang=EN-GB>5.2&nbsp;&nbsp;&nbsp;&nbsp; Pharmacokinetic
properties</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Not applicable.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid'><b><span lang=EN-GB>5.3&nbsp;&nbsp;&nbsp;&nbsp; Preclinical safety data</span></b></p>

<p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>Single-dose and
repeated-dose toxicity and local tolerance studies revealed no special hazards
to humans.</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black;layout-grid-mode:line'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>Gardasil induced
specific antibody responses against HPV types 6, 11, 16, and 18 in pregnant
rats, following one or multiple intramuscular injections. Antibodies against
all four HPV types were transferred to the offspring during gestation and
possibly during lactation.<span style='layout-grid-mode:line'> There</span>
were no treatment-related effects on developmental signs, behaviour,
reproductive performance, or fertility of the offspring.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>GARDASIL administered
to male rats at the full human dose (120 mcg total protein) had no effects on
reproductive performance including fertility, sperm count, and sperm motility,
and there were no vaccine-related gross or histomorphologic changes on the
testes and no effects on testes weights.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid'><b><span lang=EN-GB>6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; PHARMACEUTICAL
PARTICULARS</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid'><b><span lang=EN-GB>6.1&nbsp;&nbsp;&nbsp;&nbsp; List of excipients</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Sodium chloride</span></p>

<p class=MsoNormal><span lang=EN-GB>L-histidine </span></p>

<p class=MsoNormal><span lang=EN-GB>Polysorbate&nbsp;80</span></p>

<p class=MsoNormal><span lang=EN-GB>Sodium borate</span></p>

<p class=MsoNormal><span lang=EN-GB>Water for injections</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>For adjuvant, see section&nbsp;2.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid'><b><span lang=EN-GB>6.2&nbsp;&nbsp;&nbsp;&nbsp; Incompatibilities</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>In the absence of compatibility studies, this
medicinal product must not be mixed with other medicinal products.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid'><b><span lang=EN-GB>6.3&nbsp;&nbsp;&nbsp;&nbsp; Shelf life</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>3&nbsp;years.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid'><b><span lang=EN-GB>6.4&nbsp;&nbsp;&nbsp;&nbsp; Special precautions for
storage</span></b></p>

<p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><u><span lang=EN-GB>Gardasil,
suspension for injection</span></u><span lang=EN-GB> :</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>Store in a
refrigerator (2&deg;C&nbsp;-&nbsp;8&deg;C).</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Do not freeze. Keep the vial in the outer
carton in order to protect from light.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Gardasil should be administered as soon as
possible after being removed from the refrigerator.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Data from stability studies demonstrate that
the vaccine components are stable for 72&nbsp;hours when stored at temperatures
from 8&deg;C to 42&deg;C. At the end of this period Gardasil should be used or
discarded. These data are intended to guide healthcare professionals in case of
temporary temperature excursion only.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><u><span lang=EN-GB>Gardasil, suspension for injection in a
pre-filled syringe :</span></u></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>Store in a
refrigerator (2&deg;C&nbsp;-&nbsp;8&deg;C).</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Do not freeze. Keep the pre-filled syringe in
the outer carton in order to protect from light.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Gardasil should be administered as soon as
possible after being removed from the refrigerator.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Data from stability studies demonstrate
that the vaccine components are stable for 72&nbsp;hours when stored at
temperatures from 8&deg;C to &deg; 42&nbsp;C. At the end of this period
Gardasil should be used or discarded. These data are intended to guide
healthcare professionals in case of temporary temperature excursion only.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>6.5&nbsp;&nbsp;&nbsp;&nbsp; Nature
and contents of container</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>Gardasil,
suspension for injection :</span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>0.5&nbsp;ml
suspension in a vial (glass) with stopper (FluroTec-coated or Teflon-coated
chlorobutyl elastomer) and flip-off plastic cap (aluminium crimp band) in a
pack size of 1, 10 or 20.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:7.9pt'><u><span lang=EN-GB>Gardasil,
suspension for injection in a pre-filled syringe :</span></u></p>

<p class=MsoNormal style='margin-right:7.9pt'><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal><span lang=EN-GB>0.5&nbsp;ml suspension in a pre-filled
syringe (glass) with plunger stopper (siliconized FluroTec-coated bromobutyl
elastomer or non-coated chlorobutyl elastomer) and a tip cap (bromobutyl )
without needle or with one or two needle(s) - pack size of 1, 10 or 20.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Not all pack sizes are marketed.</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid'><b><span lang=EN-GB>6.6&nbsp;&nbsp;&nbsp;&nbsp; </span></b><b><span
lang=EN-GB style='color:black'>Special precautions for disposal</span></b><b><span
lang=EN-GB> and other handling</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span style='color:black'>Gardasil,
suspension for injection:</span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Gardasil may appear as a clear liquid with a
white precipitate prior to agitation.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Shake well before use to make a suspension.
After thorough agitation, it is a white, cloudy liquid.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Inspect the suspension visually for particulate
matter and discolouration prior to administration. Discard the vaccine if
particulates are present and/or if it appears discoloured. </span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
class=MsoCommentReference><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><span class=MsoCommentReference><span lang=EN-GB>Withdraw
the 0.5&nbsp;ml dose of vaccine from the single-dose vial using a sterile
needle and syringe. </span></span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Inject immediately using the intramuscular (IM)
route, preferably in the deltoid area of the upper arm or in the higher
anterolateral area of the thigh. </span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>The vaccine should be used as supplied. The full
recommended dose of the vaccine should be used. </span></p>

<p class=MsoNormal><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal><span lang=EN-GB>Any unused vaccine or waste material should
be disposed of in accordance with local requirements.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><u><span style='color:black'>Gardasil, suspension for
injection </span></u><u><span lang=EN-GB>in a pre-filled syringe</span></u><u><span
style='color:black'>:</span></u></p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Gardasil may appear as a clear liquid with a
white precipitate prior to agitation. </span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Shake well b</span><span lang=EN-GB>efore use,
the pre-filled syringe, to make a suspension. After thorough agitation, it is a
white, cloudy liquid. </span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Inspect the suspension visually for particulate
matter and discolouration prior to administration. Discard the vaccine if
particulates are present and/or if it appears discoloured. </span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Two needles of different lengths are provided in
the pack, choose the appropriate needle to ensure an intramuscular (IM)
administration depending on your patient&#8217;s size and weight. </span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Attach the needle by twisting in a clockwise
direction until the needle fits securely on the syringe. Administer the entire
dose as per standard protocol. </span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Inject immediately using the intramuscular (IM)
route, preferably in the deltoid area of the upper arm or in the higher
anterolateral area of the thigh.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>The vaccine should be used as supplied. The full
recommended dose of the vaccine should be used.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>Any unused vaccine or waste material should be disposed of in
accordance with local requirements.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'>&nbsp;</p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid'><b><span lang=FR>7.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; MARKETING
AUTHORISATION HOLDER</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=FR>&nbsp;</span></p>

<p class=MsoNormal><span lang=FR>MSD VACCINS, 162 avenue Jean Jaur&egrave;s, 69007
Lyon, France</span></p>

<p class=MsoNormal><span lang=FR>&nbsp;</span></p>

<p class=MsoNormal><span lang=FR>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid'><b><span lang=EN-GB>8.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; MARKETING
AUTHORISATION NUMBER(S)</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>Gardasil,
suspension for injection :</span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>EU/1/06/357/001</span></p>

<p class=MsoNormal><span lang=EN-GB>EU/1/06/357/002</span></p>

<p class=MsoNormal><span lang=EN-GB>EU/1/06/357/018</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:7.9pt'><u><span lang=EN-GB>Gardasil,
suspension for injection in a pre-filled syringe :</span></u></p>

<p class=MsoNormal style='margin-right:7.9pt'><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='text-autospace:none'><span lang=NL style='color:black'>EU/1/06/357/003
</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=NL style='color:black'>EU/1/06/357/004
</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=NL style='color:black'>EU/1/06/357/005
</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=NL style='color:black'>EU/1/06/357/006
</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=NL style='color:black'>EU/1/06/357/007
</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
style='color:black'>EU/1/06/357/008 </span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
style='color:black'>EU/1/06/357/019 </span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
style='color:black'>EU/1/06/357/020 </span></p>

<p class=MsoNormal><span style='color:black'>EU/1/06/357/021</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid'><b><span lang=EN-GB>9.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; DATE OF FIRST
AUTHORISATION/RENEWAL OF THE AUTHORISATION</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Date of first authorisation: 20 September
2006</span></p>

<p class=MsoNormal><span lang=EN-GB>Date of latest renewal: 27 July 2011</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid'><b><span lang=EN-GB>10.&nbsp;&nbsp;&nbsp; DATE OF REVISION OF THE TEXT</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>{MM/YYYY}</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>Detailed
information on this medicinal product is available on the website of the
European Medicines Agency http://www.ema.europa.eu.<u> </u><a name="OLE_LINK12"></a><a
name="OLE_LINK16"></a><a name="OLE_LINK20">&nbsp;</a></span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><u><span lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>&nbsp;</span></p>

<b><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span></b>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center'><b><span lang=EN-GB>ANNEX
II</span></b></p>

<p class=MsoNormal align=center style='margin-top:0in;margin-right:70.8pt;
margin-bottom:0in;margin-left:85.05pt;margin-bottom:.0001pt;text-align:center;
text-indent:-28.35pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:70.8pt;margin-bottom:
0in;margin-left:85.05pt;margin-bottom:.0001pt;text-indent:-31.05pt'><b><span
lang=EN-GB>A.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; MANUFACTURERS OF THE
BIOLOGICAL ACTIVE SUBSTANCES AND MANUFACTURER RESPONSIBLE FOR BATCH RELEASE</span></b></p>

<p class=MsoNormal style='margin-left:85.05pt;text-indent:-31.05pt'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:70.8pt;margin-bottom:
0in;margin-left:85.05pt;margin-bottom:.0001pt;text-indent:-31.05pt'><b><span
lang=EN-GB>B.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; CONDITIONS OR RESTRICTIONS
REGARDING SUPPLY AND USE</span></b></p>

<p class=MsoNormal style='margin-top:0in;margin-right:70.8pt;margin-bottom:
0in;margin-left:85.05pt;margin-bottom:.0001pt;text-indent:-31.05pt'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-top:0in;margin-right:70.8pt;margin-bottom:
0in;margin-left:85.05pt;margin-bottom:.0001pt;text-indent:-31.05pt'><b><span
lang=EN-GB>C.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; OTHER CONDITIONS AND
REQUIREMENTS OF THE MARKETING AUTHORISATION</span></b></p>

<p class=MsoNormal style='margin-top:0in;margin-right:70.8pt;margin-bottom:
0in;margin-left:85.05pt;margin-bottom:.0001pt;text-indent:-31.05pt'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-top:0in;margin-right:70.8pt;margin-bottom:
0in;margin-left:85.05pt;margin-bottom:.0001pt;text-indent:-31.05pt'><b><span
lang=EN-GB>D.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; CONDITIONS OR RESTRICTIONS
WITH REGARD TO THE SAFE AND EFFECTIVE USE OF THE MEDICINAL PRODUCT</span></b></p>

<p class=MsoNormal align=center style='margin-left:28.35pt;text-align:center;
text-indent:-28.35pt'><span lang=EN-GB>&nbsp;</span></p>

<b><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span></b>

<p class=TitleB style='page-break-after:avoid;text-autospace:ideograph-numeric'><span
lang=EN-GB>A.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; MANUFACTURERS OF THE BIOLOGICAL
ACTIVE SUBSTANCES AND MANUFACTURER RESPONSIBLE FOR BATCH RELEASE</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><u><span lang=EN-GB>Name and address of the manufacturers of
the biological active substances</span></u></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Merck Sharp &amp; Dohme Corp.</span></p>

<p class=MsoNormal><span lang=EN-GB>Sumneytown Pike</span></p>

<p class=MsoNormal><span lang=EN-GB>P.O.Box 4</span></p>

<p class=MsoDate><span lang=EN-GB>West Point</span></p>

<p class=MsoNormal><span lang=EN-GB>PA 19486</span></p>

<p class=MsoDate><span lang=EN-GB>USA</span></p>

<p class=MsoDate><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>Merck Sharp
&amp; Dohme Corp.</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>2778 South East
Side Highway</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>Elkton</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>Virginia 22827</span></p>

<p class=MsoNormal><span lang=EN-GB>USA</span></p>

<p class=TitleB style='page-break-after:avoid;text-autospace:ideograph-numeric'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><u><span lang=EN-GB>Name and address of the manufacturer
responsible for batch release</span></u></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=NL>Merck Sharp &amp; Dohme BV</span></p>

<p class=MsoNormal><span lang=NL>Waarderweg 39</span></p>

<p class=MsoNormal>2031 BN Haarlem</p>

<p class=MsoNormal>The Netherlands</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal><span lang=EN-GB>The printed package leaflet of the
medicinal product must state the name and address of the manufacturer
responsible for the release of the concerned batch.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=TitleB style='page-break-after:avoid;text-autospace:ideograph-numeric'><span
lang=EN-GB>B.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; CONDITIONS OR RESTRICTIONS
REGARDING SUPPLY AND USE</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Medicinal product subject to medical
prescription</span><span lang=EN-GB>.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.05pt;margin-bottom:
0in;margin-left:.5in;margin-bottom:.0001pt;text-indent:-.5in'><span lang=EN-GB
style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><b><span lang=EN-GB>Official batch release</span></b></p>

<p class=MsoNormal style='margin-right:-.05pt'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-right:-.05pt'><span lang=EN-GB>In accordance
with Article&nbsp;114 of Directive&nbsp;2001/83/EC, the official batch release
will be undertaken by a state laboratory or a laboratory designated for that
purpose.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:28.35pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=TitleB style='page-break-after:avoid;text-autospace:ideograph-numeric'><span
lang=EN-GB>C. &nbsp;&nbsp;&nbsp;&nbsp; OTHER CONDITIONS AND REQUIREMENTS OF THE
MARKETING AUTHORISATION</span></p>

<p class=MsoNormal style='margin-right:-.05pt'><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.05pt;margin-bottom:
0in;margin-left:.5in;margin-bottom:.0001pt;text-indent:-.5in'><span lang=EN-GB
style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><b><span lang=EN-GB>Periodic Safety Update Reports</span></b></p>

<p class=MsoNormal style='margin-right:28.35pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:28.35pt'><span lang=EN-GB>The requirement
for submission of &nbsp;</span><span lang=EN-GB>periodic safety update reports
for this medicinal product are set out in the list of Union reference dates
(EURD list) provided for under Article&nbsp;107c(7) of Directive&nbsp;2001/83/EC
and any subsequent updates published on the European medicines web-portal.</span></p>

<p class=MsoNormal style='margin-right:28.35pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:28.35pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=TitleB style='page-break-after:avoid;text-autospace:ideograph-numeric'><span
lang=EN-GB>D.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; CONDITIONS OR RESTRICTIONS WITH
REGARD TO THE SAFE AND EFFECTIVE USE OF THE MEDICINAL PRODUCT </span></p>

<p class=MsoNormal style='margin-right:-.05pt;page-break-after:avoid'><u><span
lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.05pt;margin-bottom:
0in;margin-left:.5in;margin-bottom:.0001pt;text-indent:-.5in;page-break-after:
avoid'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><b><span lang=EN-GB>Risk Management Plan (RMP)</span></b></p>

<p class=MsoNormal style='margin-right:-.05pt;page-break-after:avoid'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-right:28.35pt'><span lang=EN-GB>The MAH shall
perform the required pharmacovigilance activities and interventions detailed in
the agreed RMP presented in Module&nbsp;1.8.2 of the Marketing Authorisation
and any agreed subsequent updates of the RMP.</span></p>

<p class=MsoNormal style='margin-right:-.05pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.05pt'><span lang=EN-GB>An updated RMP should
be submitted:</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>At the request of the European Medicines Agency;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Whenever the risk management system is modified,
especially as the result of new information being received that may lead to a
significant change to the benefit/risk profile or as the result of an important
(pharmacovigilance or risk minimisation) milestone being reached.</span></p>

<p class=MsoNormal style='margin-right:-.05pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:28.35pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<b><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span></b>

<p class=MsoNormal style='text-autospace:none'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='text-autospace:none'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='text-autospace:none'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='text-autospace:none'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='text-autospace:none'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='text-autospace:none'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='text-autospace:none'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='text-autospace:none'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='text-autospace:none'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='text-autospace:none'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='text-autospace:none'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='text-autospace:none'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='text-autospace:none'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='text-autospace:none'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='text-autospace:none'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='text-autospace:none'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='text-autospace:none'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='text-autospace:none'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='text-autospace:none'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='text-autospace:none'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='text-autospace:none'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='text-autospace:none'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='text-autospace:none'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center;text-autospace:none'><b><span
lang=EN-GB>ANNEX III</span></b></p>

<p class=MsoNormal align=center style='text-align:center;text-autospace:none'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center;text-autospace:none'><b><span
lang=EN-GB>LABELLING AND PACKAGE LEAFLET</span></b></p>

<b><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span></b>

<p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='text-autospace:none'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='text-autospace:none'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='text-autospace:none'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='text-autospace:none'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='text-autospace:none'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='text-autospace:none'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='text-autospace:none'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='text-autospace:none'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='text-autospace:none'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='text-autospace:none'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='text-autospace:none'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='text-autospace:none'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='text-autospace:none'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='text-autospace:none'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='text-autospace:none'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='text-autospace:none'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='text-autospace:none'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='text-autospace:none'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='text-autospace:none'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='text-autospace:none'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='text-autospace:none'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='text-autospace:none'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=TitleA><span lang=EN-GB>A. LABELLING</span></p>

<p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>

<b><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span></b>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>PARTICULARS
TO APPEAR ON THE OUTER PACKAGING </span></b></p>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>OUTER
CARTON TEXT</span></b></p>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>Gardasil,
suspension for injection &#8211; single dose vial, pack of 1, 10, 20</span></b></p>

</div>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; NAME OF
THE MEDICINAL PRODUCT</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoEndnoteText><span lang=EN-GB>Gardasil suspension for injection</span></p>

<p class=MsoNormal><span lang=EN-GB>Human Papillomavirus Vaccine [Types&nbsp;6,
11, 16, 18] (Recombinant, adsorbed)</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB>2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; STATEMENT
OF ACTIVE SUBSTANCE(S)</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=FR>1 dose (0.5&nbsp;ml) contains:</span></p>

<p class=MsoNormal><span lang=FR>HPV Type 6 L1 protein&nbsp; 20&nbsp;&micro;g</span></p>

<p class=MsoNormal><span lang=DE>HPV Type 11 L1 protein 40&nbsp;&micro;g</span></p>

<p class=MsoNormal><span lang=DE>HPV Type 16 L1 protein 40&nbsp;&micro;g </span></p>

<p class=MsoNormal><span lang=DE>HPV Type 18 L1 protein 20&nbsp;&micro;g </span></p>

<p class=MsoNormal><span lang=DE>&nbsp;</span></p>

<p class=MsoNormal><span lang=DE>adsorbed on amorphous aluminium
hydroxyphosphate sulphate (0.225&nbsp;mg Al).</span></p>

<p class=MsoNormal><span lang=DE>&nbsp;</span></p>

<p class=MsoNormal><span lang=DE>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB>3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; LIST OF
EXCIPIENTS</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Sodium chloride, L-histidine, polysorbate
80, sodium borate, water for injections.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB>4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; PHARMACEUTICAL
FORM AND CONTENTS</span></b></p>

</div>

<p class=MsoEndnoteText><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoEndnoteText><span lang=EN-GB>Suspension for injection.</span></p>

<p class=MsoEndnoteText><span lang=EN-GB>1 dose vial, 0.5&nbsp;ml.</span></p>

<p class=MsoEndnoteText><span lang=EN-GB style='color:black;background:#BFBFBF'>10
single dose vials, 0.5&nbsp;ml each.</span></p>

<p class=MsoEndnoteText><span lang=EN-GB style='color:black;background:#BFBFBF'>20
single dose vials, 0.5&nbsp;ml each.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB>5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; METHOD
AND ROUTE(S) OF ADMINISTRATION</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Intramuscular (IM) use.</span></p>

<p class=MsoNormal><span lang=EN-GB>Shake well before use.</span></p>

<p class=MsoNormal><span lang=EN-GB>Read the package leaflet before use.</span></p>

<p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB>6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; SPECIAL
WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF
CHILDREN</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Keep out of the sight and reach of
children.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB>7.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; OTHER
SPECIAL WARNING(S), IF NECESSARY</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid;border:none;padding:0in'><b><span lang=EN-GB>8.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; EXPIRY
DATE</span></b></p>

</div>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>EXP</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid;border:none;padding:0in'><b><span lang=EN-GB>9.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; SPECIAL
STORAGE CONDITIONS</span></b></p>

</div>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Store in a refrigerator.</span></p>

<p class=MsoNormal><span lang=EN-GB>Do not freeze. </span></p>

<p class=MsoNormal><span lang=EN-GB>Keep the vial in the outer carton in order
to protect from light.</span></p>

<p class=MsoBodyText2 style='text-indent:-28.35pt'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoBodyText2 style='text-indent:-28.35pt'><b><span lang=EN-GB>&nbsp;</span></b></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoBodyText2 style='text-indent:-28.35pt;border:none;padding:0in'><b><span
lang=EN-GB>10.&nbsp;&nbsp;&nbsp;&nbsp; SPECIAL PRECAUTIONS FOR DISPOSAL OF
UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL
PRODUCTS, IF APPROPRIATE</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB>11.&nbsp;&nbsp;&nbsp;&nbsp; NAME AND ADDRESS
OF THE MARKETING AUTHORISATION HOLDER</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=FR>MSD VACCINS</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=FR>162 avenue Jean Jaur&egrave;s</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>69007 Lyon</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>France</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB>12.&nbsp;&nbsp;&nbsp;&nbsp; MARKETING
AUTHORISATION NUMBER(S) </span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>EU/1/06/357/001 <span style='color:black;
background:#BFBFBF'>&#8211; pack of 1</span></span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black;background:#BFBFBF'>EU/1/06/357/002&#8211;
pack of 10</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black;background:#BFBFBF'>EU/1/06/357/018&#8211;
pack of 20</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB>13.&nbsp;&nbsp;&nbsp;&nbsp; BATCH NUMBER</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Lot</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB>14.&nbsp;&nbsp;&nbsp;&nbsp; GENERAL CLASSIFICATION
FOR SUPPLY</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB>15.&nbsp;&nbsp;&nbsp;&nbsp; INSTRUCTIONS ON
USE</span></b></p>

</div>

<p class=MsoNormal><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal><i><span lang=EN-GB>&nbsp;</span></i></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB>16.&nbsp;&nbsp;&nbsp;&nbsp; INFORMATION IN
BRAILLE</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 0in 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>17.&nbsp;&nbsp;&nbsp;&nbsp; UNIQUE
IDENTIFIER &#8211; 2D BARCODE</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='background:silver'>2D barcode
carrying the unique identifier included.</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:green'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 0in 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>18.&nbsp;&nbsp;&nbsp;&nbsp; UNIQUE
IDENTIFIER - HUMAN READABLE DATA</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>PC:</span></p>

<p class=MsoNormal><span lang=EN-GB>SN:</span></p>

<p class=MsoNormal><span lang=EN-GB>NN:</span></p>

<b><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span></b>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>MINIMUM
PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS</span></b></p>

<h6 align=left style='margin:0in;text-align:left;border:none;padding:0in'><b><span
lang=EN-GB style='font-family:"Times New Roman",serif;font-style:normal'>VIAL
LABEL TEXT</span></b></h6>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; NAME OF
THE MEDICINAL PRODUCT AND ROUTE(S) OF ADMINISTRATION</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Gardasil suspension for injection</span></p>

<p class=MsoEndnoteText><span lang=EN-GB>IM use.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB>2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; METHOD
OF ADMINISTRATION</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB>3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; EXPIRY
DATE</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>EXP</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB>4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; BATCH
NUMBER</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Lot</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB>5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; CONTENTS
BY WEIGHT, BY VOLUME OR BY UNIT</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>1 dose, 0.5&nbsp;ml. </span></p>

<p class=MsoEndnoteText><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB>6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; OTHER</span></b></p>

</div>

<p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal><span lang=EN-GB>MSD VACCINS</span></p>

<b><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span></b>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>PARTICULARS
TO APPEAR ON THE OUTER PACKAGING</span></b></p>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>OUTER
CARTON TEXT</span></b></p>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>Gardasil,
suspension for injection &#8211; pre-filled syringe without needle, pack of 1,
10, 20 </span></b></p>

</div>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; NAME OF
THE MEDICINAL PRODUCT</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoEndnoteText><span lang=EN-GB>Gardasil suspension for injection in a
pre-filled syringe</span></p>

<p class=MsoNormal><span lang=EN-GB>Human Papillomavirus Vaccine [Types&nbsp;6,
11, 16, 18] (Recombinant, adsorbed)</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB>2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; STATEMENT
OF ACTIVE SUBSTANCE(S)</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=FR>1 dose (0.5&nbsp;ml) contains:</span></p>

<p class=MsoNormal><span lang=FR>HPV Type 6 L1 protein&nbsp; 20&nbsp;&micro;g </span></p>

<p class=MsoNormal><span lang=DE>HPV Type 11 L1 protein 40&nbsp;&micro;g</span></p>

<p class=MsoNormal><span lang=DE>HPV Type 16 L1 protein 40&nbsp;&micro;g</span></p>

<p class=MsoNormal><span lang=DE>HPV Type 18 L1 protein 20&nbsp;&micro;g</span></p>

<p class=MsoNormal><span lang=DE>&nbsp;</span></p>

<p class=MsoNormal><span lang=DE>adsorbed on amorphous aluminium
hydroxyphosphate sulphate (0.225&nbsp;mg Al).</span></p>

<p class=MsoNormal><span lang=DE>&nbsp;</span></p>

<p class=MsoNormal><span lang=DE>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB>3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; LIST OF
EXCIPIENTS</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Sodium chloride, L-histidine, polysorbate
80, sodium borate, water for injections.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB>4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; PHARMACEUTICAL
FORM AND CONTENTS</span></b></p>

</div>

<p class=MsoEndnoteText><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoEndnoteText><span lang=EN-GB>Suspension for injection in a
pre-filled syringe.</span></p>

<p class=MsoEndnoteText><span lang=EN-GB>1 dose, 0.5&nbsp;ml pre-filled syringe
without needle.</span></p>

<p class=MsoEndnoteText><span lang=EN-GB style='color:black;background:#BFBFBF'>10
single doses, 0.5&nbsp;ml pre-filled syringes without needles.</span></p>

<p class=MsoEndnoteText><span lang=EN-GB style='color:black;background:#BFBFBF'>20
single doses, 0.5&nbsp;ml pre-filled syringes without needles.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB>5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; METHOD
AND ROUTE(S) OF ADMINISTRATION</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Intramuscular (IM) use.</span></p>

<p class=MsoNormal><span lang=EN-GB>Shake well before use.</span></p>

<p class=MsoNormal><span lang=EN-GB>Read the package leaflet before use.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB>6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; SPECIAL
WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF
CHILDREN</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Keep out of the sight and reach of
children.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB>7.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; OTHER
SPECIAL WARNING(S), IF NECESSARY</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid;border:none;padding:0in'><b><span lang=EN-GB>8.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; EXPIRY
DATE</span></b></p>

</div>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>EXP</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid;border:none;padding:0in'><b><span lang=EN-GB>9.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; SPECIAL
STORAGE CONDITIONS</span></b></p>

</div>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Store in a refrigerator.</span></p>

<p class=MsoNormal><span lang=EN-GB>Do not freeze. </span></p>

<p class=MsoBodyText2 style='text-indent:-28.35pt'><span lang=EN-GB>Keep the
syringe in the outer carton in order to protect from light. </span></p>

<p class=MsoBodyText2 style='text-indent:-28.35pt'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoBodyText2 style='text-indent:-28.35pt'><b><span lang=EN-GB>&nbsp;</span></b></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoBodyText2 style='text-indent:-28.35pt;border:none;padding:0in'><b><span
lang=EN-GB>10.&nbsp;&nbsp;&nbsp;&nbsp; SPECIAL PRECAUTIONS FOR DISPOSAL OF
UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL
PRODUCTS, IF APPROPRIATE</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB>11.&nbsp;&nbsp;&nbsp;&nbsp; NAME AND ADDRESS
OF THE MARKETING AUTHORISATION HOLDER</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=FR>MSD VACCINS</span></p>

<p class=MsoNormal><span lang=FR>162 avenue Jean Jaur&egrave;s</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>69007 Lyon</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>France</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB>12.&nbsp;&nbsp;&nbsp;&nbsp; MARKETING AUTHORISATION
NUMBER(S) </span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>EU/1/06/357/003 <span style='color:black;
background:#BFBFBF'>&#8211; pack of 1</span></span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black;background:#BFBFBF'>EU/1/06/357/004
&#8211; pack of 10</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black;background:#BFBFBF'>EU/1/06/357/019
&#8211; pack of 20</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB>13.&nbsp;&nbsp;&nbsp;&nbsp; BATCH NUMBER</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Lot</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB>14.&nbsp;&nbsp;&nbsp;&nbsp; GENERAL
CLASSIFICATION FOR SUPPLY</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB>15.&nbsp;&nbsp;&nbsp;&nbsp; INSTRUCTIONS ON
USE</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><i><span lang=EN-GB>&nbsp;</span></i></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB>16.&nbsp;&nbsp;&nbsp;&nbsp; INFORMATION IN
BRAILLE</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 0in 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>17.&nbsp;&nbsp;&nbsp;&nbsp; UNIQUE
IDENTIFIER &#8211; 2D BARCODE</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='background:silver'>2D barcode
carrying the unique identifier included.</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:green'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 0in 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>18.&nbsp;&nbsp;&nbsp;&nbsp; UNIQUE
IDENTIFIER - HUMAN READABLE DATA</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>PC:</span></p>

<p class=MsoNormal><span lang=EN-GB>SN:</span></p>

<p class=MsoNormal><span lang=EN-GB>NN:</span></p>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>PARTICULARS
TO APPEAR ON THE OUTER PACKAGING</span></b></p>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>OUTER
CARTON TEXT</span></b></p>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>Gardasil,
suspension for injection &#8211; pre-filled syringe with 1 needle, pack of 1,
10, 20</span></b></p>

</div>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; NAME OF
THE MEDICINAL PRODUCT</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoEndnoteText><span lang=EN-GB>Gardasil suspension for injection in a
pre-filled syringe</span></p>

<p class=MsoNormal><span lang=EN-GB>Human Papillomavirus Vaccine [Types&nbsp;6,
11, 16, 18] (Recombinant, adsorbed)</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB>2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; STATEMENT
OF ACTIVE SUBSTANCE(S)</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=FR>1 dose (0.5&nbsp;ml) contains:</span></p>

<p class=MsoNormal><span lang=FR>HPV Type 6 L1 protein&nbsp; 20&nbsp;&micro;g </span></p>

<p class=MsoNormal><span lang=DE>HPV Type 11 L1 protein 40&nbsp;&micro;g</span></p>

<p class=MsoNormal><span lang=DE>HPV Type 16 L1 protein 40&nbsp;&micro;g</span></p>

<p class=MsoNormal><span lang=DE>HPV Type 18 L1 protein 20&nbsp;&micro;g</span></p>

<p class=MsoNormal><span lang=DE>&nbsp;</span></p>

<p class=MsoNormal><span lang=DE>adsorbed on amorphous aluminium
hydroxyphosphate sulphate (0.225&nbsp;mg Al).</span></p>

<p class=MsoNormal><span lang=DE>&nbsp;</span></p>

<p class=MsoNormal><span lang=DE>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB>3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; LIST OF
EXCIPIENTS</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Sodium chloride, L-histidine, polysorbate
80, sodium borate, water for injections.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB>4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; PHARMACEUTICAL
FORM AND CONTENTS</span></b></p>

</div>

<p class=MsoEndnoteText><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoEndnoteText><span lang=EN-GB>Suspension for injection in a
pre-filled syringe.</span></p>

<p class=MsoEndnoteText><span lang=EN-GB>1 dose, 0.5&nbsp;ml pre-filled syringe
with 1 needle.</span></p>

<p class=MsoEndnoteText><span lang=EN-GB style='color:black;background:#BFBFBF'>10
single doses, 0.5&nbsp;ml pre-filled syringes with 1 needle each.</span></p>

<p class=MsoEndnoteText><span lang=EN-GB style='color:black;background:#BFBFBF'>20
single doses, 0.5&nbsp;ml pre-filled syringes with 1 needle each.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB>5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; METHOD
AND ROUTE(S) OF ADMINISTRATION</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Intramuscular (IM) use.</span></p>

<p class=MsoNormal><span lang=EN-GB>Shake well before use.</span></p>

<p class=MsoNormal><span lang=EN-GB>Read the package leaflet before use.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB>6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; SPECIAL
WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF
CHILDREN</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Keep out of the sight and reach of
children.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB>7.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; OTHER
SPECIAL WARNING(S), IF NECESSARY</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid;border:none;padding:0in'><b><span lang=EN-GB>8.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; EXPIRY
DATE</span></b></p>

</div>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>EXP</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid;border:none;padding:0in'><b><span lang=EN-GB>9.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; SPECIAL
STORAGE CONDITIONS</span></b></p>

</div>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Store in a refrigerator.</span></p>

<p class=MsoNormal><span lang=EN-GB>Do not freeze. </span></p>

<p class=MsoBodyText2 style='text-indent:-28.35pt'><span lang=EN-GB>Keep the
syringe in the outer carton in order to protect from light. </span></p>

<p class=MsoBodyText2 style='text-indent:-28.35pt'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoBodyText2 style='text-indent:-28.35pt'><b><span lang=EN-GB>&nbsp;</span></b></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoBodyText2 style='text-indent:-28.35pt;border:none;padding:0in'><b><span
lang=EN-GB>10.&nbsp;&nbsp;&nbsp;&nbsp; SPECIAL PRECAUTIONS FOR DISPOSAL OF
UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL
PRODUCTS, IF APPROPRIATE</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB>11.&nbsp;&nbsp;&nbsp;&nbsp; NAME AND ADDRESS
OF THE MARKETING AUTHORISATION HOLDER</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=FR>MSD VACCINS</span></p>

<p class=MsoNormal><span lang=FR>162 avenue Jean Jaur&egrave;s</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>69007 Lyon</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>France</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB>12.&nbsp;&nbsp;&nbsp;&nbsp; MARKETING
AUTHORISATION NUMBER(S) </span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>EU/1/06/357/005 <span style='color:black;
background:#BFBFBF'>&#8211; pack of 1</span></span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black;background:#BFBFBF'>EU/1/06/357/006
&#8211; pack of 10</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black;background:#BFBFBF'>EU/1/06/357/020
&#8211; pack of 20</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB>13.&nbsp;&nbsp;&nbsp;&nbsp; BATCH NUMBER</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Lot</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB>14.&nbsp;&nbsp;&nbsp;&nbsp; GENERAL
CLASSIFICATION FOR SUPPLY</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB>15.&nbsp;&nbsp;&nbsp;&nbsp; INSTRUCTIONS ON
USE</span></b></p>

</div>

<p class=MsoNormal><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal><i><span lang=EN-GB>&nbsp;</span></i></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB>16.&nbsp;&nbsp;&nbsp;&nbsp; INFORMATION IN
BRAILLE</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 0in 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>17.&nbsp;&nbsp;&nbsp;&nbsp; UNIQUE
IDENTIFIER &#8211; 2D BARCODE</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='background:silver'>2D barcode
carrying the unique identifier included.</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:green'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 0in 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>18.&nbsp;&nbsp;&nbsp;&nbsp; UNIQUE
IDENTIFIER - HUMAN READABLE DATA</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>PC:</span></p>

<p class=MsoNormal><span lang=EN-GB>SN:</span></p>

<p class=MsoNormal><span lang=EN-GB>NN:</span></p>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>PARTICULARS
TO APPEAR ON THE OUTER PACKAGING</span></b></p>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>OUTER
CARTON TEXT</span></b></p>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>Gardasil,
suspension for injection &#8211; pre-filled syringe with 2 needles, pack of 1,
10, 20</span></b></p>

</div>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; NAME OF
THE MEDICINAL PRODUCT</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoEndnoteText><span lang=EN-GB>Gardasil suspension for injection in a
pre-filled syringe</span></p>

<p class=MsoNormal><span lang=EN-GB>Human Papillomavirus Vaccine [Types&nbsp;6,
11, 16, 18] (Recombinant, adsorbed)</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB>2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; STATEMENT
OF ACTIVE SUBSTANCE(S)</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=FR>1 dose (0.5&nbsp;ml) contains:</span></p>

<p class=MsoNormal><span lang=FR>HPV Type 6 L1 protein&nbsp; 20&nbsp;&micro;g </span></p>

<p class=MsoNormal><span lang=DE>HPV Type 11 L1 protein 40&nbsp;&micro;g</span></p>

<p class=MsoNormal><span lang=DE>HPV Type 16 L1 protein 40&nbsp;&micro;g</span></p>

<p class=MsoNormal><span lang=DE>HPV Type 18 L1 protein 20&nbsp;&micro;g</span></p>

<p class=MsoNormal><span lang=DE>&nbsp;</span></p>

<p class=MsoNormal><span lang=DE>adsorbed on amorphous aluminium
hydroxyphosphate sulphate (0.225&nbsp;mg Al).</span></p>

<p class=MsoNormal><span lang=DE>&nbsp;</span></p>

<p class=MsoNormal><span lang=DE>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB>3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; LIST OF
EXCIPIENTS</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Sodium chloride, L-histidine, polysorbate
80, sodium borate, water for injections.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB>4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; PHARMACEUTICAL
FORM AND CONTENTS</span></b></p>

</div>

<p class=MsoEndnoteText><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoEndnoteText><span lang=EN-GB>Suspension for injection in a
pre-filled syringe.</span></p>

<p class=MsoEndnoteText><span lang=EN-GB>1 dose, 0.5&nbsp;ml pre-filled syringe
with 2 needles.</span></p>

<p class=MsoEndnoteText><span lang=EN-GB style='color:black;background:#BFBFBF'>10
single doses, 0.5&nbsp;ml pre-filled syringes with 2 needles each.</span></p>

<p class=MsoEndnoteText><span lang=EN-GB style='color:black;background:#BFBFBF'>20
single doses, 0.5&nbsp;ml pre-filled syringes with 2 needles each.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB>5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; METHOD
AND ROUTE(S) OF ADMINISTRATION</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Intramuscular (IM) use.</span></p>

<p class=MsoNormal><span lang=EN-GB>Shake well before use.</span></p>

<p class=MsoNormal><span lang=EN-GB>Read the package leaflet before use.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB>6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; SPECIAL
WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF
CHILDREN</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Keep out of the sight and reach of
children.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB>7.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; OTHER
SPECIAL WARNING(S), IF NECESSARY</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid;border:none;padding:0in'><b><span lang=EN-GB>8.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; EXPIRY
DATE</span></b></p>

</div>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>EXP</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid;border:none;padding:0in'><b><span lang=EN-GB>9.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; SPECIAL
STORAGE CONDITIONS</span></b></p>

</div>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Store in a refrigerator.</span></p>

<p class=MsoNormal><span lang=EN-GB>Do not freeze. </span></p>

<p class=MsoBodyText2 style='text-indent:-28.35pt'><span lang=EN-GB>Keep the
syringe in the outer carton in order to protect from light. </span></p>

<p class=MsoBodyText2 style='text-indent:-28.35pt'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoBodyText2 style='text-indent:-28.35pt'><b><span lang=EN-GB>&nbsp;</span></b></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoBodyText2 style='text-indent:-28.35pt;border:none;padding:0in'><b><span
lang=EN-GB>10.&nbsp;&nbsp;&nbsp;&nbsp; SPECIAL PRECAUTIONS FOR DISPOSAL OF
UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL
PRODUCTS, IF APPROPRIATE</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB>11.&nbsp;&nbsp;&nbsp;&nbsp; NAME AND ADDRESS
OF THE MARKETING AUTHORISATION HOLDER</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=FR>MSD VACCINS</span></p>

<p class=MsoNormal><span lang=FR>162 avenue Jean Jaur&egrave;s</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>69007 Lyon</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>France</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB>12.&nbsp;&nbsp;&nbsp;&nbsp; MARKETING
AUTHORISATION NUMBER(S) </span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>EU/1/06/357/007 <span style='color:black;
background:#BFBFBF'>&#8211; pack of 1</span></span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black;background:#BFBFBF'>EU/1/06/357/008
&#8211; pack of 10</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black;background:#BFBFBF'>EU/1/06/357/021
&#8211; pack of 20</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB>13.&nbsp;&nbsp;&nbsp;&nbsp; BATCH NUMBER</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Lot</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB>14.&nbsp;&nbsp;&nbsp;&nbsp; GENERAL CLASSIFICATION
FOR SUPPLY</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB>15.&nbsp;&nbsp;&nbsp;&nbsp; INSTRUCTIONS ON
USE</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><i><span lang=EN-GB>&nbsp;</span></i></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB>16.&nbsp;&nbsp;&nbsp;&nbsp; INFORMATION IN
BRAILLE</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 0in 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>17.&nbsp;&nbsp;&nbsp;&nbsp; UNIQUE
IDENTIFIER &#8211; 2D BARCODE</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='background:silver'>2D barcode
carrying the unique identifier included.</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:green'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 0in 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>18.&nbsp;&nbsp;&nbsp;&nbsp; UNIQUE
IDENTIFIER - HUMAN READABLE DATA</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>PC:</span></p>

<p class=MsoNormal><span lang=EN-GB>SN:</span></p>

<p class=MsoNormal><span lang=EN-GB>NN:</span></p>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:0in 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>MINIMUM
PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS</span></b></p>

<h6 align=left style='margin:0in;text-align:left;border:none;padding:0in'><b><span
lang=EN-GB style='font-family:"Times New Roman",serif;font-style:normal'>Pre-filled
syringe label text</span></b></h6>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; NAME OF
THE MEDICINAL PRODUCT AND ROUTE(S) OF ADMINISTRATION</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Gardasil suspension for injection in a
pre-filled syringe</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoEndnoteText><span lang=EN-GB>IM use.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB>2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; METHOD
OF ADMINISTRATION</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB>3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; EXPIRY
DATE</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>EXP</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB>4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; BATCH
NUMBER</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Lot</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB>5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; CONTENTS
BY WEIGHT, BY VOLUME OR BY UNIT</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>1 dose, 0.5&nbsp;ml.</span></p>

<p class=MsoEndnoteText><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB>6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; OTHER</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>MSD VACCINS</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=TitleA><span lang=EN-GB>B. PACKAGE LEAFLET</span></p>

<p class=MsoNormal align=center style='text-align:center'><b><span lang=EN-GB>(VIAL)</span></b></p>

<b><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span></b>

<p class=MsoNormal align=center style='text-align:center'><b><span lang=EN-GB
style='text-transform:uppercase'>Package leaflet: Information for the user</span></b></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<h1 align=center style='text-align:center;page-break-after:auto'><span
lang=EN-GB>Gardasil, suspension for injection</span></h1>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>Human
Papillomavirus Vaccine [Types 6, 11, 16, 18] (Recombinant, adsorbed)</span></p>

<p class=MsoHeader><b><span lang=EN-GB style='font-size:11.0pt;font-family:
"Times New Roman",serif'>&nbsp;</span></b></p>

<p class=MsoNormal><b><span lang=EN-GB>Read all of this leaflet carefully
before you or your child are vaccinated.</span></b></p>

<p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-left:28.1pt;text-indent:-28.1pt'><span
lang=EN-GB>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Keep this leaflet. You
may need to read it again.</span></p>

<p class=MsoNormal style='margin-left:28.1pt;text-indent:-28.1pt'><span
lang=EN-GB>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you have any further
questions, please ask your doctor or pharmacist.</span></p>

<p class=MsoNormal style='margin-left:28.1pt;text-indent:-28.1pt;text-autospace:
none'><span lang=EN-GB>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If any of
the side effects gets serious, or if you notice any side effects not listed in
this leaflet, please tell your doctor or pharmacist. See section&nbsp;4.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><b><span lang=EN-GB>What is in this leaflet</span></b></p>

<p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-left:28.1pt;text-indent:-28.1pt'><span
lang=EN-GB>1. &nbsp;&nbsp;&nbsp;&nbsp;&nbsp; What Gardasil is and what it is
used for </span></p>

<p class=MsoNormal style='margin-left:28.1pt;text-indent:-28.1pt'><span
lang=EN-GB>2. &nbsp;&nbsp;&nbsp;&nbsp;&nbsp; What you need to know before you
receive Gardasil</span></p>

<p class=MsoNormal style='margin-left:28.1pt;text-indent:-28.1pt'><span
lang=EN-GB>3. &nbsp;&nbsp;&nbsp;&nbsp;&nbsp; How Gardasil is given</span></p>

<p class=MsoNormal style='margin-left:28.1pt;text-indent:-28.1pt'><span
lang=EN-GB>4. &nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Possible side effects</span></p>

<p class=MsoNormal style='margin-left:28.1pt;text-indent:-28.1pt'><span
lang=EN-GB>5. &nbsp;&nbsp;&nbsp;&nbsp;&nbsp; How to store Gardasil </span></p>

<p class=MsoNormal style='margin-left:28.1pt;text-indent:-28.1pt'><span
lang=EN-GB>6. &nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Contents of the pack and other
information</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><b><span lang=EN-GB>1. &nbsp;&nbsp;&nbsp;&nbsp; What
Gardasil is and what it is used for</span></b></p>

<p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal><span lang=EN-GB>Gardasil is a vaccine. Vaccination with
Gardasil is intended to protect against diseases caused by Human Papillomavirus
(HPV) types&nbsp;6, 11, 16, and 18. </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>These diseases include pre-cancerous
lesions of the female genitals (cervix, vulva, and vagina); pre-cancerous
lesions of the anus and genital warts in males and females; cervical and anal
cancers. HPV types 16 and 18 are responsible for approximately 70% of cervical
cancer cases, 75-80% of anal cancer cases; 70% of HPV-related pre-cancerous
lesions of the vulva and vagina; 75% of HPV related pre-cancerous lesions of
the anus. HPV types&nbsp;6 and 11 are responsible for approximately 90% of
genital wart cases.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>Gardasil is
intended to prevent these diseases. The vaccine is not used to treat HPV
related diseases. Gardasil does not have any effect in individuals who already
have a persistent infection or disease associated with any of the HPV types in
the vaccine. However, in individuals who are already infected with one or more
of the vaccine HPV types, Gardasil can still protect against diseases associated
with the other HPV types in the vaccine.</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Gardasil cannot cause the diseases it
protects against.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Gardasil produces type-specific antibodies
and has been shown in clinical trials to prevent HPV&nbsp;6-, 11&#8209;, 16-,
and 18-related diseases in women 16-45&nbsp;years of age and in men 16-26&nbsp;years
of age. The vaccine also produces type-specific antibodies in 9- to 15-year-old
children and adolescents. </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Gardasil should be used in accordance with
official guidelines.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>2. &nbsp;&nbsp;&nbsp;&nbsp; What
you need to know before you receive Gardasil</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><b><span
lang=EN-GB>Do not receive Gardasil if:</span></b></p>

<p class=MsoNormal style='margin-left:27.0pt;text-indent:-27.0pt;vertical-align:
baseline'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>you or your child is allergic (hypersensitive)
to any of the active substances or any of the other ingredients of Gardasil
(listed under &#8220;other ingredients&#8221;&#8211; see section&nbsp;6).</span></p>

<p class=MsoNormal style='margin-left:27.0pt;text-indent:-27.0pt;vertical-align:
baseline'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>you or your child developed an allergic reaction
after receiving a dose of Gardasil. </span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>you or your child suffer from an illness </span><span
lang=EN-GB>with high fever. However, a mild fever or upper respiratory
infection (for example cold) itself is not a reason to delay vaccination.</span></p>

<p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>Warnings
and precautions</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
style='color:black'>Talk to your doctor,</span><span lang=EN-GB> pharmacist<span
style='color:black'> or nurse before vaccination if you or your child</span></span><span
lang=EN-GB> </span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>has a bleeding disorder (a disease that makes
you bleed more than normal), for example haemophilia </span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>has a weakened immune system, for example due to
a genetic defect, HIV infection or medicines that affect the immune system.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Fainting, sometimes accompanied by falling,
can occur (mostly in adolescents) following any needle injection. Therefore,
tell the doctor or nurse if you fainted with a previous injection.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>As with any vaccine, Gardasil may not fully
protect 100% of those who get the vaccine.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Gardasil will not protect against every
type of Human Papillomavirus. Therefore, appropriate precautions against
sexually transmitted disease should continue to be used.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Gardasil will not protect against other
diseases </span><span lang=EN-GB>that are not caused by </span><span
lang=EN-GB>Human Papillomavirus</span><span lang=EN-GB>.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Vaccination is not a substitute for routine
cervical screening<b><i>.</i></b></span><span lang=EN-GB> You should continue
to follow your doctor&#8217;s advice on cervical smear/Pap tests and
preventative and protective measures.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><i><span lang=EN-GB>What
other important information should you or your child know about Gardasil</span></i></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Longer term follow-up studies were
conducted to determine the duration of protection. The need for a booster dose has
not been established. </span></p>

<p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>Other
medicines or vaccines and Gardasil</span></b></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>Gardasil can be given
with a Hepatitis B vaccine or with a combined booster vaccine containing
diphtheria (d) and tetanus (T) with either pertussis [acellular, component]
(ap) and/or poliomyelitis [inactivated] (IPV) (dTap, dT-IPV, dTap-IPV vaccines)
at a separate injection site (another part of your body, e.g. the other arm or
leg) during the same visit.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Gardasil may
not have an optimal effect if:</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-size:10.0pt;font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>used with medicines that suppress the immune system.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>In clinical trials, oral or other
contraceptives (e.g. the pill) did not reduce the protection obtained by
Gardasil.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Please tell your doctor or pharmacist if
you or your child are taking or have taken recently any other medicines,
including medicines obtained without a prescription.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>Pregnancy,
breast-feeding and fertility </span></b></p>

<p class=MsoNormal><span lang=EN-GB>If you are pregnant or breast-feeding,
think you may be pregnant or are planning to have a baby, ask your doctor for
advice before taking this medicine.</span></p>

<p class=MsoNormal><span lang=EN-GB>Gardasil may be given to women who are
breast-feeding or intend to breast-feed.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>Driving
and using machines</span></b></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>No studies on the
effects on the ability to drive and use machines have been performed.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid'><b><span lang=EN-GB>3. &nbsp;&nbsp;&nbsp;&nbsp;&nbsp; How Gardasil is
given</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal><span lang=EN-GB>Gardasil is given as an injection by your
doctor. Gardasil is intended for adolescents and adults from 9 years of age
onwards.</span><span lang=EN-GB> </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><i><u><span lang=EN-GB>If
you are from 9 to and including 13&nbsp;years of age</span></u></i></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Gardasil can
be administered according to a 2-dose schedule:</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:"Arial",sans-serif'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>First injection: at chosen date</span></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in'><span
lang=EN-GB style='font-family:"Arial",sans-serif;color:black'>-<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Second injection: <span style='color:black'>6&nbsp;months
after first injection</span></span></p>

<p class=MsoNormal><span lang=EN-GB>If the second vaccine dose is administered
earlier than 6 months after the first dose, a third dose should always be
administered.</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Alternatively,
Gardasil can be administered according to a 3-dose schedule:</span></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in'><span
lang=EN-GB style='font-family:"Arial",sans-serif'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>First injection: at chosen date</span></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in'><span
lang=EN-GB style='font-family:"Arial",sans-serif'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Second injection: 2&nbsp;months after first
injection</span></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in'><span
lang=EN-GB style='font-family:"Arial",sans-serif'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Third injection: 6&nbsp;months after first
injection</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>The second dose should
be administered at least one month after the first dose and the third dose should
be administered at least 3&nbsp;months after the second dose. All three doses
should be given within a 1-year period. Please speak to your doctor for more
information.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><i><u><span lang=EN-GB>If
you are from 14&nbsp;years of age</span></u></i></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Gardasil should
be administered according to a 3-dose schedule:</span></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in'><span
lang=EN-GB style='font-family:"Arial",sans-serif'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>First injection: at chosen date</span></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in'><span
lang=EN-GB style='font-family:"Arial",sans-serif'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Second injection: 2&nbsp;months after first
injection</span></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in'><span
lang=EN-GB style='font-family:"Arial",sans-serif'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Third injection: 6 months after first injection</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>The second dose should
be administered at least one month after the first dose and the third dose should
be administered at least 3&nbsp;months after the second dose. All three doses
should be given within a 1-year period. Please speak to your doctor for more
information.</span></p>

<p class=MsoNormal><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal><span lang=EN-GB>It is recommended that individuals who
receive a first dose of Gardasil complete the vaccination course with Gardasil.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Gardasil will be given as an injection
through the skin into the muscle (preferably the muscle of the upper arm or
thigh).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>The vaccine should not be mixed in the same
syringe with any other vaccines and solutions.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>If you
forget one dose of Gardasil:</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal><span lang=EN-GB>If you miss a scheduled injection, your
doctor will decide when to give the missed dose.</span></p>

<p class=MsoNormal><span lang=EN-GB>It is important that you follow the
instructions of your doctor or nurse regarding return visits for the follow-up
doses. If you forget or are not able to go back to your doctor at the scheduled
time, ask your doctor for advice. When Gardasil is given as your first dose,
the completion of the vaccination course should be done with Gardasil, and not with
another HPV vaccine.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>If you have any further questions on the
use of this medicine, ask your doctor or pharmacist<b>.</b></span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid'><b><span lang=EN-GB>4. &nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Possible side
effects</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal><span lang=EN-GB>Like all vaccines and medicines, Gardasil
can cause side effects, although not everybody gets them.</span></p>

<p class=MsoNormal style='margin-right:9.0pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:9.0pt'><span lang=EN-GB>The following
side effects can be seen after the use of Gardasil:</span></p>

<p class=MsoNormal style='margin-right:9.0pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:9.0pt'><span lang=EN-GB>Very commonly
(more than 1 in 10 patients), side effects found at the injection site include:
pain, swelling and redness. Headache was also seen.</span></p>

<p class=MsoNormal style='margin-right:9.0pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:9.0pt'><span lang=EN-GB>Commonly (more
than 1 in 100 patients), side effects found at the injection site include:
bruising, itching, pain in extremity. Fever and nausea have also been reported.</span></p>

<p class=MsoNormal style='margin-right:9.0pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:9.0pt'><span lang=EN-GB>Rarely (less
than 1 in 1000 patients): hives (urticaria).</span></p>

<p class=MsoNormal style='margin-right:9.0pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:9.0pt'><span lang=EN-GB>Very rarely
(less than 1 in 10,000 patients), difficulty breathing (bronchospasm) has been
reported.</span></p>

<p class=MsoNormal style='margin-right:9.0pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:9.0pt'><span lang=EN-GB
style='color:black'>When Gardasil was given with a combined diphtheria,
tetanus, pertussis [acellular, component] and poliomyelitis [inactivated]
booster vaccine during the same visit, there was more headache and
injection-site swelling. </span></p>

<p class=MsoNormal style='margin-right:9.0pt'><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal style='margin-right:9.0pt;page-break-after:avoid'><i><span
lang=EN-GB>Side effects that have been reported during marketed use include:</span></i></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Fainting, sometimes accompanied by <span
style='color:black'>shaking or stiffening,</span> has been reported. Although
fainting episodes are uncommon, patients should be observed for 15&nbsp;minutes
after they receive HPV vaccine.&nbsp; </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Allergic reactions that may include
difficulty breathing, wheezing (bronchospasm), hives and rash have been
reported. Some of these reactions have been severe.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>As with other vaccines, side effects that
have been reported during general use include: swollen glands (neck, armpit, or
groin); </span><span lang=EN-GB>muscle weakness, abnormal sensations, tingling
in the arms, legs and upper body, or confusion (</span><span lang=EN-GB>Guillain-Barr&eacute;
Syndrome, Acute disseminated encephalomyelitis</span><span lang=EN-GB>)</span><span
lang=EN-GB>; dizziness, vomiting, joint pain, aching muscles, unusual tiredness
or weakness, chills, generally feeling unwell, bleeding or bruising more easily
than normal, and skin infection at the injection site.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>Reporting
of side effects</span></b></p>

<p class=BodytextAgency style='margin-bottom:0in;line-height:normal'><span
lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>If you
get any side effects, talk to your doctor or pharmacist.</span><span
lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif;
color:red'> </span><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>This
includes any possible side effects not listed in this leaflet. You can also
report side effects directly via <span style='color:black;background:#BFBFBF'>the
national reporting system listed in </span><u><span style='color:blue;
background:#BFBFBF'><a
href="http://www.ema.europa.eu/docs/en_GB/document_library/Template_or_form/2013/03/WC500139752.doc"><u><span
style='color:blue'>Appendix V</span></u></a></span></u>. By reporting side
effects you can help provide more information on the safety of this medicine.</span></p>

<p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-left:27.0pt;text-indent:-27.0pt'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-left:27.0pt;text-indent:-27.0pt;page-break-after:
avoid'><b><span lang=EN-GB>5. &nbsp;&nbsp;&nbsp;&nbsp; How to store Gardasil</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB>Keep this vaccine out of the sight and reach of
children.</span></p>

<p class=MsoNormal><span lang=EN-GB>Do not use this vaccine after the expiry
date which is stated on the vial label and the outer carton (after EXP). The
expiry date refers to the last day of that month.</span></p>

<p class=MsoNormal><span lang=EN-GB>Store in a refrigerator (2&ordm;C&nbsp;&#8209;&nbsp;8&ordm;C).</span></p>

<p class=MsoNormal><span lang=EN-GB>Do not freeze.</span></p>

<p class=MsoNormal><span lang=EN-GB>Keep the vial in the outer carton in order
to protect from light.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Do not throw away any medicines via
wastewater or household waste. Ask your pharmacist how to throw away medicines
you no longer use. These measures will help to protect the environment.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid'><b><span lang=EN-GB>6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Contents of
the pack and other information</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>What
Gardasil contains</span></b></p>

<p class=MsoNormal><span lang=EN-GB>The active substances are: highly purified
non-infectious protein for each of the Human Papillomavirus types (6, 11, 16,
and 18).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>1 dose (0.5&nbsp;ml) contains approximately:</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Human Papillomavirus<sup>1</sup> Type 6 L1
protein<span class=MsoFootnoteReference>2,3</span>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 20&nbsp;micrograms</span></p>

<p class=MsoNormal><span lang=EN-GB>Human Papillomavirus<sup>1</sup> Type 11 L1
protein<sup>2,3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </sup>40&nbsp;micrograms</span></p>

<p class=MsoNormal><span lang=EN-GB>Human Papillomavirus<sup>1</sup> Type 16 L1
protein<span class=MsoFootnoteReference>2,3</span>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 40&nbsp;micrograms</span></p>

<p class=MsoNormal><span lang=EN-GB>Human Papillomavirus<sup>1</sup> Type 18 L1
protein<sup>2,3</sup>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 20&nbsp;micrograms</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><sup><span lang=EN-GB>1</span></sup><span lang=EN-GB>Human
Papillomavirus = HPV</span></p>

<p class=MsoNormal><sup><span lang=EN-GB>2</span></sup><span lang=EN-GB>L1
protein in the form of virus like particles produced in yeast cells (<i>Saccharomyces
cerevisiae</i> CANADE&nbsp;3C&#8209;5 (Strain&nbsp;1895)) by recombinant DNA
technology.</span></p>

<p class=MsoNormal><sup><span lang=EN-GB>3</span></sup><span lang=EN-GB>adsorbed
on amorphous aluminium hydroxyphosphate sulphate adjuvant (0.225&nbsp;milligrams
Al).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>The other ingredients in the vaccine
suspension are:</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Sodium chloride, L-histidine,
polysorbate&nbsp;80, sodium borate and water for injections.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>What
Gardasil looks like and contents of the pack</span></b></p>

<p class=MsoNormal style='margin-right:9.0pt'><span lang=EN-GB>1 dose of
Gardasil suspension for injection contains 0.5&nbsp;ml.</span></p>

<p class=MsoNormal style='margin-right:9.0pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>Prior to
agitation, Gardasil may appear as a clear liquid with a white precipitate. </span><span
lang=EN-GB>After thorough agitation, it is a white, cloudy liquid. </span></p>

<p class=MsoNormal style='margin-right:9.0pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Gardasil is available in packs of 1, 10 or
20 vials.</span></p>

<p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal><span lang=EN-GB>Not all pack sizes are marketed.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>Marketing
Authorisation Holder and Manufacturer</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>Marketing
Authorisation Holder</span></u></p>

<p class=MsoNormal><span lang=FR>MSD VACCINS</span></p>

<p class=MsoNormal><span lang=FR>162 avenue Jean Jaur&egrave;s</span></p>

<p class=MsoNormal><span lang=EN-GB>69007 Lyon</span></p>

<p class=MsoNormal><span lang=EN-GB>France</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>Manufacturer</span></u></p>

<p class=MsoNormal><span lang=EN-GB>Merck Sharp &amp; Dohme BV</span></p>

<p class=MsoNormal><span lang=EN-GB>Waarderweg 39</span></p>

<p class=MsoNormal><span lang=EN-GB>2031 BN Haarlem</span></p>

<p class=MsoNormal><span lang=EN-GB>The Netherlands</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>For any
information about this medicinal product, please contact the local
representative of the Marketing Authorisation Holder.</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 width=624
 style='margin-left:-1.7pt;border-collapse:collapse'>
 <tr style='page-break-inside:avoid'>
  <td style='border:none;padding:0in 0in 0in 0in' width=2><p class='MsoNormal'>&nbsp;</td>
  <td width=310 valign=top style='width:232.2pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-autospace:none'><b><span lang=FR-BE>Belgi&euml;/Belgique/Belgien</span></b></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=FR-BE>MSD Belgium BVBA/SPRL<br>
  T&eacute;l/Tel: +32 (0) 27766211</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=FR-BE>dpoc_belux@merck.com</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=FR-BE>&nbsp;</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-autospace:none'><b><span lang=EN-GB>Lietuva</span></b></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>UAB Merck
  Sharp &amp; Dohme<br>
  Tel.: +370.5.2780.247<br>
  msd_lietuva@merck.com</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td style='border:none;padding:0in 0in 0in 0in' width=2><p class='MsoNormal'>&nbsp;</td>
  <td width=310 valign=top style='width:232.2pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-autospace:none'><b><span lang=EN-GB>&#1041;&#1098;&#1083;&#1075;&#1072;&#1088;&#1080;&#1103;</span></b></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&#1052;&#1077;&#1088;&#1082;
  &#1064;&#1072;&#1088;&#1087; &#1080; &#1044;&#1086;&#1091;&#1084;
  &#1041;&#1098;&#1083;&#1075;&#1072;&#1088;&#1080;&#1103;
  &#1045;&#1054;&#1054;&#1044;, <br>
  &#1090;&#1077;&#1083;.: + 359 2 819 3737<br>
  info-msdbg@merck.com</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-autospace:none'><b><span lang=EN-GB>Luxembourg/Luxemburg</span></b></p>
  <p class=MsoNormal style='text-autospace:none'>MSD Belgium BVBA/SPRL<br>
  T&eacute;l: +32 (0) 27766211</p>
  <p class=MsoNormal style='text-autospace:none'><span lang=NL>dpoc_belux@merck.com</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=NL>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:38.2pt'>
  <td style='border:none;padding:0in 0in 0in 0in' width=2><p class='MsoNormal'>&nbsp;</td>
  <td width=310 valign=top style='width:232.2pt;padding:0in 5.4pt 0in 5.4pt;
  height:38.2pt'>
  <p class=MsoNormal style='text-autospace:none'><b><span lang=EN-GB>&#268;esk&aacute;
  republika</span></b></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>Merck Sharp
  &amp; Dohme s.r.o. <br>
  Tel.: +420 233 010 111<br>
  dpoc_czechslovak@merck.com</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt;
  height:38.2pt'>
  <p class=MsoNormal style='text-autospace:none'><b><span lang=EN-GB>Magyarorsz&aacute;g</span></b></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>MSD Pharma
  Hungary Kft.<br>
  Tel.: + 36.1.888.5300</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>hungary_msd@merck.com</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td style='border:none;padding:0in 0in 0in 0in' width=2><p class='MsoNormal'>&nbsp;</td>
  <td width=310 valign=top style='width:232.2pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-autospace:none'><b><span lang=EN-GB>Danmark</span></b></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=SV>MSD Danmark ApS</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=SV>Tlf: + 45 4482
  4000</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>dkmail@merck.com</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-autospace:none'><b><span lang=EN-GB>Malta</span></b></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>Merck Sharp
  &amp; Dohme Cyprus Limited.<br>
  Tel: 8007 4433 (+356 99917558)</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>malta_info@merck.com</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td style='border:none;padding:0in 0in 0in 0in' width=2><p class='MsoNormal'>&nbsp;</td>
  <td width=310 valign=top style='width:232.2pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-autospace:none'><b><span lang=EN-GB>Deutschland</span></b></p>
  <p class=MsoNormal style='text-autospace:none'>MSD SHARP &amp; DOHME GMBH</p>
  <p class=MsoNormal style='text-autospace:none'>Tel: 0800 673 673 673 (+49 (0)
  89 4561 2612)</p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>e-mail@msd.de</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-autospace:none'><b><span lang=EN-GB>Nederland</span></b></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>Merck Sharp
  &amp; Dohme B.V.</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>Tel: 0800
  9999000 </span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>(+31 23
  5153153)</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>medicalinfo.nl@merck.com
  <br>
  <br>
  </span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td style='border:none;padding:0in 0in 0in 0in' width=2><p class='MsoNormal'>&nbsp;</td>
  <td width=310 valign=top style='width:232.2pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-autospace:none'><b><span lang=EN-GB>Eesti</span></b></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>Merck Sharp
  &amp; Dohme O&Uuml;</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=FI>Tel.:
  +372&nbsp;6144 200</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=FI>msdeesti@merck.com</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-autospace:none'><b><span lang=EN-GB>Norge</span></b></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>MSD (Norge)
  AS</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>Tlf: +47 32
  20 73 00</span></p>
  <p class=MsoNormal style='text-autospace:none'>msdnorge@msd.no</p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td style='border:none;padding:0in 0in 0in 0in' width=2><p class='MsoNormal'>&nbsp;</td>
  <td width=310 valign=top style='width:232.2pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-autospace:none'><b><span lang=EL>&#917;&#955;&#955;&#940;&#948;&#945;</span></b></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>MSD</span><span
  lang=EL> &#913;.&#934;.&#914;.&#917;.&#917;.</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EL>&#932;&#951;&#955;:
  +30 210 98 97 300</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>dpoc_greece@merck.com</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-autospace:none'><b><span lang=EN-GB>&Ouml;sterreich</span></b></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=FI>Merck Sharp
  &amp; Dohme Ges.m.b.H.</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>Tel: +43 (0)
  1 26 044</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>msd-medizin@merck.com</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=FR-BE>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=312 colspan=2 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-autospace:none'><b><span lang=EN-GB>Espa&ntilde;a</span></b></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=ES-TRAD>Merck Sharp
  &amp; Dohme de Espa&ntilde;a, S.A.</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=DE>Tel: +34 91 321
  06 00</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=DE>msd_info@merck.com</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=FR-BE>&nbsp;</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-autospace:none'><b><span lang=EN-GB>Polska</span></b></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>MSD Polska
  Sp. z o.o.<br>
  Tel.: +48.22.549.51.00</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>msdpolska@merck.com</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=312 colspan=2 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-autospace:none'><b><span lang=FR-BE>France</span></b></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=FR-BE>MSD VACCINS<br>
  T&eacute;l: +33 (0) 1 80 46 40 40</span></p>
  <p class=MsoNormal style='text-autospace:none'><b><span lang=FR-BE>&nbsp;</span></b></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-autospace:none'><b><span lang=FR-BE>Portugal</span></b></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=PT-BR>Merck Sharp
  &amp; Dohme, Lda</span></p>
  <p class=MsoNormal style='text-autospace:none'>Tel: +351 21 4465<span
  lang=EN-GB>700</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=PT>clic@merck.com</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=FR-BE>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=312 colspan=2 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-autospace:none'><b><span lang=EN-GB>Hrvatska</span></b></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>Merck Sharp
  &amp; Dohme d.o.o.<br>
  Tel: +385 1 66 11 333</span></p>
  <p class=MsoNormal style='text-autospace:none'>croatia_info@merck.com</p>
  <p class=MsoNormal style='text-autospace:none'><u><span lang=EN-GB><span
   style='text-decoration:none'>&nbsp;</span></span></u></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-autospace:none'><b><span lang=EN-GB>Rom&acirc;nia</span></b></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>Merck Sharp
  &amp; Dohme Romania S.R.L</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>Tel: + 4021
  529 29 00</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>msdromania@merck.com</span></p>
  <p class=MsoNormal style='text-autospace:none'><b><span lang=EN-GB>&nbsp;</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=312 colspan=2 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'><span
  lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
  clear=all style='page-break-before:always'>
  </span>
  <p class=MsoNormal style='text-autospace:none'><b><span lang=EN-GB>Ireland</span></b></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>Merck Sharp
  &amp; Dohme Ireland (Human Health) Limited</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>Tel: +353
  (0)1 2998700</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>medinfo_ireland@merck.com</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-autospace:none'><b><span lang=EN-GB>Slovenija</span></b></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>Merck Sharp
  &amp; Dohme, inovativna zdravila d.o.o.<br>
  Tel: +386.1.520.4201</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=FR>msd.slovenia@merck.com</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=312 colspan=2 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-autospace:none'><b><span lang=EN-GB>&Iacute;sland</span></b></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>Vistor hf.</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>S&iacute;mi:
  + 354 535 7000</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-autospace:none'><b><span lang=EN-GB>Slovensk&aacute;
  republika</span></b></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>Merck Sharp
  &amp; Dohme, s. r. o<br>
  Tel: +421 2 58282010</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=ES-TRAD>dpoc_czechslovak@merck.com</span></p>
  <p class=MsoNormal style='text-autospace:none'><b><span lang=EN-GB>&nbsp;</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=312 colspan=2 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-autospace:none'><b><span lang=EN-GB>Italia</span></b></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=ES-MX>MSD Italia
  S.r.l. </span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>Tel: +39 06
  361911</span></p>
  <p class=MsoNormal style='text-autospace:none'>medicalinformation.it@merck.com</p>
  <p class=MsoNormal style='text-autospace:none'><b><span lang=FR-BE>&nbsp;</span></b></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-autospace:none'><b><span lang=FR-BE>Suomi/Finland</span></b></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=SV>MSD Finland Oy</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=SV>Puh/Tel: +358
  (0)9 804 650</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>info@msd.fi</span><span
  lang=EN-GB> </span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=312 colspan=2 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-autospace:none'><b><span lang=EN-GB>&#922;&#973;&#960;&#961;&#959;&#962;</span></b></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>Merck Sharp
  &amp; Dohme Cyprus Limited<br>
  &#932;&#951;&#955;:&nbsp; 800 00 673 (+357 22866700)</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>cyprus</span><span
  lang=EL>_</span><span lang=EN-GB>info</span><span lang=EL>@</span><span
  lang=EN-GB>merck</span><span lang=EL>.</span><span lang=EN-GB>com</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-autospace:none'><b><span lang=EN-GB>Sverige</span></b></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=DE>Merck Sharp
  &amp; Dohme (Sweden) AB</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=DE>Tel: +46 77
  5700488</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>medicinskinfo@merck.com</span></p>
  <p class=MsoNormal style='text-autospace:none'><b><span lang=EN-GB>&nbsp;</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=312 colspan=2 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-autospace:none'><b><span lang=EN-GB>Latvija</span></b></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>SIA Merck
  Sharp &amp; Dohme Latvija<br>
  Tel: +371.67364.224<br>
  msd_lv@merck.com</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-autospace:none'><b><span lang=EN-GB>United
  Kingdom</span></b></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>Merck Sharp
  &amp; Dohme Limited</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>Tel: +44 (0)
  1992 467272</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>medicalinformationuk@merck.com</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=FR-BE>&nbsp;</span></p>
  </td>
 </tr>
 <tr height=0>
  <td width=2 style='border:none'></td>
  <td width=310 style='border:none'></td>
  <td width=312 style='border:none'></td>
 </tr>
</table>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>This
leaflet was last revised in: {MM/YYYY}.</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Detailed information on this medicine is
available on the European Medicines Agency web site: http://www.ema.europa.eu</span></p>

<p class=MsoNormal><span lang=EN-GB>------------------------------------------------------------------------------------------------------------------------</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>The
following information is intended for medical or healthcare professionals only:</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal><span lang=EN-GB>The vaccine should be used as supplied; no
dilution or reconstitution is necessary. The full recommended dose of the
vaccine should be used. </span><span lang=EN-GB>Any unused product or waste
material should be disposed of in accordance with local requirements.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><u><span lang=EN-GB>Shake well before use</span></u><span
lang=EN-GB>. Thorough agitation immediately before administration is necessary
to maintain suspension of the vaccine. </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Parenteral drug products should be
inspected visually for particulate matter and discolouration prior to
administration. Discard the product if particulates are present or if it
appears discoloured.</span></p>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=TitleA><span lang=EN-GB>B. PACKAGE LEAFLET</span></p>

<p class=MsoNormal align=center style='text-align:center'><b><span lang=EN-GB>(PREFILLED
SYRINGE)</span></b></p>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span>

<p class=MsoNormal align=center style='text-align:center'><a name="OLE_LINK1"></a><a
name="OLE_LINK8"><b><span lang=EN-GB style='text-transform:uppercase'>Package
leaflet: Information for the user</span></b></a></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><b><span lang=EN-GB>Gardasil,
suspension for injection in a pre-filled syringe</span></b></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>Human
Papillomavirus Vaccine [Types 6, 11, 16, 18] (Recombinant, adsorbed)</span></p>

<p class=MsoHeader><b><span lang=EN-GB style='font-size:11.0pt;font-family:
"Times New Roman",serif'>&nbsp;</span></b></p>

<p class=MsoNormal><b><span lang=EN-GB>Read all of this leaflet carefully
before you or your child are vaccinated.</span></b></p>

<p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-left:28.1pt;text-indent:-28.1pt'><span
lang=EN-GB>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Keep this leaflet. You
may need to read it again.</span></p>

<p class=MsoNormal style='margin-left:28.1pt;text-indent:-28.1pt'><span
lang=EN-GB>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you have any further
questions, please ask your doctor or pharmacist.</span></p>

<p class=MsoNormal style='margin-left:28.1pt;text-indent:-28.1pt;text-autospace:
none'><span lang=EN-GB>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If any of
the side effects gets serious, or if you notice any side effects not listed in
this leaflet, please tell your doctor or pharmacist. See section&nbsp;4.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><b><span lang=EN-GB>What is in this leaflet</span></b></p>

<p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-left:28.1pt;text-indent:-28.1pt'><span
lang=EN-GB>1. &nbsp;&nbsp;&nbsp;&nbsp;&nbsp; What Gardasil is and what it is
used for </span></p>

<p class=MsoNormal style='margin-left:28.1pt;text-indent:-28.1pt'><span
lang=EN-GB>2. &nbsp;&nbsp;&nbsp;&nbsp;&nbsp; What you need to know before you
receive Gardasil</span></p>

<p class=MsoNormal style='margin-left:28.1pt;text-indent:-28.1pt'><span
lang=EN-GB>3. &nbsp;&nbsp;&nbsp;&nbsp;&nbsp; How Gardasil is given</span></p>

<p class=MsoNormal style='margin-left:28.1pt;text-indent:-28.1pt'><span
lang=EN-GB>4. &nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Possible side effects</span></p>

<p class=MsoNormal style='margin-left:28.1pt;text-indent:-28.1pt'><span
lang=EN-GB>5. &nbsp;&nbsp;&nbsp;&nbsp;&nbsp; How to store Gardasil </span></p>

<p class=MsoNormal style='margin-left:28.1pt;text-indent:-28.1pt'><span
lang=EN-GB>6. &nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Contents of the pack and other
information</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>1. &nbsp;&nbsp;&nbsp;&nbsp; What
Gardasil is and what it is used for </span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal><span lang=EN-GB>Gardasil is a vaccine. Vaccination with
Gardasil is intended to protect against diseases caused by Human Papillomavirus
(HPV) types&nbsp;6, 11, 16, and 18. </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>These diseases include pre-cancerous
lesions of the female genitals (cervix, vulva, and vagina); pre-cancerous
lesions of the anus and genital warts in males and females; cervical and anal
cancers. HPV types&nbsp;16 and 18 are responsible for approximately 70% of
cervical cancer cases, 75-80% of anal cancer cases; 70% of HPV-related
pre-cancerous lesions of the vulva and vagina, 75% of HPV related pre-cancerous
lesions of the anus. HPV types&nbsp;6 and 11 are responsible for approximately
90% of genital wart cases.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>Gardasil is
intended to prevent these diseases. The vaccine is not used to treat HPV
related diseases. Gardasil does not have any effect in individuals who already
have a persistent infection or disease associated with any of the HPV types in
the vaccine. However, in individuals who are already infected with one or more
of the vaccine HPV types, Gardasil can still protect against diseases
associated with the other HPV types in the vaccine.</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Gardasil cannot cause the diseases it
protects against.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Gardasil produces type-specific antibodies
and has been shown in clinical trials to prevent HPV&nbsp;6-, 11&#8209;, 16-,
and 18-related diseases in women 16-45&nbsp;years of age and in men 16-26&nbsp;years
of age. The vaccine also produces type-specific antibodies in 9- to 15-year-old
children and adolescents. </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Gardasil should be used in accordance with
official guidelines.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>2. &nbsp;&nbsp;&nbsp;&nbsp; What
you need to know before you receive Gardasil</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><b><span
lang=EN-GB>Do not receive Gardasil if:</span></b></p>

<p class=MsoNormal style='margin-left:27.0pt;text-indent:-27.0pt;vertical-align:
baseline'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>you or your child is allergic (hypersensitive)
to any of the active substances or any of the other ingredients of Gardasil
(listed under &#8220;other ingredients&#8221;&#8211; see section&nbsp;6).</span></p>

<p class=MsoNormal style='margin-left:27.0pt;text-indent:-27.0pt;vertical-align:
baseline'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>you or your child developed an allergic reaction
after receiving a dose of Gardasil. </span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>you or your child suffer from an illness </span><span
lang=EN-GB>with high fever. However, a mild fever or upper respiratory
infection (for example cold) itself is not a reason to delay vaccination.</span></p>

<p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>Warnings
and precautions</span></b></p>

<p class=MsoNormal style='margin-right:9.05pt;page-break-after:avoid'><span
lang=EN-GB style='color:black'>Talk to your doctor,</span><span lang=EN-GB>
pharmacist<span style='color:black'> or nurse before vaccination if you or your
child</span></span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>has a bleeding disorder (a disease that makes
you bleed more than normal), for example haemophilia </span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>has a weakened immune system, for example due to
a genetic defect, HIV infection or medicines that affect the immune system. </span></p>

<p class=MsoNormal style='margin-right:9.0pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:9.0pt'><span lang=EN-GB>Fainting,
sometimes accompanied by falling, can occur (mostly in adolescents) following
any needle injection. Therefore, tell the doctor or nurse if you fainted with a
previous injection.</span></p>

<p class=MsoNormal style='margin-right:9.35pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:9.0pt'><span lang=EN-GB>As with any
vaccine, Gardasil may not fully protect 100% of those who get the vaccine.</span></p>

<p class=MsoNormal style='margin-right:9.0pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Gardasil will not protect against every
type of Human Papillomavirus. Therefore, appropriate precautions against
sexually transmitted disease should continue to be used.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Gardasil will not protect against other
diseases </span><span lang=EN-GB>that are not caused by </span><span
lang=EN-GB>Human Papillomavirus</span><span lang=EN-GB>.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Vaccination is not a substitute for routine
cervical screening<b><i>.</i></b></span><span lang=EN-GB> You should continue
to follow your doctor&#8217;s advice on cervical smear/Pap tests and
preventative and protective measures.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:9.05pt;page-break-after:avoid'><i><span
lang=EN-GB>What other important information should you or your child know about
Gardasil</span></i></p>

<p class=MsoNormal style='margin-right:9.05pt;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Longer term follow-up studies were
conducted to determine the duration of protection. The need for a booster dose has
not been established. </span></p>

<p class=MsoNormal style='margin-right:9.0pt'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>Other
medicines or vaccines and Gardasil</span></b></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>Gardasil can be given
with a Hepatitis B vaccine or with a combined booster vaccine containing
diphtheria (d) and tetanus (T) with either pertussis [acellular, component]
(ap) and/or poliomyelitis [inactivated] (IPV) (dTap, dT-IPV, dTap-IPV vaccines)
at a separate injection site (another part of your body, e.g. the other arm or
leg) during the same visit.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Gardasil may
not have an optimal effect if:</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-size:10.0pt;font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>used with medicines that suppress the immune
system.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>In clinical trials, oral or other
contraceptives (e.g. the pill) did not reduce the protection obtained by Gardasil.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Please tell your doctor or pharmacist if
you or your child are taking or have taken recently any other medicines,
including medicines obtained without a prescription.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>Pregnancy,
breast-feeding and fertility </span></b></p>

<p class=MsoNormal><span lang=EN-GB>If you are pregnant or breast-feeding,
think you may be pregnant or are planning to have a baby, ask your doctor for
advice before taking this medicine.</span></p>

<p class=MsoNormal><span lang=EN-GB>Gardasil may be given to women who are
breast-feeding or intend to breast-feed.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>Driving
and using machines</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='color:black'>No studies on the effects on the ability to
drive and use machines have been performed.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid'><b><span lang=EN-GB>3. &nbsp;&nbsp;&nbsp;&nbsp;&nbsp; How Gardasil is
given</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal><span lang=EN-GB>Gardasil is given as an injection by your
doctor. Gardasil is intended for adolescents and adults from 9&nbsp;years of
age onwards.</span><span lang=EN-GB> </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><i><u><span lang=EN-GB>If
you are from 9 to and including 13&nbsp;years of age</span></u></i></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Gardasil can
be administered according to a 2-dose schedule:</span></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in'><span
lang=EN-GB style='font-family:"Arial",sans-serif'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>First injection: at chosen date</span></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in'><span
lang=EN-GB style='font-family:"Arial",sans-serif;color:black'>-<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Second injection: <span style='color:black'>6&nbsp;months
after first injection</span></span></p>

<p class=MsoNormal><span lang=EN-GB>If the second vaccine dose is administered
earlier than 6 months after the first dose, a third dose should always be
administered.</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Alternatively,
Gardasil can be administered according to a 3-dose schedule:</span></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in'><span
lang=EN-GB style='font-family:"Arial",sans-serif'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>First injection: at chosen date</span></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in'><span
lang=EN-GB style='font-family:"Arial",sans-serif'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Second injection: 2&nbsp;months after first injection</span></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in'><span
lang=EN-GB style='font-family:"Arial",sans-serif'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Third injection: 6&nbsp;months after first
injection</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>The second dose should
be administered at least one month after the first dose and the third dose should
be administered at least 3&nbsp;months after the second dose. All three doses
should be given within a 1-year period. Please speak to your doctor for more
information.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><i><u><span lang=EN-GB>If
you are from 14&nbsp;years of age</span></u></i></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Gardasil
should be administered according to a 3-dose schedule:</span></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in'><span
lang=EN-GB style='font-family:"Arial",sans-serif'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>First injection: at chosen date</span></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in'><span
lang=EN-GB style='font-family:"Arial",sans-serif'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Second injection: 2&nbsp;months after first
injection</span></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in'><span
lang=EN-GB style='font-family:"Arial",sans-serif'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Third injection: 6&nbsp;months after first
injection</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>The second dose should
be administered at least one month after the first dose and the third dose should
be administered at least 3&nbsp;months after the second dose. All three doses
should be given within a 1-year period. Please speak to your doctor for more
information.</span></p>

<p class=MsoNormal><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal><span lang=EN-GB>It is recommended that individuals who
receive a first dose of Gardasil complete the vaccination course with Gardasil.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Gardasil will be given as an injection
through the skin into the muscle (preferably the muscle of the upper arm or
thigh).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>The vaccine should not be mixed in the same
syringe with any other vaccines and solutions.</span></p>

<p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>If you
forget one dose of Gardasil:</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal><span lang=EN-GB>If you miss a scheduled injection, your
doctor will decide when to give the missed dose.</span></p>

<p class=MsoNormal><span lang=EN-GB>It is important that you follow the
instructions of your doctor or nurse regarding return visits for the follow-up
doses. If you forget or are not able to go back to your doctor at the scheduled
time, ask your doctor for advice. When Gardasil is given as your first dose, the
completion of the vaccination course should be done with Gardasil, and not with
another HPV vaccine.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>If you have any further questions on the
use of this medicine, ask your doctor or pharmacist<b>.</b></span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid'><b><span lang=EN-GB>4. &nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Possible side
effects</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal><span lang=EN-GB>Like all vaccines and medicines, Gardasil
can cause side effects, although not everybody gets them.</span></p>

<p class=MsoNormal style='margin-right:9.0pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:9.0pt'><span lang=EN-GB>The following
side effects can be seen after the use of Gardasil:</span></p>

<p class=MsoNormal style='margin-right:9.0pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:9.0pt'><span lang=EN-GB>Very commonly
(more than 1 in 10 patients), side effects found at the injection site include:
pain, swelling and redness. Headache was also seen.</span></p>

<p class=MsoNormal style='margin-right:9.0pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:9.0pt'><span lang=EN-GB>Commonly (more
than 1 in 100 patients), side effects found at the injection site include:
bruising, itching, pain in extremity. Fever and nausea have also been reported.
</span></p>

<p class=MsoNormal style='margin-right:9.0pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:9.0pt'><span lang=EN-GB>Rarely (less
than 1 in 1000 patients): hives (urticaria).</span></p>

<p class=MsoNormal style='margin-right:9.0pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:9.0pt'><span lang=EN-GB>Very rarely
(less than 1 in 10,000 patients), difficulty breathing (bronchospasm) has been
reported.</span></p>

<p class=MsoNormal style='margin-right:9.0pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:9.0pt'><span lang=EN-GB>When Gardasil
was given with a combined diphtheria, tetanus, pertussis [acellular, component]
and poliomyelitis [inactivated] booster vaccine during the same visit, there
was more headache and injection-site swelling. </span></p>

<p class=MsoNormal style='margin-right:9.0pt'><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal style='page-break-after:avoid'><i><span lang=EN-GB>Side
effects that have been reported during marketed use include:</span></i></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Fainting, sometimes accompanied by <span
style='color:black'>shaking or stiffening,</span> has been reported. Although
fainting episodes are uncommon, patients should be observed for 15 minutes after
they receive HPV vaccine.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Allergic reactions that may include
difficulty breathing, wheezing (bronchospasm), hives and rash have been
reported. Some of these reactions have been severe.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>As with other vaccines, side effects that
have been reported during general use include: swollen glands (neck, armpit, or
groin); </span><span lang=EN-GB>muscle weakness, abnormal sensations, tingling
in the arms, legs and upper body, or confusion (</span><span lang=EN-GB>Guillain-Barr&eacute;
Syndrome, Acute disseminated encephalomyelitis</span><span lang=EN-GB>)</span><span
lang=EN-GB>; dizziness, vomiting, joint pain, aching muscles, unusual tiredness
or weakness, chills, generally feeling unwell, bleeding or bruising more easily
than normal, and skin infection at the injection site.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>Reporting
of side effects</span></b></p>

<p class=BodytextAgency style='margin-bottom:0in;line-height:normal'><span
lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>If you
get any side effects, talk to your doctor or pharmacist.</span><span
lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif;
color:red'> </span><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>This
includes any possible side effects not listed in this leaflet. You can also
report side effects directly via <span style='color:black;background:#BFBFBF'>the
national reporting system listed in </span></span><a
href="http://www.ema.europa.eu/docs/en_GB/document_library/Template_or_form/2013/03/WC500139752.doc"><u><span
lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif;
color:blue;background:#BFBFBF'>Appendix V</span></u></a><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif'>. By reporting
side effects you can help provide more information on the safety of this
medicine.</span></p>

<p class=MsoNormal style='margin-left:27.0pt;text-indent:-27.0pt'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-left:27.0pt;text-indent:-27.0pt'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-left:27.0pt;text-indent:-27.0pt;page-break-after:
avoid'><b><span lang=EN-GB>5. &nbsp;&nbsp;&nbsp;&nbsp; How to store Gardasil</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB>Keep this vaccine out of the sight and reach of
children.</span></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>Do not use this vaccine
after the expiry date which is stated on the syringe label and the outer carton
(after EXP). The expiry date refers to the last day of that month.</span></p>

<p class=MsoNormal><span lang=EN-GB>Store in a refrigerator (2&ordm;C&nbsp;&#8209;&nbsp;8&ordm;C).</span></p>

<p class=MsoNormal><span lang=EN-GB>Do not freeze.</span></p>

<p class=MsoNormal><span lang=EN-GB>Keep the syringe in the outer carton in
order to protect from light.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Do not throw away any medicines via
wastewater or household waste. Ask your pharmacist how to throw away medicines
you no longer use. These measures will help to protect the environment.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid'><b><span lang=EN-GB>6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Contents of
the pack and other information</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>What
Gardasil contains</span></b></p>

<p class=MsoNormal><span lang=EN-GB>The active substances are: highly purified
non-infectious protein for each of the Human Papillomavirus types (6, 11, 16,
and 18).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>1 dose (0.5&nbsp;ml) contains
approximately:</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Human Papillomavirus<sup>1</sup> Type 6 L1
protein<span class=MsoFootnoteReference>2,3</span>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 20&nbsp;micrograms</span></p>

<p class=MsoNormal><span lang=EN-GB>Human Papillomavirus<sup>1</sup> Type 11 L1
protein<sup>2,3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </sup>40&nbsp;micrograms</span></p>

<p class=MsoNormal><span lang=EN-GB>Human Papillomavirus<sup>1</sup> Type 16 L1
protein<span class=MsoFootnoteReference>2,3</span>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 40&nbsp;micrograms</span></p>

<p class=MsoNormal><span lang=EN-GB>Human Papillomavirus<sup>1</sup> Type 18 L1
protein<sup>2,3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </sup>20&nbsp;micrograms</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><sup><span lang=EN-GB>1</span></sup><span lang=EN-GB>Human
Papillomavirus = HPV</span></p>

<p class=MsoNormal><sup><span lang=EN-GB>2</span></sup><span lang=EN-GB>L1
protein in the form of virus like particles produced in yeast cells (<i>Saccharomyces
cerevisiae</i> CANADE&nbsp;3C&#8209;5 (Strain&nbsp;1895)) by recombinant DNA
technology.</span></p>

<p class=MsoNormal><sup><span lang=EN-GB>3</span></sup><span lang=EN-GB>adsorbed
on amorphous aluminium hydroxyphosphate sulphate adjuvant (0.225&nbsp;milligrams
Al).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>The other ingredients in the vaccine
suspension are:</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Sodium chloride, L-histidine,
polysorbate&nbsp;80, sodium borate and water for injections.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>What
Gardasil looks like and contents of the pack</span></b></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>1 dose of
Gardasil suspension for injection contains 0.5&nbsp;ml.</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>Prior to
agitation, Gardasil may appear as a clear liquid with a white precipitate. </span><span
lang=EN-GB>After thorough agitation, it is a white, cloudy liquid. </span></p>

<p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal><span lang=EN-GB>Gardasil is available in packs of 1, 10 or
20 pre-filled syringes.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Not all pack sizes are marketed.</span></p>

<p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>Marketing
Authorisation Holder and Manufacturer</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>Marketing
Authorisation Holder</span></u></p>

<p class=MsoNormal><span lang=FR>MSD VACCINS</span></p>

<p class=MsoNormal><span lang=FR>162 avenue Jean Jaur&egrave;s</span></p>

<p class=MsoNormal><span lang=EN-GB>69007 Lyon</span></p>

<p class=MsoNormal><span lang=EN-GB>France</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>Manufacturer</span></u></p>

<p class=MsoNormal><span lang=EN-GB>Merck Sharp &amp; Dohme BV</span></p>

<p class=MsoNormal><span lang=EN-GB>Waarderweg 39</span></p>

<p class=MsoNormal><span lang=EN-GB>2031 BN Haarlem</span></p>

<p class=MsoNormal><span lang=EN-GB>The Netherlands</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>For any
information about this medicinal product, please contact the local representative
of the Marketing Authorisation Holder.</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 width=624
 style='margin-left:-1.7pt;border-collapse:collapse'>
 <tr style='page-break-inside:avoid'>
  <td style='border:none;padding:0in 0in 0in 0in' width=2><p class='MsoNormal'>&nbsp;</td>
  <td width=310 valign=top style='width:232.2pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-autospace:none'><b><span lang=FR-BE>Belgi&euml;/Belgique/Belgien</span></b></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=FR-BE>MSD Belgium BVBA/SPRL<br>
  T&eacute;l/Tel: +32 (0) 27766211</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=FR-BE>dpoc_belux@merck.com</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=FR-BE>&nbsp;</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-autospace:none'><b><span lang=EN-GB>Lietuva</span></b></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>UAB Merck
  Sharp &amp; Dohme<br>
  Tel.: +370.5.2780.247<br>
  msd_lietuva@merck.com</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td style='border:none;padding:0in 0in 0in 0in' width=2><p class='MsoNormal'>&nbsp;</td>
  <td width=310 valign=top style='width:232.2pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-autospace:none'><b><span lang=EN-GB>&#1041;&#1098;&#1083;&#1075;&#1072;&#1088;&#1080;&#1103;</span></b></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&#1052;&#1077;&#1088;&#1082;
  &#1064;&#1072;&#1088;&#1087; &#1080; &#1044;&#1086;&#1091;&#1084;
  &#1041;&#1098;&#1083;&#1075;&#1072;&#1088;&#1080;&#1103;
  &#1045;&#1054;&#1054;&#1044;, <br>
  &#1090;&#1077;&#1083;.: + 359 2 819 3737<br>
  info-msdbg@merck.com</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-autospace:none'><b><span lang=EN-GB>Luxembourg/Luxemburg</span></b></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>MSD Belgium BVBA/SPRL<br>
  T&eacute;l: +32 (0) 27766211</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>dpoc_belux@merck.com</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:38.2pt'>
  <td style='border:none;padding:0in 0in 0in 0in' width=2><p class='MsoNormal'>&nbsp;</td>
  <td width=310 valign=top style='width:232.2pt;padding:0in 5.4pt 0in 5.4pt;
  height:38.2pt'>
  <p class=MsoNormal style='text-autospace:none'><b><span lang=EN-GB>&#268;esk&aacute;
  republika</span></b></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>Merck Sharp
  &amp; Dohme s.r.o. <br>
  Tel.: +420 233 010 111<br>
  dpoc_czechslovak@merck.com</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt;
  height:38.2pt'>
  <p class=MsoNormal style='text-autospace:none'><b><span lang=EN-GB>Magyarorsz&aacute;g</span></b></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>MSD Pharma Hungary
  Kft.<br>
  Tel.: + 36.1.888.5300</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>hungary_msd@merck.com</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td style='border:none;padding:0in 0in 0in 0in' width=2><p class='MsoNormal'>&nbsp;</td>
  <td width=310 valign=top style='width:232.2pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-autospace:none'><b><span lang=EN-GB>Danmark</span></b></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=SV>MSD Danmark ApS</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=SV>Tlf: + 45 4482
  4000</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>dkmail@merck.com</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-autospace:none'><b><span lang=EN-GB>Malta</span></b></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>Merck Sharp
  &amp; Dohme Cyprus Limited.<br>
  Tel: 8007 4433 (+356 99917558)</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>malta_info@merck.com</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td style='border:none;padding:0in 0in 0in 0in' width=2><p class='MsoNormal'>&nbsp;</td>
  <td width=310 valign=top style='width:232.2pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-autospace:none'><b><span lang=EN-GB>Deutschland</span></b></p>
  <p class=MsoNormal style='text-autospace:none'>MSD SHARP &amp; DOHME GMBH</p>
  <p class=MsoNormal style='text-autospace:none'>Tel: 0800 673 673 673 (+49 (0)
  89 4561 2612)</p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>e-mail@msd.de</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-autospace:none'><b><span lang=EN-GB>Nederland</span></b></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>Merck Sharp
  &amp; Dohme B.V.</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>Tel: 0800
  9999000 </span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>(+31 23
  5153153)</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>medicalinfo.nl@merck.com
  <br>
  <br>
  </span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td style='border:none;padding:0in 0in 0in 0in' width=2><p class='MsoNormal'>&nbsp;</td>
  <td width=310 valign=top style='width:232.2pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-autospace:none'><b><span lang=EN-GB>Eesti</span></b></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>Merck Sharp
  &amp; Dohme O&Uuml;</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=FI>Tel.:
  +372&nbsp;6144 200</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=FI>msdeesti@merck.com</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-autospace:none'><b><span lang=EN-GB>Norge</span></b></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>MSD (Norge)
  AS</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>Tlf: +47 32 20
  73 00</span></p>
  <p class=MsoNormal style='text-autospace:none'>msdnorge@msd.no</p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td style='border:none;padding:0in 0in 0in 0in' width=2><p class='MsoNormal'>&nbsp;</td>
  <td width=310 valign=top style='width:232.2pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-autospace:none'><b><span lang=EL>&#917;&#955;&#955;&#940;&#948;&#945;</span></b></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>MSD</span><span
  lang=EL> &#913;.&#934;.&#914;.&#917;.&#917;.</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EL>&#932;&#951;&#955;:
  +30 210 98 97 300</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>dpoc_greece@merck.com</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-autospace:none'><b><span lang=EN-GB>&Ouml;sterreich</span></b></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=FI>Merck Sharp
  &amp; Dohme Ges.m.b.H.</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>Tel: +43 (0)
  1 26 044</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>msd-medizin@merck.com</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=FR-BE>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=312 colspan=2 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-autospace:none'><b><span lang=EN-GB>Espa&ntilde;a</span></b></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=ES-TRAD>Merck Sharp
  &amp; Dohme de Espa&ntilde;a, S.A.</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=DE>Tel: +34 91 321
  06 00</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=DE>msd_info@merck.com</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=FR-BE>&nbsp;</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-autospace:none'><b><span lang=EN-GB>Polska</span></b></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>MSD Polska
  Sp. z o.o.<br>
  Tel.: +48.22.549.51.00</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>msdpolska@merck.com</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=312 colspan=2 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-autospace:none'><b><span lang=FR-BE>France</span></b></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=FR-BE>MSD VACCINS<br>
  T&eacute;l: +33 (0) 1 80 46 40 40</span></p>
  <p class=MsoNormal style='text-autospace:none'><b><span lang=FR-BE>&nbsp;</span></b></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-autospace:none'><b><span lang=FR-BE>Portugal</span></b></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=PT-BR>Merck Sharp
  &amp; Dohme, Lda</span></p>
  <p class=MsoNormal style='text-autospace:none'>Tel: +351 21 4465<span
  lang=EN-GB>700</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=PT>clic@merck.com</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=FR-BE>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=312 colspan=2 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-autospace:none'><b><span lang=EN-GB>Hrvatska</span></b></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>Merck Sharp
  &amp; Dohme d.o.o.<br>
  Tel: +385 1 66 11 333</span></p>
  <p class=MsoNormal style='text-autospace:none'>croatia_info@merck.com</p>
  <p class=MsoNormal style='text-autospace:none'><u><span lang=EN-GB><span
   style='text-decoration:none'>&nbsp;</span></span></u></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-autospace:none'><b><span lang=EN-GB>Rom&acirc;nia</span></b></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>Merck Sharp
  &amp; Dohme Romania S.R.L</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>Tel: + 4021
  529 29 00</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>msdromania@merck.com</span></p>
  <p class=MsoNormal style='text-autospace:none'><b><span lang=EN-GB>&nbsp;</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=312 colspan=2 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'><span
  lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
  clear=all style='page-break-before:always'>
  </span>
  <p class=MsoNormal style='text-autospace:none'><b><span lang=EN-GB>Ireland</span></b></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>Merck Sharp
  &amp; Dohme Ireland (Human Health) Limited</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>Tel: +353
  (0)1 2998700</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>medinfo_ireland@merck.com</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-autospace:none'><b><span lang=EN-GB>Slovenija</span></b></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>Merck Sharp
  &amp; Dohme, inovativna zdravila d.o.o.<br>
  Tel: +386.1.520.4201</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=FR>msd.slovenia@merck.com</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=312 colspan=2 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-autospace:none'><b><span lang=EN-GB>&Iacute;sland</span></b></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>Vistor hf.</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>S&iacute;mi:
  + 354 535 7000</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-autospace:none'><b><span lang=EN-GB>Slovensk&aacute;
  republika</span></b></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>Merck Sharp
  &amp; Dohme, s. r. o<br>
  Tel: +421 2 58282010</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=ES-TRAD>dpoc_czechslovak@merck.com</span></p>
  <p class=MsoNormal style='text-autospace:none'><b><span lang=EN-GB>&nbsp;</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=312 colspan=2 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-autospace:none'><b><span lang=EN-GB>Italia</span></b></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=ES-MX>MSD Italia
  S.r.l. </span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>Tel: +39 06
  361911</span></p>
  <p class=MsoNormal style='text-autospace:none'>medicalinformation.it@merck.com</p>
  <p class=MsoNormal style='text-autospace:none'><b><span lang=FR-BE>&nbsp;</span></b></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-autospace:none'><b><span lang=FR-BE>Suomi/Finland</span></b></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=SV>MSD Finland Oy</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=SV>Puh/Tel: +358
  (0)9 804 650</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>info@msd.fi</span><span
  lang=EN-GB> </span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=312 colspan=2 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-autospace:none'><b><span lang=EN-GB>&#922;&#973;&#960;&#961;&#959;&#962;</span></b></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>Merck Sharp
  &amp; Dohme Cyprus Limited<br>
  &#932;&#951;&#955;:&nbsp; 800 00 673 (+357 22866700)</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>cyprus</span><span
  lang=EL>_</span><span lang=EN-GB>info</span><span lang=EL>@</span><span
  lang=EN-GB>merck</span><span lang=EL>.</span><span lang=EN-GB>com</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-autospace:none'><b><span lang=EN-GB>Sverige</span></b></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=DE>Merck Sharp
  &amp; Dohme (Sweden) AB</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=DE>Tel: +46 77
  5700488</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>medicinskinfo@merck.com</span></p>
  <p class=MsoNormal style='text-autospace:none'><b><span lang=EN-GB>&nbsp;</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=312 colspan=2 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-autospace:none'><b><span lang=EN-GB>Latvija</span></b></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>SIA Merck
  Sharp &amp; Dohme Latvija<br>
  Tel: +371.67364.224<br>
  msd_lv@merck.com</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-autospace:none'><b><span lang=EN-GB>United
  Kingdom</span></b></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>Merck Sharp
  &amp; Dohme Limited</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>Tel: +44 (0)
  1992 467272</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>medicalinformationuk@merck.com</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=FR-BE>&nbsp;</span></p>
  </td>
 </tr>
 <tr height=0>
  <td width=2 style='border:none'></td>
  <td width=310 style='border:none'></td>
  <td width=312 style='border:none'></td>
 </tr>
</table>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>This
leaflet was last revised in: {MM/YYYY}.</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal><span lang=EN-GB>Detailed information on this medicine is
available on the European Medicines Agency web site: http://www.ema.europa.eu</span></p>

<p class=MsoNormal><span lang=EN-GB>------------------------------------------------------------------------------------------------------------------------</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>The
following information is intended for medical or healthcare professionals only:</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-left:27.0pt;text-indent:-27.0pt'><span
lang=EN-GB style='font-family:"Arial",sans-serif'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Gardasil is available in a pre-filled syringe
ready to use for intramuscular injection (IM), preferably in the deltoid area
of the upper arm. </span></p>

<p class=MsoNormal style='margin-left:27.0pt;text-indent:-27.0pt'><span
lang=EN-GB style='font-family:"Arial",sans-serif'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>If 2 needles of different lengths are provided
in the pack, choose the appropriate needle to ensure an IM administration
depending on your patient&#8217;s size and weight. </span></p>

<p class=MsoNormal style='margin-left:27.0pt;text-indent:-27.0pt'><span
lang=EN-GB style='font-family:"Arial",sans-serif'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Parenteral drug products should be inspected
visually for particulate matter and discolouration prior to administration.
Discard the product if particulates are present or if it appears discoloured.
Any unused product or waste material should be disposed of in accordance with
local requirements.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><u><span lang=EN-GB>Shake well before use</span></u><span
lang=EN-GB>. Attach the needle by twisting in a clockwise direction until the
needle fits securely on the syringe. Administer the entire dose as per standard
protocol.</span></p>

<p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>

</div>

</body>

</html>
